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ABSTRACT 
Natural products are widely used in the pharmaceutical industry, in agriculture, 
and as specialty chemicals. Methodology development focuses on optimizing the key 
organic reactions to access these natural products while trying to limit the overall number 
of synthetic steps. Key bond forming strategies are sought to provide new ways to 
address carbon-carbon or carbon-heteroatom bonds. The advancement of new 
asymmetric reactions to generate enantiopure products from achiral starting materials is a 
vital area of research. The objectives addressed in this dissertation include: 1) the 
development of a general reductive conversion of esters to ethers with a broad substrate 
scope accessing both aromatic and non-aromatic esters as well as accessing challenging 
α-substituted ethers, 2) the development of synthetic strategies for the preparation of 
trisubstituted biaryl quinoline scaffolds and subsequent derivatization to produce a library 
of heterocyclic substrates for the inhibition of HIV-1 integrase, and 3) the use of 
organocatalysis to explore new reactions and, through π-π and H-π bonding interactions 
between catalysts and substrates, to result in improved enantioselection as compared to 
transition-metal catalyzed reactions. 
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 – INTRODUTION 
1.1 Natural Product Isolation 
Herbal remedies have been used throughout human history to treat a variety of 
medical ailments encompassing acute, chronic, and terminal illnesses. The source of 
these herbal remedies typically originates from a small molecule that has been produced 
by its biological counterpart, otherwise known as a natural product. Medicinally, these 
natural products have been an extremely productive source for new therapeutics and 
provide continual inspiration for the development of even more potent treatments. 
However, isolation of these natural products is complicated two-fold. First, isolation of 
natural products can be extremely difficult and typically requires extensive isolation 
procedures, destroying the natural source in the process. Second, the percentage of the 
desired natural product within the plant is often extremely low. Natural product total 
synthesis enables chemists to provide the desired compound in abundant quantities and 
allows the synthesis of more potent derivatives. 
Of specific interest in the vast library of natural products are the alkaloids. This 
subset contains extensive and structurally intriguing heterocyclic substructures 
encompassing fused, bicyclic, and spirocyclic ring systems. These heterocyclic moieties 
are of great synthetic interest to chemists as they pose challenges in forming carbon-
carbon, carbon-oxygen, and carbon-nitrogen bonds within unique architectures. 
Although, total synthesis can increase the yield of the natural product versus the 
extraction from plants, there are often specific synthetic steps that are difficult and 
drastically decrease the total yield. New methodology must continually be developed to 
overcome these processes in natural product total synthesis. 
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1.2 Noncovalent Interactions in Organic Chemistry 
Manipulation of noncovalent interactions is a key tool for organic chemists to 
enhance the desired product and/or introduce selectivity for one stereoisomer by reducing 
the energy barrier to access that product. While minute in impact alone, the collective of 
all these interactions ultimately dictate the outcome of the reaction. Some examples of 
noncovalent interactions in organic chemistry include: 1) transition-state manipulation of 
bifurcated reactions, 2) small molecule interactions within an enzyme binding site and, 3) 
organocatalyzed enantioselective C-C bond forming reactions. Noncovalent interactions 
include ionic or hydrogen bonding, Van der Waals forces, π-effects, as well as 
hydrophobic effects. An investigation of the contributions of noncovalent interactions 
present in asymmetric organocatalyzed reactions will enable the rational design of new 
catalysts.   
The ultimate goal of this dissertation is to understand and exploit the subtle 
noncovalent interactions between two molecules to design effective and enantioselective 
bond forming methodologies for the synthesis of substructures found within natural 
products. In the following chapters, three individual projects will be presented. Each 
chapter presents a unique concept regarding noncovalent interactions and their use in 
organic methodology as it relates to natural product and synthon synthesis. 
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 –Conservative Reduction of Esters to Ethers via an Oxonium Ion 
Intermediate  
2.1 Introduction 
2.1.1 The Importance of Ethers in Natural Product Synthesis 
The development of a predictable method for the interconversion of common 
organic functional groups is highly sought in the field of organic chemistry. Ethers are a 
common functional group that can be found within a plethora of organic compounds and 
natural products. Some examples of ether containing natural products are non-small cell 
growth inhibitor trichoethers,1 cholesterol blocking cyclic terpendoles,2 and anti-
inflammatory flavonolignans.3 Ethers can also be used as stabilizing agents for Grignard 
reagents and boron-containing compounds due to their capacity to form coordinate 
covalent bonds, as well as in crown ethers as phase transfer catalysts for increased 
solubility.4 Ethers are also found in cosmetics,5 as constituents in essential oils,6-7, and as 
organic solvents due to their generally inert properties such as tetrahydrofuran (THF), 
diethyl ether (Et2O), and dioxane. 
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Figure 2.1 A selection of natural products with ether functional groups 
 
2.1.2 The General Synthesis of Ethers 
The most common method to form ethers is the Williamson ether synthesis between 
alkyl halides and alkoxides.4 The reaction works best with primary alkyl halides and non-
bulky alkoxides. Due to the SN2 reaction mechanism, tertiary or bulky alkyl halides do not 
react at all or undergo an E2 elimination. Other general synthetic methods to form ethers 
include acid-catalyzed condensation of alcohols,8-12 which is limited to forming symmetric 
ethers of primary alcohols, or alkoxymercuration-demercuration of alkenes,13 which uses 
toxic mercury compounds. None of these methods are stereoselective and often fail in 
reactions with increased alcohol substitution. 
 
2.1.3 Reduction of Esters 
Esters are fairly easy to synthesize by either using a coupling reaction with a 
carboxylic acid and alcohol14-15 or by converting the carboxylic acid to an acid chloride 
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before reaction with the alcohol.16 The standard ester reduction schemes and 
consideration are shown in Scheme 2.1. The typical loss of oxidation state moves from 
ester 2.5 to aldehyde 2.9 or alternatively from ester 2.5 directly to alcohol 2.8. Early work 
with complete reduction of esters to primary alcohols began by reducing with either 
lithium aluminum hydride,17 sodium borohydride18, or a derivative19-20 thereof in the 
presence of an expensive metal catalyst or a Lewis acid.21-23  Recent literature has shown 
that ester 2.5 can be reduced to aldehyde 2.9 by using special reducing agents such as 
diisobutyl aluminium hydride (DIBAL-H),24 or other similar aluminum reducing 
agents,25-28 which prevents over-reduction by forming an aluminate-acetal intermediate, 
such as 2.6. Intermediate 2.6 is stable at cold temperatures and, after quenching with an 
aqueous solution, can form the desired aldehyde 2.9. Hence this is a conservative 
reduction moving from an oxidation state of 3 (ester) to 2 (aldehyde). 
 
Scheme 2.1 Considerations during ester reduction 
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2.1.4 Historical Conversion of Esters to Ethers 
Alternatively, the formation of an ether from an ester can be envisioned by 
capturing the aluminate-acetal intermediate 2.6 with a trapping reagent. This would form 
the protected acetal 2.7 or ether 2.10, the latter via a one-pot reduction. These 
applications have been most widely applied to non-aromatic esters in comparison to 
aromatic esters.29-34 Aromatic esters have the carbonyl group in conjugation with the 
aromatic ring, making it more difficult for the initial reduction and less stable during the 
intermediate stages, leading to low conversions or more side products (Figure 2.2).  
 
Figure 2.2 Classification of aromatic and non-aromatic esters. 
Early attempts for ester to ether conversion were completed by Pettit in the 
1960s.35-37 His group focused on reacting steroid natural products with BF3·OEt2, then 
adding the solution to lithium aluminum hydride (LAH) in an ice bath before refluxing to 
achieve moderate to low yields. An advancement in the conversion of esters to ethers 
utilized Lawesson’s reagent to convert lactones to thiolactones, and then reduce the 
carbon-sulfur bond in a second step.38 This was initially done by Baxter utilizing Raney 
nickel as the reducing agent,29 followed by Nicolaou and Jang who both used a 
combination of diphenylsilane with an organotin hydride to form a tin-protected 
thioacetal, which then went through a radical cleavage using AIBN to produce the 
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ether.34, 39-40 In these examples, cyclic thiolactams were typically used but in some 
instances, non-aromatic and more importantly aromatic thioesters were also present.   
Another area of ester to ether conversion focuses on the use of transition metal or 
Lewis acid catalysts. Beller et al. utilized 10% mol loading of a Fe3(CO)12 catalyst in the 
presence of tetramethyldisiloxane (TMDS) for the conversion of non-aromatic esters and 
lactones to their respective ether counterparts.32 The Buchwald group used a titanocene 
diphenoxide and difluoride catalyst in the presence of polymethylhydrosiloxane (PMHS) 
to convert five- and six-membered lactones to cyclic ethers in moderate to excellent 
yields.31 Sakai and coworkers also used PMHS with an indium tribromide catalyst for a 
one pot conversion of carboxylic acids and alcohols to ethers, however all instances were 
using non-aromatic with moderate to good yields.33, 41 Additionally, silanes in the 
presence of a Lewis acid were also used in the conversion of esters to ethers. Tsurugi 
developed two methods, the first of which used Et3SiH in the presence of NiCl3 and the 
second used Cl3SiH. Both reactions were exposed to γ-radiation to produce only non-
aromatic ethers in good to excellent yields.42  
Homma and Pagenkopf both created a ‘super’ Lewis acid by initially reacting 
TMSOTf with either TiCl4 or BF3·OEt2, respectively, before adding Et3SiH.
43-44 However 
in both instances, only non-aromatic esters were used and the ethers were obtained in low 
to moderate yields due to over-reduction to the alcohol or the formation of silyl ether.  
 
2.1.5 Rychnovsky’s Work on the Conversion of Esters to Ethers 
Current research has focused on the reduction of ester 2.5 to ether 2.10 utilizing 
aluminate-acetal intermediate 2.6 (Scheme 2.2).45 At the forefront is the work done by the 
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Rychnovsky group.46-49 His group established a two-step protocol for ester to ether 
conversion in which the intermediate is trapped as an acetoxy-protected acetal 2.12. This 
intermediate is prepared by the addition of DIBAL to the ester at -78 C to initially form 
the aluminate 2.6 (Scheme 2). This intermediate (2.6) is stable at -78 C, but if it is 
quenched with an aqueous workup, it will form aldehyde 2.9. To prevent this, 2.6 can be 
trapped in situ with acetic anhydride in the presence of pyridine and DMAP to form 
acetal 2.12.46 This stable acetal can be isolated and purified by chromatography. 
Alternatively, if it is exposed to a Lewis acid and hydride source, the desired ether 2.10 is 
obtained via oxonium ion 2.13. Although excellent yields are obtained, these reactions 
take a combined 16-20 hours at cold temperatures and have not been shown to work with 
aromatic esters or α,β-unsaturated esters.  
 
Scheme 2.2 Rychnovsky's method for the reduction of esters to ethers 
 
2.1.6 Interception of Oxonium Ion Intermediate by Nucleophiles 
Alternatively, oxonium ion 2.13 can be intercepted with other nucleophiles to 
form α-substituted ethers in isochroman acetals (Scheme 2.3). Jacobsen utilized thiourea 
organocatalysts to add vinyl nucleophiles enantioselectively in good to excellent yields.50-
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51 Schaus52-53 and Rueping54-55 both exploited the use of a catalytic Brønsted/Lewis acid 
system to add vinyl boronates and aldehydes, respectively. A copper-catalyzed addition 
of alkynes in the presence of TMSOTf was also presented by Watson in good to excellent 
yields.56 Rychnovsky also intercepted the oxonium ion of acetals with nucleophiles 
including the addition allyl silanes, silyl enol ethers, and silyl ketene acetals.49  
 
Scheme 2.3 Synthesis of α-substituted ethers by adding nucleophiles to the oxonium ion. 
 
2.2 Research Hypothesis 
Through the use of different trapping reagents and monitoring by ReactIR, the 
time to form the acetal can be decreased, thereby shortening the overall reaction time. 
Through a one pot reaction with careful selection of reagents and timing, the reduction of 
aromatic esters can be achieved. Additionally, the oxonium ion formed by these reductive 
methods can be intercepted by a range of nucleophiles to form α-substituted ethers, a 
class of compounds that is not easy to synthesize by conventional methods such as the 
Williamson ether synthesis. 
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2.3 Research Design and Methods 
2.3.1 Ester Substrate Scope 
To develop a general and tunable method for the conversion of esters to ethers, a 
broad spectrum of esters must be synthesized in good yield using known methods. 
Aromatic and non-aromatic esters with both electron donating and withdrawing groups 
will be synthesized (Figure 3). Other general types of esters will include cyclic esters, 
those with branching on either the carbonyl or alcohol side, or various substituents that 
are considered sensitive to the reaction conditions, such as a halide or amine group. 
Ideally, the goal is to enable chemists to be able to match their substrates with the 
proposed ester scope and to have a predictable reductive method for the conversion of 
esters to either acetals or ethers. 
 
Figure 2.3 Substrate scope for the reduction of esters to ethers 
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2.3.2 In Situ Monitoring by ReactIR 
React IR, in situ infrared spectroscopy, is ideal for monitoring the interconversion 
of functional groups during a reaction.57 This technique was found to be better suited for 
cold temperature reactions compared to thin layer chromatography (TLC).58 Reactive 
intermediates will likely be unstable in the TLC spotter and will break down on the TLC 
plate, whereas this will not occur with React IR. It is also capable of identifying any side 
products that are formed in the reaction as they will have their own distinct peaks. 
Specifically, React IR is an essential tool for monitoring the conversion of an 
ester to acetal because it can monitor the loss of the carbonyl peak without the need for 
TLC. An IR spectrum is produced every minute and stacked to create a three-dimensional 
surface monitoring time, wavenumber, and absorbance units that accurately denotes the 
progress of a reaction. Due to this capability, React IR enables the determination of exact 
reaction times and the timing necessary for the addition of each reagent, therefore 
indicating the shortest possible reaction times. To do this, the carbonyl peak of the ester 
at ~1720 cm-1 will be monitored and then trapping reagents will be added when full 
reduction of the ester is observed. Also, because React IR monitors the loss of the 
carbonyl peak, it can also aid in determining the precise molar equivalents of reducing 
agent necessary for each individual ester substrate. React IR can also monitor the 
formation of any possible side products formed, such as aldehyde (C-H stretch at 2700 
cm-1) or alcohol (O-H stretch at 3200 cm-1). 
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Figure 2.4 React IR 3D plot 
 
2.3.3 Reduction of Non-Aromatic Esters to Ethers 
The reduction of non-aromatic esters to ethers can be achieved through a two-step 
pathway. First, reduction of the ester will be screened using mild reducing agents such a 
DIBAL-H to form an aluminate acetal intermediate. This intermediate (2.16) can then be 
stabilized through the use of trapping agents such as silyl derivatives or sulfonylating 
reagents with the goal of reducing overall reaction times and potentially increasing 
reaction temperatures.59 
 
Scheme 2.4 Considerations for the reduction of esters to ethers 
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The reduction of the protected acetal to the ether can potentially have problems 
with the Lewis acid complexing at two different positions (Scheme 2.4). If the reaction 
proceeds as desired, the Lewis acid will complex with the acetal oxygen forming 
oxonium ion 2.13 which can be intercepted with a hydride to form the desired ether. 
Alternatively, if the Lewis acid complexes with the ether oxygen, it will form the 
undesired oxonium ion 2.19 resulting in the formation of byproducts. Ideally, the 
trapping reagent that is chosen will be electron donating so that the acetal oxygen is more 
susceptible to Lewis acid binding versus the ether oxygen. 
 
2.3.4 Reduction of Aromatic Esters via One-Pot Reductive Method and Synthesis of 
α-Substituted Ethers 
One of the goals of this project is to successfully reduce aromatic esters to ethers. 
This is more complex due to the conjugation of the aromatic ring with the carbonyl, 
making the aluminate acetal unstable and more prone to over-reduction. One instance 
where aromatic esters have been successfully converted to their ether counterparts using a 
hydride source is the work done by Batey and coworkers.60 His group employed 
Rychnovsky’s method (DIBAL then Ac2O, DMAP, pyr) to produce the acetoxy-protected 
acetal using a picolinate ester. The nitrogen in the pyridine ring complexes to and 
stabilizes the aluminate-acetal intermediate, preventing it from breaking down and 
enabling the acetoxy-protected acetal to form (Figure 2.5). While the picolinate ester 
provides the desired stabilization, it also limits the ester substrate scope considerably. 
Alternatively, SDBBA or LDBBA have be used in this fashion. These reagents can form 
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a six-membered transition state after the initial reduction of the carbonyl group, resulting 
in the stabilized aluminate acetal 2.21 (Figure 2.5).  
 
Figure 2.5 Comparison stabilized aromatic aluminate acetal intermediates 
With the development of a one pot procedure, the synthesis of α-substituted ethers 
is an additional goal for this project by intercepting oxonium ion 2.13 with a carbon 
nucleophile. Although the synthesis of α-substituted ethers has been demonstrated in the 
literature by capturing the oxonium ion with nucleophiles, it has not been shown via a 
one-pot variant starting from an ester. While diastereoselective nucleophilic addition has 
been achieved using either a chiral auxiliary or substrate control via a cyclic oxonium, it 
has not been accomplished in an enantioselective manner with acyclic ethers.  
 15 
 
Scheme 2.5 Planned α-substituted ether scope with carbon nucleophiles 
 
2.4  Results and Discussion 
2.4.1 Synthesis of Esters to Fulfill Substrate Scope 
Multiple ester substrates were synthesized using either an acid chloride method 
(oxalyl chloride or thionyl chloride) or a coupling reagent method (EDC or DCC). 
Aromatic and non-aromatic esters were synthesized successfully with varying yields 
(esters 2.5a-2.5z, Figure 5). Coupling reactions utilizing DCC and EDC were initially 
attempted, however they occurred in low to moderate yields ranging from below 20% to 
mid-70%.  
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Figure 2.6 Substrate scope of esters synthesized by EDC/DCC or thionyl/oxalyl chloride  
The low yields when using DCC (2.36) could be attributed to the production of 
the solid urea by-product which presented difficulties during filtration and purification. 
The benefit of EDC (2.39) is that the urea by-product is water soluble, however, this did 
not result in increased yields. Both methods rely on the formation of an adduct between 
the coupling reagent and the carboxylic acid (2.37 and 2.40, Scheme 6). This is known as 
the active ester intermediate and it is much more reactive than the initial carboxylic acid. 
This intermediate is then intercepted by the alcohol (2.34), which forms the urea by-
product (2.38 with DCC and 2.41 with EDC) and the desired ester product 2.5u. Both 
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reactions are slow and generally require overnight stirring and can be low yielding. The 
EDC by-product 2.41 also dissolves into the water layer, which can be seen by TLC as it 
is UV active. Also, by removing an aliquot of the reaction before quenching, the DCC 
2.37 and EDC 2.40 adducts can be observed by 1H NMR. Because the adducts do not 
fully convert to product in reasonable times, this likely resulted in the low yields that 
were observed.  
 
Scheme 2.6 Complications using DCC or EDC coupling procedures 
Much higher yields were achieved on average using the acid chloride method, 
producing most esters in the mid 80% range. The acid chloride is produced by oxalyl 
chloride after stirring for 1 hour, followed by removal of volatiles and then the addition 
of the alcohol and amine base and stirring for an additional hour to generate the ester. 
Use of thionyl chloride generally required refluxing at 40 C for 1-3 hours and was used 
to make the aromatic carboxylic acids. Esters 2.5u, 2.5w, and 2.5x were the aromatic 
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substrates synthesized, and esters 2.5a-2.5s and 2.5v show an expanded substrate scope 
for non-aromatic esters. Esters 2.5e-g contain bulky groups in either the carbonyl or ether 
side. Other esters including 2.5c-d and 2.5s contain sensitive functional group such as 
halogens or tertiary amines, which will help to establish the parameters for the substrate 
scope. All products have been fully characterized by 1H and 13C NMR, as well as IR. 
 
2.4.2 Conversion of Esters to Acetals Using Non-Aromatic Esters 
The first step in the reduction of esters to ethers is to form the protected acetal 
intermediate 2.7. ReactIR was chosen to follow the loss of the carbonyl peak found at 
1728 cm-1 as these reactions are run at very cold temperatures to prevent the over 
reduction to alcohol (Figure 2.7). One non-aromatic ester (2.5a) was chosen for screening 
the reaction progress which included the UV active tolyl-ring and a long carbon chain for 
increased weight preventing evaporation of acetal and ether products. 
 
Figure 2.7 React IR surface of the reduction of non-aromatic ester 2.5a depicting the loss 
of the carbonyl stretch at 1728 cm-1 
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The intensity of the absorbance of the carbonyl peak, recorded in absorbance units 
(A.U.) decreased from 0.52 to 0.02 during the addition of DIBAL-H over a 10 minute 
period. DIBAL-H was added slowly at a rate of one drop every 5 seconds to prevent an 
increase in temperature of the reaction and subsequent over-reduction. This also ensured 
that the ReactIR would be able to gain clean spectra without error. It was found that 
complete reduction of ester 2.5a to the corresponding aluminum acetal intermediate 
occurred within the 10 minutes that it took to add DIBAL-H dropwise. Previous work by 
the Rychnovsky group, whom did not use ReactIR monitoring, allowed the reductions to 
stir for at least 30-45 minutes.46 ReactIR also allowed determination of the number of 
equivalents of DIBAL-H required to fully reduce the ester (for 2.5a it was found to be 1.2 
eq). This was verified by taking 1H NMR of the crude reaction after quenching and 
extraction. 
With the reduction determined, the next step was to screen several trimethylsilyl 
(TMS) reagents in which to capture the aluminate intermediate as the protected acetal 
2.42a. Table 2.1 shows a range of TMS-trapping reagents used in the screening process 
as well as any additives that might have aided in the trapping of the acetal intermediate.59 
TMSOTf was chosen due to the good triflate leaving group, however as shown in Table 
2.1, no acetal was produced. TMSCl along with an amine base was chosen due to its cost 
efficiency and the highest yielding example was in the presence of N-methylimidazole 
(69%).The presence of the amine base was to prevent the formation of HCl. TMS-
imidazole (TMS-imid) proved to be the ideal choice and additional base was not needed. 
Using three equivalents of TMS-imid at -78 C provided protected acetal 2.42a with 98% 
conversion. The acetal intermediate could be produced at lower equivalents of TMS-imid 
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(1.5, 2.0, and 2.5 of TMS-imid.), however, the crude NMR was not as clean and so 
required purification before moving onto the second step. A similar yield was achieved at 
a warmer temperature of -40 C (94%) which proves promising for industrial 
applications.  
Table 2.1 TMS trapping reagent screen where base additives used are indicated 
 
Entry Trapping Reagent Base Temperature (C) Crude Yield (%) 
1 TMSOTf ------ -78 ------ 
2 TMSCl pyridine -78 20 
3 TMSCl N-Me-imid -78 69 
4 TMS-imid ------ -78 98 
5 TMS-imid ------ -40 94 
6 TMS-imid ------ 0 32 
 
When compared to the Rychnovsky method, which uses acetic anhydride as the 
trapping reagent, TMS-imid significantly decreases the time required to form the 
protected acetal from 12-14 hours to 35 min. Shorter reaction times are very desirable 
since the reaction is carried out at -78 C using dry ice and acetone and requires either 
more expensive chillers to maintain the temperature or refilling the dry ice bath every few 
hours. Additionally, while column chromatography could be performed on TMS-acetal 
2.42a, it was more advantageous to carry the material through to the desired ether product 
without further purification, highlighting an additional benefit of TMS-imid. 
 An extensive substrate scope was conducted by using ReactIR to monitor the 
reduction of the ester and to determine the number of equivalencies of DIBAL-H 
necessary to achieve reduction to the acetal (Table 2.2). The scope includes esters with 
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alkyl groups (2.5a and 2.5b), halogens situated on either side of the ester (2.5c and 2.5d), 
a variety of bulky groups (2.5e-g), lactones (2.5h-j), as well as esters containing alkenes, 
alkynes, and benzyl substitutions on the ether side (2.5k-r). General observations of the 
reduction were noted regarding the functional groups within the scope. Largely, esters 
containing halogens (entry 3), or bulky side groups on either side of the ester (entry 5 - 
7), required a larger amount of the reducing agent. Additionally, the presence of a tertiary 
amine also required an additional excess of DIBAL-H while also decreasing the overall 
yield (entry 19). This is most likely due to the halogen (entry 3) and nitrogen (entry 19) 
interacting with DIBAL-H, requiring the increased equivalencies. Additionally, the 
bulkiness at the carbonyl group can obstruct hydride delivery and so additional DIBAL 
was necessary. Otherwise, all substrates converted to the TMS-acetal in excellent yields 
(81-99%) excluding entry 12 bearing the oxyallyl silane moiety (65%), entry 19 
containing the nitrogen substituent (27%), and entry 20 containing a phenoxy group (no 
acetal observed). 
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Table 2.2 Substrate scope for the synthesis of TMS-protected non-aromatic acetals 
 
Entry Substrate Ester DIBAL (eq) Crude (%) Product Acetal 
1 2.5a 
 
1.2 98 2.42a 
 
2 2.5b 
 
1.2 98 2.42b 
 
3 2.5c 
 
1.6 81 2.42c 
 
4 2.5d 
 
1.2 99 2.42d 
 
5 2.5e 
 
1.7 97 2.42e 
 
6 2.5f 
 
1.6 89 2.42f 
 
7 2.5g 
 
1.5 91 2.42g 
 
8 2.5h 
 
1.2 98 2.42h 
 
9 2.5i 
 
1.2 98 2.42i 
 
10 2.5j 
 
1.1 85 2.42j 
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11 2.5k 
 
1.2 95 2.42k 
 
12 2.5l 
 
1.2 65 2.42l 
 
14 2.5m 
 
1.2 92 2.42m 
 
15 2.5n 
 
1.2 91 2.42n 
 
16 2.5o 
 
1.2 93 2.42o 
 
17 2.5p 
 
1.2 98 2.42p 
 
18 2.5q 
 
1.2 95 2.42q 
 
19 2.5r 
 
1.6 27 2.42r 
 
20 2.5s 
 
1.2 0 2.42s 
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2.4.3 Conversion of Esters to Acetals Using Aromatic Esters 
A second goal is to apply this reductive conversion to aromatic esters which has 
not been demonstrated previously by the Rychnovsky group. Only two cases could be 
found that demonstrated success with aromatic esters. The first was by Nicolaou, who 
used the foul smelling Lawesson’s reagent to convert the ester to a thioester in the first 
step.40 The second was by Batey who utilized Rychnovsky’s method with a stabilized 
picolinic ester.61 
The conjugation with the aromatic ring weakens the π-bond in aromatic esters. 
While this allows for an easier reduction of aromatic esters to alcohols using nucleophilic 
hydride reagents such as DIBAL-H, it is also much more difficult to stop at the acetal 
intermediate. As with the non-aromatic ester model system, the aromatic ester 2.5u 
reduction was first monitored by ReactIR and can be seen in Figure 2.8. The carbonyl 
peak is observed at 1708 cm-1. The decrease in wavenumbers as compared to a non-
aromatic ester (1728 cm-1) can be attributed to the carbonyl group conjugation with the 
aromatic ring causing electrons to delocalize and decrease the double bond character.  
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Figure 2.8 ReactIR surface depicting the reduction of aromatic ester 2.5u by decrease of 
the carbonyl stretch at 1708 cm-1. 
 It was determined by ReactIR that the aromatic ester could be reduced in just 10 
minutes, same as with the non-aromatic ester. However, the aromatic ester required 2 
equivalents of DIBAL-H while the non-aromatic ester required only 1.2 equivalents. 
When crude products were observed by 1H NMR, only alcohol (over-reduction) and 
aldehyde (desired single reduction) were observed. The aromatic aluminate intermediate 
2.44 is considerably less stable and more susceptible to over-reduce to alcohol 2.45. 
 
Scheme 2.7 DIBAL-H reduction of aromatic ester 2.43. 
To be able to capture the protected acetal, TMS-imid was again chosen using the 
same conditions as for the non-aromatic ester substrate. The standard method of DIBAL-
H then TMS-imid did not provide any of the desired protected acetal product. Other 
iterations, such as having TMS-imid present before adding DIBAL, prevented complete 
reduction of the ester. It was found that to form the protected acetal product, a unique 
addition method was applied in which DIBAL-H and TMS-imid were added in 
alternating increments. First, 1.2 equivalents of DIBAL-H was added followed by 2.0 
equivalents of TMS-imid, then the remaining 0.8 equivalents of DIBAL-H was added 
followed by the remaining 1.0 equivalents of TMS-imid. This addition process allowed 
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for the formation of a small amount of the protected aromatic acetal 2.42u as identified 
by crude 1H NMR (11-16%, Table 2.3). 
The ratios of products were calculated from 1H NMR based on integration of the 
starting ester 2.5u, desired acetal product 2.42u, and the following potential side 
products: alcohol 2.45, aldehyde 2.46, and TMS-protected alcohol 2.47. To try to 
increase the yield, a solvent screen was performed (Table 2.3), which identified MTBE 
was the highest yielding solvent providing 19% of the desired acetal. Reaction times were 
increased from 30 minutes for the non-aromatic ester to 3-6 hours for the aromatic ester, 
which resulted in a slight increase in yield, but these were not always consistent. 
Unfortunately, a method could not be determined to make this a viable process. 
 
Table 2.3 Solvent screen for the reduction of aromatic ester 2.5u  
 
Entry Solvent Time Starting 
Materialb 
Aldehyde Alcohol and 
TMS-Prodc 
Product 
1 MTBE 3 21.0 1.8 60.6 16.4 
2 MTBE 6 21.5 0.6 58.1 19.8 
3 DCM 2 13.8 2.0 64.1 16.6 
4 DCM 4.5 11.4 10.0 67.1 11.4 
5 toluene 3 11.0 8.2 62.0 15.7 
6 toluene 6 4.1 12.4 69.0 14.5 
7 hexanes 2 10.4 0.8 80.0 8.8 
8 ACN 4 70.5 2.2 27.3 -- 
9 THF 3 100 -- -- -- 
10 -- 3 44.6 0.8 42.9 11.6 
Note: a) Added in the order of 1.2. eq DIBAL, 2 eq TMS-imid, 0.8 eq DIBAL, 1 eq TMS-imid. b) All amounts above are NMR yields 
based on the relative integration of the CH3 peaks. c) Ratio of the alcohol and the TMS protected acetal combined integrate together 
due to the overlapping of the peaks. 
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2.4.4 Reduction of the TMS-Protected Acetal to the Ether Product  
The second step of the reduction process to form the ether starting from the acetal 
has been accomplished successfully for the non-aromatic acetal model system only.62 The 
conditions used by Rychnovsky were initially followed since this step was not predicted 
to be as difficult, however, there are differences between acetal 2.42 and Rychnovsky’s 
acetal 2.12. 
 
Scheme 2.8 Two routes for Lewis acid complexion with the protected acetal 
As shown in Scheme 2.9, two routes are possible for the Lewis acid to complex 
with the protected acetal. If the Lewis acid complexes with the protected oxygen (O-X), it 
follows route A, forming oxonium 2.13 retaining both R1 and R2 to produce the desired 
ether product 2.10 and with the potential to produce aldehyde by-product 2.9. The 
production of aldehyde 2.9 is dependent on the reactivity of R2 and its ability to leave as a 
stabilized group from oxonium 2.13. The second route B occurs when the Lewis acid 
complexes with the ether oxygen bearing the R2 group, resulting in the formation of 
oxonium ion 2.51. This produces aldehyde 2.9 with the potential for over-reduction to 
alcohol 2.8. If the protecting group X is an electron withdrawing acetate group, as in 
Rychnovsky’s case, the more likely path is route B based on the electron density of the 
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oxygen binding, however an equilibrium with route A would still allow formation of 
ether 2.10. In this work, the TMS group is electron donating and so more likely to start 
with route A and bind the Lewis acid, however it may not break down to the oxonium as 
readily (not as good of a leaving group) and equilibrate with the undesired route B. 
Because of this ability of the protecting group to affect the direction of the Lewis acid 
binding, the choice of Lewis acid is key for optimizing this step.  
Initially the acetal was treated with Et3SiH at -78 C and then BF3·Et2O was 
added dropwise 10 minutes later as demonstrated by the Rychnovsky group. The reaction 
was monitored by TLC, which indicated complete conversion of the acetal in 1.25 hours. 
Using this method, the desired ether product was only isolated in 46% yield, with 
aldehyde accounting for the mass balance.  
With these initial results in hand, a screen of common Lewis acids and hydride 
sources was performed (Table 4). The use of Bu3SnH was chosen as a hydride source due 
to its increased reactivity compared to Et3SiH. Despite the increased reactivity, Bu3SnH 
was harder to remove by chromatography as both it and the ether are very non-polar, 
resulting in lower yields. TMSOTf was chosen as a Lewis acid due to the excellent 
triflate leaving group, increasing the reactivity. The optimal pairing was found using 2.5 
equivalents of Et3SiH and TMSOTf (entry 4) producing the desired ether product 2.10a 
in an 84% yield. This represents an overall two step yield of 79% from ester 2.5a. 
To see if yields could be improved further, a brief solvent screen was completed, 
which identified DCM as the best solvent giving an overall yield of 84%, followed 
closely by toluene with an 80% yield (Table 4). Although these yields are promising, it 
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was determined that product loss of the ether still occurred during solvent removal, even 
with the increased molecular weight, and therefore careful protocols were followed. 
Table 2.4 Lewis acid and hydride screen for the conversion of TMS-protected acetals to 
ethers.  
 
Entry Solvent Lewis acid Hydride Eqa Yield (%) 
1 DCM BF3·OEt2 Bu3SnH 2.5 59 
2 DCM TMSOTf Bu3SnH 2.5 47 
3 DCM BF3·OEt2 Et3SiH 2.5 46 
4 DCM TMSOTf Et3SiH 2.5 84 
5 DCM TMSOTf Et3SiH 1.2 50 
6 toluene TMSOTf Et3SiH 2.5 80 
7 hexanes TMSOTf Et3SiH 2.5 57 
8 THF TMSOTf Et3SiH 1.2 0 
Note: a) Number of equivalencies added to the reaction for both the Lewis acid and hydride source. 
 
After the development of the two-step reduction of esters to ethers for non-
aromatic esters was defined, the substrate scope screen was completed (Table 2.2, step 1; 
Table 2.5, step 2). This method works for alkyl (entry 1, 2, 5, and 7), halo (entry 3), and 
cyclic ethers (entry 8-9), which tend to convert in good yields. A few exceptions are 
when the halogen is on the carbonyl side (entry 4) or the ether is phenolic (entry 10), both 
resulting in no ether product. Bulky alkyl groups are tolerated on the ether oxygen (entry 
5), but not on the carbonyl side (entry 6). Terminal alkenes are tolerated with a decreased 
yield (entry 11-12) and alkynes to a lesser extent (entry 14-15). Benzyl groups on the 
ether side produced lower yields (entry 16). This is likely due to the loss of the benzyl 
group during oxonium ion formation. To further investigate this hypothesis, both electron 
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withdrawing and electron donating derivatives were utilized (entry 17 and 18 
respectively). As predicted the electron withdrawing group gave a similar yield to the 
benzyl group, and the electron donating group further stabilized the loss of the benzyl 
group giving no ether product. 
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Table 2.5 Substrate scope for the reduction of TMS-protected acetals to ethers  
 
Entry Substrate Acetal Yield (%) Substrate Ether 
1 2.42a 
 
84 2.10a 
 
2 2.42b 
 
82 2.10b 
 
3 2.42c 
 
94 2.10c 
 
4 2.42d 
 
0 2.10d 
 
5 2.42e 
 
73 2.10e 
 
6 2.42f 
 
0 2.10f 
 
7 2.42g 
 
59 2.10g 
 
8 2.42h 
 
59 2.10h 
 
9 2.42i 
 
80 2.10i 
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10 2.42j 
 
0 2.10j 
 
11 2.42k 
 
56 2.10k 
 
12 2.42l 
 
61 2.10l 
 
14 2.42m 
 
39 2.10m 
 
15 2.42n 
 
22 2.10n 
 
16 2.42o 
 
36 2.10o 
 
17 2.42p 
 
30 2.10p 
 
18 2.42q 
 
0 2.10q 
 
19 2.42r 
 
0 2.10r 
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Due to inconsistent yields, additives such as 2,6-di-tert-butylpyridine (DTBP) 
were added to counteract the presence of triflic acid, however this did not improve 
yields.49 Additionally on some of the lower yielding substrates (entry 14-18), it was 
determined that a symmetric ether was being produced. Symmetric ether 2.10b is most 
likely synthesized through the formation of undesired oxonium 2.55 (Scheme 2.9), which 
can be reduced to the silyl protected alcohol 2.56. Then 2.56 can couple with oxonium 
ion 2.55 to form di-silyl acetal 2.57. Acetal 2.57 then undergoes a TMS transfer to 
produce 2.58, which collapses to form oxonium ion 2.59. After hydride delivery, 
symmetric ether 2.10b is formed (Scheme 2.10). A similar synthetic route was published 
by Olah for the synthesis of symmetric and asymmetric ethers.63 The identity of 
symmetric ether 2.10b was confirmed by 1H NMR using an authentic sample prepared by 
this reductive conversion method (Table 2.2 entry 2; Table 2.5 entry 2).  
 
Scheme 2.9 Proposed mechanism for the formation of the symmetric ether byproduct 
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2.4.5 Bifurcation Determination of TMS-Acetal Conversion to Ethers 
While the formation of a variety of by-products was unexpected for this 
conversion, a better understanding of the energetics of Lewis acid complexation was 
sought using computational analysis. Bifurcated transition states are a common 
occurrence in organic chemistry where undesired by-products from two or more 
competing pathways are produced and can be determined through computational 
analysis.64  
Upon reconsideration of the two reactive pathways as seen in Scheme 2.8, the 
Lewis acid was replaced with TMS. While the preferred route A would require the TMS 
group to complex with the acetal oxygen, there is a potential for it to complex with the 
ether oxygen. Additionally, the TMS group can equilibrate between 2.60 and 2.62, 
creating a potential reaction bifurcation (Scheme 2.10). The bifurcation could lead to 
insight on why certain substrates were lower yielding. 
 
Scheme 2.10 Post transition state bifurcation to desired A and undesired B products 
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Work was completed to determine if there is an energetically favorable substrate-
based pathway for the conversion of TMS acetals to their ether counterparts. Structures 
were inputted using AMPAC software and transition states were calculated using 
Gaussian09 with the B3LYP/6-31G (d,p) level of theory. Initial computations have been 
calculated using the Mississippi Center for Supercomputing Research (MCSR), showing 
a bifurcation is present between 2.60 and 2.62, but due to the number of atoms present, 
the calculations took long to acquire. To speed up initial calculations, an acetal with 
methyl group on either side was used. Calculations were completed in a three-step 
process starting with the optimization of TMS-acetal 2.42 with the Lewis acid TMS+. 
This was then followed by a constrained optimization where the structures were frozen 
and the bond between TMS+ and either oxygen within TMS-acetal 2.42 were extended or 
shortened between 1.2 and 3.2 Å using a 0.1 Å step size. After the constrained 
optimizations were completed a 2-D scan was produced, plotting the step count versus 
the overall energy as shown in Figure 2.9 where the overall energy increases at step 10 
before decreasing.  
The structural geometry was then saved at the energy maximum and resubmitted 
to Gaussian09 to complete a transition state (TS) search. If the TS fell into a rotational 
TS, or local energy maximum, the distance between the TMS+ was adjusted and the TS 
was resubmitted. It was determined that for acetal 2.42 where R1=R2=Me there was a 
0.36 kcal difference in energy from 2.13 and 2.63, where 2.63 was lower in energy and 
thus more favorable. Work will continue in this endeavor with acetals 2.42a, c, e, h, l, n, 
o, and p to help better understand the correlation substrate and yield.  
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Figure 2.9: Geometry of starting TMS-acetal moving towards bifurcation  
 
2.4.6 One-Pot Conversion and Addition of Nucleophiles to the Oxonium Ion 
Intermediate 
With the conversion of esters to ethers established,62 efforts were made towards 
developing a one-pot method to convert esters to ethers as well as synthesizing α-
substituted ethers using carbon-based nucleophiles (Scheme 2.11). A one-pot reduction of 
esters to ethers has been completed before either starting with carboxylic acids,65 or 
through the use of stronger Lewis acids.44, 66 The goal is to adjust the current method 
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from a  two-pot to a one-pot conversion of esters to ethers by directly binding to and 
reducing aluminate acetal 2.67 (Scheme 2.11). 
 
Scheme 2.11 One-pot reduction with aluminate acetal intermediate 
As seen in Table 2.6, a variety of Lewis acids, hydride sources, and solvents were 
screened as well as the order of addition. However, it was difficult to isolate the desired 
ether product, and the formation of byproducts such as aldehyde 2.69, octanol 2.70, and 
the symmetric ether 2.10b became predominate as determined by 1H NMR. A solvent 
screen was performed (entries 1-4) and DCM was again found to be ideal (entry 4, 
producing 82% ether and 10% of symmetric ether 2.10b). For entries 1-4, the Lewis acid 
was added prior to the hydride source, using 2.5 equivalents of both. Changing the order 
of addition such that hydride was added first initially decreased the amount of ether 
(entry 5), but increasing reducing the hydride equivalents and increasing the Lewis acid 
worked well (81% ether, entry 6). Unfortunately, aldehyde 2.69 and ether 2.10b became 
more prevalent with this order of addition. Other Lewis acids were tried but did not yield 
any desired product. While the ratio of ether to other byproducts could be optimized 
based on crude 1H NMR to 82% (entry 4), the yield of isolated ether was low (44%). 
Disappointingly, a reliable one-pot method for the reduction of esters to ethers could not 
be realized. 
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Table 2.6 One-pot reduction of esters to ethers 
 
Entry Reagent 1 Eq Reagent 2 Eq Solvent 2.10aa 2.10a (Isolated)b 2.70a 2.69a 2.10ba 
1 TMSOTf 2.5 Et3SiH 2.5 Et2O 44% 26% -- 54% -- 
2 TMSOTf 2.5 Et3SiH 2.5 DCE 57% 55% -- -- 26% 
3 TMSOTf 2.5 Et3SiH 2.5 heptane 71% 57% -- 12% 18% 
4 TMSOTf 2.5 Et3SiH 2.5 DCM 82% 44% -- -- 10% 
5 Et3SiH 1.1 TMSOTf 5 DCM 16% -- 55% 29% -- 
6 Et3SiH 1.1 TMSOTf 5 DCM 81% -- -- 3% 16% 
7 Et3SiH 2.5 TMSOTf 5 DCM 74% -- 16% 2% 9% 
8 Et3SiH 2.5 TiCl4 2.5 DCM -- -- -- -- -- 
9 Et3SiH 2.5 SnCl4 2.5 DCM -- -- -- -- -- 
Note: a) Ratios were calculated through 1H NMR integrations using the CH3 peak unless otherwise noted. b) yield after column chromatography
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A variety of carbon nucleophiles such as allyl silane, silyl enol ethers, and 
dialkylzincs were screened with various Lewis acids in DCM in an attempt to isolate α-
substituted ethers (Scheme 2.12). Rychnovsky was successful in addition of allyl silane 
2.23 and a variety of vinyl enol ethers to acetoxy-protected acetals.49 Again, formation of 
by-products was fairly predominant. It was found that addition of the nucleophile after 
the Lewis acid was critical towards preventing the production of octanol 2.69 and 
aldehyde 2.70 (entry 3-4). Of note, TiCl4 and SnCl4 as the Lewis acid increased yields to 
82% and 86%, respectively, with the production of a separate by-product in each case 
(entries 5-6). Other chlorine-based Lewis acids were not able to produce the desired 
product or by-product (entries 7-8). This new by-product was determined to be alcohol 
2.72. It likely formed after the addition of allyl silane to oxonium ion 2.55, producing the 
alcohol 2.72 and/or the TMS-protected variant 2.73 (Scheme 2.13). This also confirms a 
new product as a result of an undesired pathway of breakdown of acetal 2.42. 
 
Scheme 2.12 Proposed mechanism for the synthesis of secondary allyl alcohols. 
At this point the one-pot method using either a hydride or carbon nucleophile do 
not prove to be viable, likely confirming why these have not been noted in the literature.  
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Table 2.7 One-pot nucleophile addition for the synthesis of α-substituted ethers 
 
Entry Reagent 1 Eq Reagent 2 Eq 2.73a 2.70a 2.69a 2.72a 2.10ba 
1  2.5 TMSOTf 5 50% 44% ------ 6% ------ 
2  2.5 ------ ------ ------ ------ ------ ------ ------ 
3 TMSOTf 2.5  2.5 19% 58% 17% 6% ------ 
4 TMSOTf 2.5  5 19% 56% 18% 7% ------ 
5  2.5 TiCl4 2.5 82% ------ ------ 18% ------ 
6  2.5 SnCl4 2.5 86% ------ ------ ------ 14% 
7  2.5 AlCl3 2.5 ------ ------ ------ ------ ------ 
8  2.5 ZnCl2 2.5 ------ ------ ------ ------ ------ 
Note: a) Ratios calculated by 1H NMR integration of the CH3 peaks. 
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2.5 Summary and Conclusion 
A successful method for the reduction of non-aromatic esters to ethers has been 
developed.62 Use of the React IR was paramount in decreasing reaction times of the ester 
to the acetal aluminate to only 10 minutes and was also crucial in determining the amount 
of reducing agent necessary for complete reduction. A screen of trapping reagents 
identified TMS-imidazole as the ideal reagent, which led to complete reaction times of 45 
minutes, a significant decrease to current literature times by almost 90%. This drastic 
decrease in reaction times is crucial especially for industrial synthesis, along with the fact 
that the reduction worked at -40 C. Formation and work up of the protected acetal 
intermediate produced clean 1H NMR spectra and no additional purification was needed, 
allowing material to be carried through to the ether directly.  
 It was also determined that aromatic esters completely reduced within 10 minutes 
after the addition of reducing agent, however, a unique addition along with trapping 
reagent was needed and unfortunately only small amounts of product could be formed. 
As hydride reduction of aromatic esters to ethers has not been demonstrated within the 
literature as a general method, this result is promising, and yields can likely be increased 
through an understanding of acetal complexation to Lewis acids with computational 
analysis.  
A simple screening of Lewis acids and hydride sources led to the discovery that 
TMSOTf and Et3SiH optimized the production of the desired ether product, in moderate 
to excellent yields in a total reaction time of 1.25 hours. Esters that can be submitted to 
this reductive method include alkyl, halogenated, cyclic, and those that contain bulky 
substituents on the ether side. Alkene and alkyne groups can also be submitted to this 
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method at reduced yields. Substitution of the hydride with different nucleophiles has not 
been realized at this point with the current method but would provide a way to access 
challenging α-substituted ethers if it were successful. An ultimate goal would be the 
development of a one-pot reductive alkylation of esters. 
 
2.6 Experimental 
2.6.1 General Methods 
2.6.1.1 Experimental Techniques 
Unless otherwise noted, all reactions were carried out using flame-dried glassware 
and standard syringe, cannula, and septa techniques when necessary.67 Tetrahydrofuran 
(THF), diethyl ether (Et2O), hexanes, dichloromethane (DCM), and toluene were dried by 
passage through a column of activated alumina on an mBraun solvent purification 
system.68 Triethylamine (TEA), N,N-dimethylformamide (DMF), and acetonitrile (ACN) 
were dried by passage through a column of activated alumina on an Innovative 
Technologies system. Trimethylsilyl chloride and Hunig’s base were distilled from 
calcium hydride under argon. Pyridine was distilled from potassium hydroxide under 
nitrogen. Analytical thin layer chromatography was performed using Sorbent 
Technologies 250 m glass-backed UV254 silica gel plates. The plates were first 
visualized by fluorescence upon 254 nm irradiation then by iodine chamber. The plates 
were then dipped in one of the following stains followed by heating: p-anisaldehyde, 
phosphomolybdic acid, vanillin, ceric ammonium molybdate, potassium iodoplatinate, 
ninhydrin or bromocresol green. Flash column chromatography was performed using 
Sorbent Technologies 40-63 µm, pore size 60 Å silica gel with solvent systems indicated. 
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Solvent removal was achieved using a Buchi R3 rotary evaporator with a V900 
diaphragm pump (~10 mmHg).  All yields refer to isolated material that is 
chromatographically (TLC or HPLC) and spectroscopically (1H NMR) homogenous.   
 
2.6.1.2 Characterization 
All melting points were taken with a Thomas Hoover melting point apparatus and 
are uncorrected. Infrared spectra were recorded on a Nicolet Nexus 470 FTIR 
spectrometer as neat liquids, oils, solids or as thin films formed from evaporation of 
NMR solvent over the ATR plate. High-resolution mass spectra were recorded at the Old 
Dominion University College of Science Major Instrumentation Center (COSMIC) on a 
Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source. 
 
2.6.1.3 NMR Parameters 
Proton nuclear magnetic resonance spectra were recorded on a Bruker UltraShield 
Plus 400 MHz spectrometer and are reported in parts per million from internal 
chloroform (7.26 ppm), methanol (3.35, 4.78 ppm), benzene (7.26 ppm), or 
dimethylsulfoxide (2.49 ppm) on the  scale and are reported as follows: chemical shift 
[multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, qu=quintet, m=multiplet, or 
derivatives thereof), coupling constant(s) in hertz, integration, interpretation].69 13C NMR 
data were recorded on a Bruker UltraShield Plus 100 MHz spectrometer and are reported 
as follows: chemical shift (multiplicity as determined from DEPT (CH, CH3 up and CH2 
down and/or HSQC experiments). 
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2.6.2 Synthesis of Intermediates 
General Method A for the Synthesis of Non-Aromatic Esters (2.5a-s, u) 
Carboxylic acid (1.0 eq) was added to a 100 mL, flame dried, round bottom flask and 
purged under N2 before anhydrous DCM (0.2 M) was added. Alcohol (1.1 eq) was added 
followed by either DCC or EDC (1.1 eq) and DMAP (0.5 eq). The reaction was then left 
to stir until complete conversion was observed by TLC.  
• When using DCC as the coupling agent the reaction mixture was filtered through 
Celite® and then added to distilled water before being extracted three times with 
DCM.  
• When using EDC as the coupling agent the reaction mixture was concentrated in 
vacuo and the remaining oil was taken up into distilled water and extracted three 
times with EtOAc. 
The combined organic layers were dried over Na2SO4, filtered, and concentrated in 
vacuo. Column chromatography - SiO2 using EtOAc/hexanes.  
 
General Method B for the Synthesis of Non-Aromatic Esters (2.5a-s, u) 
Carboxylic acid (1.0 eq) was placed in a 25 mL, flame dried, round bottom flask, and 
purged under N2 before being dissolved in DCM (1.0 M). Two drops of DMF were added 
to the reaction before oxalyl chloride (1.1 eq) was added dropwise via syringe. The 
reaction stirred for 1 hour before the solvent and excess oxalyl chloride was removed in 
vacuo. The flask was then purged under N2 again before alcohol (3.5 eq) was added 
followed by pyridine (4.8 eq) dropwise via syringe. The reaction stirred at RT until 
completion as monitored by TLC. The reaction was quenched with saturated aqueous 
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sodium bicarbonate and taken up in DCM. The aqueous layer was extracted three times 
with DCM. The organic layers were combined, dried over Na2SO4, filtered through 
Celite®, and concentrated in vacuo. Column chromatography – SiO2 with 
EtOAc/hexanes. 
 
General Method C for the Synthesis of Aromatic Esters (2.5t, u, v) 
Carboxylic acid (1.0 eq) was added to a 25 mL flame dried, round bottom flask and 
purged under N2 before being dissolved in DCM (1.0 M). Two drops of DMF were added 
to the reaction before thionyl chloride (1.1 eq) was added dropwise via syringe. The 
reaction stirred for 1 hour at 40 C before the solvent and excess thionyl chloride was 
removed in vacuo. The flask was then purged under N2 again before alcohol (3.5 eq) was 
added followed by pyridine (4.8 eq) dropwise via syringe. The reaction stirred at RT until 
completion as monitored by TLC. The reaction was quenched with saturated aqueous 
sodium bicarbonate and taken up in DCM. The aqueous layer was extracted three times 
with DCM. The organic layers were combined, dried over Na2SO4, filtered through 
Celite®, and concentrated in vacuo. Column chromatography – SiO2 with 
EtOAc/hexanes. 
 
General Method D for the Synthesis of TMS-Protected Acetals (2.42a-2.42s) 
Ester (1.0 eq) was added to a 10 mL, flame dried, round bottom flask and purged under 
N2 before being dissolved in DCM (1.0 M). The ReactIR was prepared by cleaning the 
probe with MeOH and taking a background spectrum. A solvent reference for DCM and 
hexanes was also loaded into the experiment file. The flask was attached to the ReactIR 
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and spectra were set to collect every minute. The reaction was placed in a dewar and 
cooled to -78 C with dry ice and acetone. After cooling for 15-30 minutes, DIBAL-H 
(1.2 eq.) was added dropwise over a period of 10 minutes. The reduction of the carbonyl 
peak was monitored by ReactIR, and the amount of DIBAL-H was increased by 
increments of 0.3 equivalents if complete reduction was not achieved within 10 minutes. 
TMS-imid (3 eq.) was added dropwise and the reaction stirred for 30 minutes before 
being quenched with saturated aqueous NH4Cl. The quenched solution was warmed to 
room temperature and then DCM was added as well as Rochelle salts to assist with 
emulsions. The aqueous layer was extracted 3 times with DCM. The combined organic 
layers were collected and dried over Na2SO4, filtered, and concentrated in vacuo using 
rotovap. The acetal product was carried on without further purification.  
 
General Method E for the Synthesis of Ethers (2.10a-2.10q) 
The acetal (from General Method D) was added to flame dried 10 mL round bottom flask 
that was purged with N2 before being dissolved in DCM (1.0 M). The reaction was 
placed in a dewar before being cooled to -78 C using a dry ice and acetone bath. After 
cooling for 15-30 minutes, Et3SiH (2.5 eq) was added dropwise via syringe. The reaction 
stirred for 10 minutes before adding TMSOTf (2.5 eq) dropwise via syringe. The reaction 
stirred for 1.25 hours and was monitored by TLC. The reaction was quenched with 
saturated aqueous NaHCO3 and allowed to warm to RT before being added to DCM. The 
aqueous layer was extracted three times with DCM and the combined organic layers were 
dried over Na2SO4, filtered, and concentrated in vacuo. Column chromatography - SiO2 
with ether/hexanes. 
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Octyl 2-(p-tolyl)acetate (2.5a): According to 
general method B, p-tolyl acetic acid (3.00 g, 20.0 
mmol) was converted to ester 2.5a. The second step was complete in 1 hour as monitored 
by TLC. Column chromatography (SiO2, 10 – 20% EtOAc/hex) yielded a pale-yellow oil; 
yield 4.9g, 93%; Rf = 0.36 (10% EtOAc/hex); IR (thin film) 2954, 2924, 1855, 1735, 
1252, 1151 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.15 (m, 4H) δ 4.07 (t, J = 6.72 Hz, 2H), 
δ 3.57 (s, 2H), δ 2.33 (s, 3H), δ 1.60 (p, J = 7.08, 2H), δ 1.38 (m, 10H), δ 0.88 (t, J = 
6.76, 3H); 13C NMR (100 MHz, CDCl3) :172.0 (s), 136.7 (s), 131.3 (s), 129.3 (d), 129.2 
(d), 65.1 (q), 41.2 (t), 31.9 (t), 31.0 (t), 29.3 (t), 28.7 (t), 26.0 (t), 22.8 (t), 21.2 (q), 14.2 
(q).  
 4-Methylphenethyl 2-(p-tolyl)acetate (2.5b): 
According to general method B, p-tolyl acetic acid 
(0.50 g, 3.34 mmol) was converted to ester 2.5b. The reaction was complete in 1.5 hours 
as monitored by TLC. Column chromatography (SiO2, 5-10-20-40% EtOAc/hex) yielded 
a pale yellow oil; yield 0.78 g, 88%; Rf  = 0.59 (20% EtOAc/hex);IR (thin film) 2952, 
2917, 1730, 1136 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.06 (d, J = 8.0 Hz, 4H), 7.03 (d, 
J = 8.0 Hz, 4H), 4.25 (t, J = 7.0 Hz, 2H), 3.55 (s, 2H), 2.86 (t, J = 7.0 Hz, 2H), 2.33 (s, 
3H), 2.32 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.7 (s), 136.6 (s), 136.0 (s), 134.7 
(s), 131.0 (s), 129.3 (d), 129.2 (d, 2 peaks), 128.8 (d), 65.5 (t), 41.0 (t), 34.6 (t), 21.1 (q), 
21.0 (q). 
2-Chloroethyl 2-phenylacetate (2.5c). Using general method A, 
phenylacetic acid (1.00 g, 5.03 mmol) was converted to ester 
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2.5c. Column chromatography (SiO2 5-10-20% EtOAc/hex) yielded a colorless liquid; 
yield 0.83 g, 57%. Characterization data can be found at the provided reference.70  
2-Chloroethyl 2-phenylacetate (2.5d). Using general method 
A, phenylacetic acid (1.00 g, 5.03 mmol) was converted to ester 
2.5d. Column chromatography (SiO2 5-10-20% EtOAc/hex) yielded a colorless liquid; 
yield 1.67 g, 79%. Characterization data can be found at the provided reference.70  
 t-Butyl-3-phenylpropanoate (2.5e): According to general 
method B, phenyl propanoic acid (1.00 g, 6.66 mmol) was 
converted to ester 2.5e. The second step was completed in 1 hour as monitored by TLC. 
Column chromatography (SiO2, 1-5-10-20% EtOAc/hex) yielded a pale yellow oil; yield 
0.67 g, 49%. Characterization data found at the provided reference.  
Phenethyl pivalate (2.5f) 71: According to general method B, 
pivalic acid (2.00 g, 19.6 mmol) was converted to ester 2.5f. The 
second step was completed in 1 hour as monitored by TLC. Column chromatography 
(SiO2, 1-5-10-20% EtOAc/hex) yielded a pale yellow oil; yield 1.55 g, 39%. 
Characterization data can be found at the reference provided. 72 
Cyclohexyl 2-phenylacetate (2.5g): Using general method A, 
phenylacetic acid (2.00 g, 14.7 mmol) was converted to ester 
2.5g. Column chromatography (SiO2 5-10-20% EtOAc/hex) yielded a pale yellow oil; 
yield 2.65 g, 83%. Characterization data can be found at the provided reference.73 
Phenyl pent-4-enoate (2.5k). Using general method A, 
pent-4-enoic acid (1.0 ml, 8.09 mmol) was converted to ester 
2.5k. Column chromatography (SiO2 5-10-20% EtOAc/hex) yielded a colorless liquid; 
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yield 0.82 g, 55%; Rf = 0.60 (20% EtOAc/hex); IR (thin film) 3100, 1732, 1243, 1165, 
698 cm-1; 1H NMR (400 MHz, CDCl3) δ: 7.35-7.20 (m, 5H), 5.79 (ddt, J = 16.7, 10.3, 6.2 
Hz, 1H), 5.07-4.98 (m, 2H), 4.31 (t, J = 7.2 Hz, 2H), 2.95 (t, J = 6.8 Hz, 2H), 2.43-2.34 
(m, 4H); 13C NMR (100 MHz, CDCl3) : 172.9 (s), 137.8 (s), 136.7 (d), 128.9 (d), 128.4 
(d), 126.5 (d), 115.4 (t), 64.8 (t), 35.1 (t), 33.5 (t), 28.8 (t); HRMS (ESI): Exact mass 
calculated for C13H16O2Na [M + Na]
+ 227.104251, found 227.104387. 
 1-(Trimethylsilyl)allyl 2-(p-tolyl)acetate (2.5l): According to 
general method B, p-tolyl acetic acid (1.00 g, 6.66 mmol) was 
converted to ester 2.5l. The reaction was complete in 3 hours as monitored by TLC. 
Column chromatography (SiO2, 5-10-20-40% EtOAc/hex) yielded a colorless oil; yield 
2.65 g, 75%; Rf  = 0.43 (10% EtOAc/hex); IR (thin film) 2957, 1731, 1633 cm
-1; 1H NMR 
(CDCl3, 400 MHz) δ: 7.19 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 2H), 5.84 (ddd, J = 
16.8, 10.9, 5.7 Hz, 1H), 5.20 (dt, J = 5.7, 1.9 Hz, 1H), 4.94 (dt, J = 11.0, 1.6 Hz, 1H), 
4.90 (dt, J = 16.8, 1.6 Hz, 1H), 3.63 (s, 2H), 2.34 (s, 3H), 0.00 (s, 9H); 13C NMR (CDCl3, 
100 MHz) δ: 171.3 (s), 136.6 (s), 134.8 (d), 131.2 (s), 129.4 (d), 129.2 (d), 111.3 (t), 70.9 
(d), 41.3 (t), 21.1 (q), ‒4.08 (q). 
Oct-3-yn-1-yl 2-(p-tolyl)acetate (2.5m): According 
to general method B, p-tolyl acetic acid (2.00 g, 13.3 
mmol) was converted to ester 2.5m. The reaction stirred overnight and was monitored by 
TLC. Column chromatography (SiO2, 5-10-20-40% EtOAc/hex) yielded a yellow oil; 
yield 3.22 g, 93%; Rf  = 0.50 (10% EtOAc/hex); IR (thin film) 2930, 2957, 1737, 1137 
cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.20 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 
4.18 (t, J = 6.2 Hz, 2H), 3.61 (s, 2H), 2.50 (tt, J = 7.0, 2.3 Hz, 2H), 2.36 (s, 3H), 2.16 (tt, 
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6.7, 2.3 Hz, 2H), 1.46 (m, 4H), 0.95 (t, 3H). 13C NMR (CDCl3, 100 MHz) δ: 171.5 (s), 
136.6 (s), 130.9 (s), 129.2 (d), 129.1 (d) 82.0 (s), 75.4 (s), 6.32 (t), 40.8 (t), 31.0 (t), 21.9 
(t), 21.0 (q), 19.2 (t), 18.4 (t), 13.6 (q). 
Oct-2-yn-1-yl 2-(p-tolyl)acetate (2.5n): According to 
general method B p-tolyl acetic acid (2.0 g, 13.3 mmol) 
was converted to ester 2.5n. The reaction was complete in 18 hours as monitored by 
TLC. Column chromatography (SiO2, 5-10-20-40% EtOAc/hex) yielded a colorless oil; 
yield 2.91 g, 85% Rf  = 0.50 (10% EtOAc/hex); IR (thin film) 2930, 2860, 2236, 1740 
cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.23 (d, J =  8.1 Hz, 2H), 7.17 (d, J = 8.1 Hz, 2H), 
4.73 (t, J = 2.2 Hz, 2H), 3.66 (s, 2H), 2.38 (s, 3H), 2.26 (tt, J = 7.1, 2.2 Hz, 2H), 1.56 (p, 
J = 7.1 Hz, 2H), 1.38 (m, 4H), 0.97  (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ: 
171.1 (s), 136.7 (s), 130.7 (s), 129.3 (d), 129.2 (d), 87.8 (s), 74.0 (s), 53.2 (t), 40.65 (t), 
31.05 (t), 28.2 (t), 22.2 (t), 21.1 (q), 18.7 (t), 14.0 (q)  
 Benzyl 2-(p-tolyl)acetate (2.5o): According to general 
method B, p-tolyl acetic acid (2.0 g, 13.3 mmol) was 
converted to ester 2.5o. The second step stirred overnight as monitored by TLC. Column 
chromatography (SiO2 3-6% EtOAc/hex) yielded a yellow oil; yield 2.28 g, 71%. 
Characterization data can be found at the provided reference.74 
 4-(Trifluoromethyl)benzyl 2-(p-tolyl)acetate (2.5p): 
According to general method B p-tolyl acetic acid (2.0 
g, 13.3 mmol) was converted to ester 2.5p. The 
reaction ran over night as was monitored by TLC. Column chromatography (SiO2, 5-10-
20-40% EtOAc/hex) yielded a pale yellow solid; yield 3.74 g, 91%; mp 45-47 C; Rf  = 
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0.43 (10% EtOAc/hex); IR (thin film) 1726 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.59 (d, 
J = 8.1 Hz, 2H), 7.39 (d, J = 8.1 Hz, 2H), 7.17 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.2 Hz, 
2H), 5.17 (s, 2H), 3.65 (s, 2H), 2.34 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.4 (s), 
139.9 (s), 139.8 (s), 136.9 (s), 136.6 (s), 130.6 (s), 129.3 (d), 129.1 (d), 128.0 (d), 125.5 
(q, J = 3.8 Hz)*, 65.5 (t), 40.9 (t), 21.1 (q). *Due to C-F splitting 
4-Methoxybenzyl 2-(p-tolyl)acetate (2.5q): 
According to general method B, p-tolyl acetic acid 
(2.00 g, 1.3 mmol) was converted to ester 2.5q. The 
reaction was complete in 2 hours as monitored by TLC. It was purified on a Combiflash 
using a linear gradient of EtOAc/hex (0 to 100%) to yield a yellow oil; yield 3.02 g, 84%; 
Rf  = 0.33 (10% EtOAc/hex); IR (thin film) 1732 cm
-1; 1H NMR (CDCl3, 400 MHz) δ: 
7.26 (m, 2H), 7.15 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 6.87 (m, 2H), 5.05 (s, 
2H), 3.80 (s, 3H), 3.60 (s, 2H), 2.33 (s, 3H). 13C NMR (CDCl3, 100 MHz) δ: 171.7 (s), 
159.6 (s), 136.7 (s), 130.9 (s), 130.0 (d), 129.3 (d), 129.2 (d), 128.1 (s), 113.9 (d), 66.4 
(t), 55.3 (q), 40.9 (t), 21.1 (q). 
 2-(Dimethylamino)ethyl 2-(p-tolyl)acetate (2.5r): 
According to general method B, p-tolyl acetic acid (2.00 g, 
13.3 mmol) was converted to ester 2.5r. The reaction stirred overnight for 18 hrs. It was 
purified on a Combiflash using a linear gradient of EtOAc/hex (0 to 100%) to furnish a 
yellow oil; Yield 1.32 g, 45%; Rf  = 0.16 (50% EtOAc/hex); IR (thin film) 1732 cm
-1; 1H 
NMR (CDCl3, 400 MHz) δ: 7.14 (m, 4H), 4.18 (t, J = 5.8 Hz, 2H), 3.60 (s, 2H), 2.26 (s, 
6H), 2.55 (t, J = 5.8 Hz, 2H), 2.32 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.9 (s), 
136.6 (s), 130.9 (s), 129.2 (d), 129.1 (d), 62.6 (t), 57.7 (t), 45.7 (q), 40.8 (t), 21.1 (q). 
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 p-Tolyl 2-(p-tolyl)acetate (2.5s): According to general 
method B, p-tolyl acetic acid (1.05 g, 4.37 mmol) was 
converted to ester 2.5s. The reaction stirred overnight and was monitored by TLC. 
Column chromatography (SiO2, 8% EtOAc/hex) yielded a white solid; yield 41%; mp 38-
43 C Rf  = 0.29 (10% EtOAc/hex); IR (thin film) 3026, 2918, 1758, 1119 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ: 7.27 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.4 
Hz, 2H), 6.93 (d, J = 8.4 Hz, 2H), 3.81 (s, 2H), 2.36 (s, 3H), 2.33 (s, 3H); 13C NMR 
(CDCl3, 100 MHz) δ: 170.4 (s), 148.5 (s), 136.9 (s), 135.4 (s), 130.5 (s), 129.9 (s), 129.4 
(s), 129.2 (s), 121.1 (s), 41.0 (t), 21.1 (q), 20.9 (q).  
 Allyl 4-fluorobenzoate (2.5t). Using general method A, 4-
fluorobenzoic acid (1.03 g, 7.35 mmol) was converted to ester 
2.5t. Column chromatography (SiO2 5-10-20% EtOAc/hex) yielded a pale-yellow oil; 
yield 0.89 g, 67%; Rf = 0.59 (20% EtOAc/hexanes); IR (thin film) 1719, 1601, 1263, 765 
cm-1; 1H NMR (400 MHz, CDCl3) δ: 8.07 (dddd, J = 2.8 Hz, 2H), 7.14-7.07 (m, 2H), 
6.03 (ddt, J = 17.2, 10.8, 5.6 Hz, 1H), 5.4 (dq, J = 17.2, 1.6 Hz, 1H), 5.29 (dq, J = 10.4, 
1.2 Hz, 1H), 4.81 (dt, J = 5.6, 1.6 Hz, 2H); 13C NMR (100 MHz, CDCl3) : 166.3 (d, J = 
255 Hz)*, 164.5 (s), 132.2 (d, J = 9.4 Hz)*, 132.10 (d), 126.4 (d, J = 2.9 Hz)*, 118.4 (t), 
115.5 (d, J = 22.4 Hz)*, 65.6 (t). *Due to C-F splitting 
Isopropyl 2-(p-tolyl)acetate (2.5u) According to general method 
B, p-tolylacetic acid (3.93 g, 26.2 mmol) was converted to ester 
2.5u. The second step was completed in 45 minutes as monitored by TLC. Column 
chromatography (SiO2, 1-2.5-5-10% EtOAc/hex) yielded a pale yellow oil; yield 4.23 g, 
83%; Rf = 0.57 (20% EtOAc/hex);IR (thin film) 2979, 2934, 1727, 1144, 1105 cm
-1. 1H 
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NMR (400 MHz, CDCl3) δ: 7.15 (m, 4H), 5.00 (m, J = 6.2 Hz, 1H), 3.53 (s, 2H), 2.32 (s, 
3H), 1.22 (d, J = 6.24 Hz, 6H). 13C NMR (100 MHz, CDCl3) : 171.5 (s), 136.7 (s), 131.4 
(s), 129.3 (d), 129.2 (d), 68.2 (d), 41.5 (t), 21.9 (q), 21.2 (q). 
 Isopropyl 4-methylbenzoate (2.5v): Using general method 
A, 4-methylbenzoic acid (1.70 g, 12.5 mmol) was converted to ester 
2.5v. Column chromatography (SiO2 5-10-20% EtOAc/hex) yielded a colorless oil; yield 
1.00 g, 58%. Characterization data can be found at the provided reference.75 
 Octyl 4-methylbenzoate (2.5w) According to 
general method C, p-toluic acid (2.00 g, 14.7 mmol) 
in DCM (9.8 mL) was converted to ester 2.5w. The second step stirred overnight for 20 
hours as monitored by TLC. Column chromatography (SiO2, 5–10% EtOAc/hex) yielded 
a pale yellow oil; yield 3.39 g, 93%; Rf = 0.69 (EtOAc/hex); IR cm
-1 (thin film): 2963, 
1730 cm-1; 1H NMR (400 MHz, CDCl3) δ: 7.93 (dt, J = 8.4, 1.9 Hz, 2H), δ 7.23 (m, 2H), 
δ 4.29 (t, J = 6.7 Hz, 2H), δ 2.41 (s, 3H), δ 1.76 (p, J = 6.8, 2H) δ 1.32 (m, 10H), δ 0.88 
(t, J = 6.8 Hz, 3H) 13C NMR (100 MHz, CDCl3) :166.7 (s), 143.34 (s), 129.54 (s), 
128.99 (d), 127.79 (d), 64.91 (t), 31.79 (t), 29.71 (t), 28.74 (t), 26.05 (t), 22.64 (t), 21.59 
(q),14.07 (q); MS: m/z (%) = 248 (6.1) [M+ ]. 
(E)-Phenethyl but-2-enoate (2.5x): (E)-but-2-enoic acid (1.00 
g, 11.6 mmol) was converted to ester 2.5x. The second step of 
the reaction was complete in 1 hour as monitored by TLC. Column chromatography 
(SiO2 5-10-20% EtOAc/hex) provided a pale yellow liquid; yield 1.90 g, 86%. 
Characterization data can be found at the provided reference.76 
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 4-Methoxyphenyl-3-butenoate (2.5aa) According to general 
method B, vinyl acetic acid (1.0 g, 11.6 mmol) was converted 
to ester 2.5aa. The reaction was completed in 16 hours as monitored by TLC. Column 
chromatography (SiO2, 1–2.5–5–10% EtOAc/hex) yielded a pale yellow oil; yield 0.79 g, 
35%; Rf = 0.46 (20% EtOAc/hex). IR (thin film)
 2935, 2837, 1753, 1504, 1245, 1191, 
1135 cm-1. 1H NMR (400 MHz, CDCl3) δ: 7.01 (td, J = 5.9, 3.6 Hz, 2H), δ 6.88 (td, J = 
5.8, 3.5 Hz, 2H), δ 6.03 (ddt, J = 17.1, 10.2, 7.0 Hz, 1H), δ 5.28 (dd, J = 13.4, 1.4 Hz, 
1H), δ 5.25 (dd, J = 6.3, 1.2 Hz, 1H), δ 3.80 (s, 3H), δ 3.32 (dt, J = 6.9, 1.4 Hz, 2H). 13C 
NMR (100 MHz, CDCl3) :170.5 (s), 157.4 (s), 144.3 (s), 129.9 (d), 122.4 (d), 119.3 (d), 
114.6 (t), 55.7 (q), 39.2 (t). 
 Pent-4-yn-1-yl 2-chloroacetate (2.5ab) According to general 
method B, 2-chloroacetic acid (0.50 g, 5.3 mmol) was converted 
to ester 2.5ab. The reaction stirred for 19 hrs as monitored by TLC. Column 
chromatography (SiO2, 5-10-20-40% EtOAc/hex) yielded a colorless oil; yield 0.30 g, 
35.8%; Rf = 0.42 (20% EtOAc/hex); IR (thin film) 3294, 2961, 1738, 1171, 1026, 640 
cm-1. 1H NMR (400 MHz, CDCl3) δ: 4.31 (t, J = 6.3 Hz, 2H), δ 4.06 (s, 2H) δ 2.31 (td, J 
= 7.0, 2.6 Hz, 2H), δ 1.92 (t, J = 2.7 Hz, 1H), δ 1.90 (p, J = 6.4 Hz, 2H). 13C NMR (100 
MHz, CDCl3) : 197.4 (s), 82.8 (s), 69.4 (d), 64.8 (t), 41.0 (t), 27.5 (t), 15.2 (t).  
 Benzyl oleate (2.5ac) 
According to general method 
B oleoyl chloride (549 µL, 1.66 mmol) was converted to ester 2.5ac by adding alcohol 
and pyridine only. The reaction was complete in  4.5 hours as monitored by TLC. 
Column chromatography (SiO2, 5-10-20-40% EtOAc/hex) yielded a pale yellow oil; 
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yield 0.52 g, 84%; Rf = 0.70 (20% EtOAc/hex); IR (thin film) 2922, 2852, 1737, 1455, 
1212, 1161, 732, 695 cm-1. 1H NMR (400 MHz, CDCl3) δ 7.35 ppm, (m, 5H); δ 5.34 
ppm, (m, 2H); δ 5.11 ppm, (s, 1H); δ 2.35 ppm, (t, J = 7.48Hz, 2H); δ 2.00 ppm, (m, 4H); 
δ 1.64 ppm, (m, 2H); δ 1.28 ppm, (m, 14H); δ 0.88 ppm, (m, 5H). 13C NMR (100 MHz, 
CDCl3) : 173.8 (s), 136.3 (d), 130.2 (s), 129.9 (d), 128.7 (d), 128.3 (d), 66.2 (t), 34.5 (t), 
32.1 (t), 30.0 (t), 29.9 (t), 29.7 (t), 29.5 (t), 29.3 (t), 29.2 (t), 27.4 (t), 27.3 (t), 25.1 (t), 
22.9 (t), 14.3 (q). 
 1-Methyl-4-(2-(octyloxy)ethyl)benzene (2.10a) 
According to general methods D/E, ester 2.5a (100 
mg, 4.03 mmol) was converted to ether 2.10a using 1.2 equivalents of DIBAL-H. 
Column chromatography (SiO2, 1-5-10 Et2O/hex) yielded a colorless oil; yield 62.1mg, 
84%; Rf = 0.31 (10% Et2O/hex).
 1H NMR (400 MHz, CDCl3) δ 7.11 (m, 4H); δ 3.60 (t, J 
= 7.4 Hz, 2H); δ 3.42 (t, J = 6.7 Hz, 2H); δ 2.85 (t, J = 7.4 Hz, 2H); δ 2.32 (s, 3H); δ 1.56 
(m, 2H); δ 1.28 (m, 10H); δ 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (100 MHz, CDCl3) ppm: 
136.1 (s), 135.7 (s), 129.2 (d), 128.0 (d), 72.2 (t), 71.3 (t), 36.1 (t), 32.0 (t), 29.9 (t), 29.6 
(t), 29.4 (t), 26.4 (t), 22.9 (t), 21.2 (q), 14.3 (q). 
4,4'-(Oxybis(ethane-2,1-diyl))bis(methylbenzene) 
(2.10b): According to general methods D/E ester 2.5b 
(335 mg, 13.2 mmol) was converted to ether 2.10b using 1.2 equivalents of DIBAL. 
Column chromatography (SiO2, 1-5-10 Et2O/hex) yielded a pale yellow oil; yield 0.20 g, 
82%; Rf  = 0.51 (10% EtOAc/hex); 
1H NMR (CDCl3, 400 MHz) δ: 7.09 (s, 8H), 3.62 (t, J 
= 7.3 Hz, 4H), 2.84 (t, J = 7.3 Hz, 4H), 2.32 (s, 6H).  
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2-(2-Chloroethoxy)ethyl)benzene (2.10c): According to 
general methods D/E ester 2.5c (410 mg, 1.50 mmol)was 
converted to ether 2.10c using 1.2 equivalents of DIBAL. Column chromatography 
(SiO2, 1-5-10 Et2O/hex) yielded a colorless oil; yield 0.26 g, 94%; Rf  = 0.42 (10% 
EtOAc/hex);1H NMR (CDCl3, 400 MHz) δ: 7.20 (m, 5H), 3.63 (t, J = 7.2 Hz, 4H), 2.88 
(t, J = 7.2 Hz, 4H). 13C NMR (100 MHz, CDCl3) : 139.0 (s), 128.9 (d), 128.3 (d), 126.2 
(d), 71.9 (t), 36.3 (t). 
(3-(tert-Butoxy)propyl)benzene (2.10e): According to general 
methods D/E ester 2.5e (470 mg, 2.44 mmol)was converted to 
ether 2.10e using 1.7 equivalents of DIBAL. Column chromatography (SiO2, 1-5-10 
Et2O/hex) yielded a colorless oil; Yield 0.344 g, 73%; Rf  = 0.52 (10% EtOAc/hex); IR 
(thin film) 2972, 1197, 1081 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.15 (m, 5H), 3.29 (t, J 
= 6.5 Hz, 2H), 2.61 (t, J = 7.4 Hz, 2H), 1.81 (t, J = 6.5 Hz, 1H), 1.77 (t, J = 7.4 Hz, 1H), 
1.11 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 142.3 (s), 128.5 (d), 128.3 (d), 125.7 (d), 
72.6 (s), 60.8 (t), 32.5 (t), 32.1 (t), 27.6 (q). 
(2-(Cyclohexyloxy)ethyl)benzene (2.10g): According to general 
methods D/E ester 2.5g (505 mg, 1.73 mmol)was converted to 
ether 2.10g using 1.5 equivalents of DIBAL. Column chromatography (SiO2, 1-5-10 
Et2O/hex) yielded a colorless oil; yield 0.24 g, 64%. Characterization data can be found 
at the provided reference.77 
2-Phenyltetrahydrofuran (2.10h): According to general methods D/E 
ester 2.5h (298 mg, 1.26 mmol)was converted to ether 2.10h using 1.2 
equivalents of DIBAL. Column chromatography (SiO2, 1-5-10 Et2O/hex) yielded a 
 57 
colorless oil; yield 0.11 g, 59%. Characterization data can be found at the provided 
reference.78 
2-Hexyltetrahydrofuran (2.10i): According to general methods 
D/E ester 2.5i (293 mg, 1.20 mmol)was converted to ether 2.10i 
using 1.2 equivalents of DIBAL. Column chromatography (SiO2, 1-5-10 Et2O/hex) 
yielded a colorless oil; yield 0.15 g, 80%. Characterization data can be found at the 
provided reference.79 
 (2-(Pent-4-en-1-yloxy)ethyl)benzene (2.10k): According 
to general methods D/E ester 2.5k (133 mg, 4.77 mmolwas 
converted to ether 2.10k using 1.2 equivalents of DIBAL. Column chromatography 
(SiO2, 1-5-10 Et2O/hex yielded a pale yellow oil; yield 0.052 g, 56%; Rf  = 0.52 (10% 
EtOAc/hex); IR (thin film)2936, 1640, 1109 cm-1; 1H NMR (CDCl3, 100 MHz) δ: 7.24 
(m, 5H), 5.80 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 4.96 (m, 2H), 3.62 (t, J = 7.2 Hz, 2H), 
3.45 (t, J = 6.6 Hz, 2H), 2.89 (t, J = 7.2 Hz, 2H), 2.10 (m, 2H), 1.66 (m, 2H). 13C NMR 
(CDCl3, 100 MHz) δ: 139.1 (s), 138.3 (d), 128.9 (d), 128.3 (d), 126.2 (d), 114.7 (t), 71.8 
(t), 70.3 (t), 36.4 (t), 30.3 (t), 28.9 (t). 
Trimethyl(1-(4-methylphenethoxy)allyl)silane (2.10l): 
According to general methods D/E ester 2.5l (644 mg, 1.91 
mmol) was converted to ether 2.10l using 1.2 equivalents of DIBAL. Column 
chromatography (SiO2, 1-5-10 Et2O/hex) yielded a colorless oil; yield 0.29 g, 61%; Rf  = 
0.64 (10% EtOAc/hex); IR (thin film) 2954, 1628, 1104 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 7.09 (m, 4H), 5.77 (ddd, J = 17.4, 10.5, 7.9 Hz, 1H), 4.98 (m, 2H), 3.82 (m, 1H), 
3.54 (d, J = 6.9 Hz, 1H), 3.38 (m, 1H), 2.31 (s, 3H), 0.00 (s, 9H); 13C NMR (CDCl3, 100 
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MHz) δ: 137.7 (d), 136.4 (s), 135.4 (s), 128.9 (d), 128.8 (d), 111.9 (t), 77.3 (d), 72.1 (t), 
36.2 (t), 21.0 (q), ‒3.99 (q). 
1-Methyl-4-(2-(oct-3-yn-1-yloxy)ethyl)benzene 
(2.10m): According to general methods D/E ester 
2.5m (553 mg, 1.66 mmol)was converted to ether 2.10m using 1.2 equivalents of 
DIBAL. Column chromatography (SiO2, 1-5-10 Et2O/hex) yielded a colorless oil; yield 
0.16 g, 39%; Rf  = 0.46 (10% EtOAc/hex); IR (thin film) 2929, 1109 cm
-1; 1H NMR 
(CDCl3, 100 MHz) δ: 6.97 (m, 4H), 3.51 (t, J = 7.3 Hz, 2H), 3.40 (t, J = 7.2 Hz, 2H), 2.72 
(t, J = 7.3 Hz, 2H), 2.29 (tt, J = 7.2, 2.4 Hz, 2H), 2.19 (s, 3H), 2.02 (tt, J = 7.0, 2.4 Hz, 
2H), 1.30 (m, 4H), 0.77 (t, J = 7.2 Hz, 1H). 13C NMR (CDCl3, 100 MHz) δ: 135.8 (s), 
135.7 (s), 129.1 (d), 128.8 (d), 81.4 (s), 76.6 (s), 72.1 (t), 69.7 (t), 35.8 (t), 31.1 (t), 22.0 
(t), 21.0 (q), 20.1 (t), 18.5 (t), 13.6 (q). 
1-Methyl-4-(2-(oct-2-yn-1-yloxy)ethyl)benzene 
(2.10n): According to general methods D/E ester 2.5n 
(675 mg, 2.03 mmol)was converted to ether 2.10n using 1.2 equivalents of DIBAL. 
Column chromatography (SiO2, 1-5-10 Et2O/hex) yielded a colorless oil; yield 0.11 g, 
22%; Rf  = 0.34 (10% EtOAc/hex); IR (thin film) 2931, 1081 cm
-1; 1H NMR (CDCl3, 100 
MHz) δ: 7.11 (m, 4H), 4.14 (t, J = 2.2 Hz, 2H), 3.70 (t, J = 7.3 Hz, 2H), 2.88 (t, J = 7.3 
Hz, 2H), 2.32 (s, 3H), 2.21 (tt, J = 7.1, 2.2 Hz, 2H), 1.52 (p, J = 7.1 Hz, 2H), 1.34 (m, 
4H), 0.90 (t, J = 7.0 Hz, 3H). 13C NMR (CDCl3, 100 MHz) δ: 135.7 (s), 135.6 (s), 129.1 
(d), 128.7 (d), 70.8 (t), 58.7 (t), 35.7 (t), 31.0 (t), 29.7 (t), 28.3 (t), 22.2 (t), 21.0 (q), 18.6 
(t), (14.0) (q) 
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1-(2-(Benzyloxy)ethyl)-4-methylbenzene (2.10p): 
According to general methods D/E ester 2.5p (189 mg, 6.00 
mmol) was converted to ether 2.10p using 1.2 equivalents of DIBAL. Column 
chromatography (SiO2, 1-5-10 Et2O/hex) yielded a colorless oil; yield 0.053 g, 39%; Rf  = 
0.57 (10% EtOAc/hex);IR (thin film) 3025, 2919, 2856, 1099 cm-1; 1H NMR (CDCl3, 
100 MHz) δ: 7.0 (m, 5H), 7.10 (m, 4H), 4.59 (s, 2H), 3.66 (t, J = 7.2 Hz, 2H), 2.89 (t, J = 
7.2 Hz, 2H), 2.31 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 138.5 (s), 135.8 (s), 135.7 (s), 
129.1 (d), 128.8 (d), 128.4 (d), 127.7 (d), 127.6 (d), 73.0 (t), 71.5 (t), 36.0 (t), 21.9 (q). 
1-Methyl-4-(2-((4-
(trifluoromethyl)benzyl)oxy)ethyl) benzene (2.10q): 
According to general methods D/E ester 2.5q (531 mg, 
1.39 mmol) was converted to ether 2.10q using 1.2 equivalents of DIBAL. Column 
chromatography (SiO2, 1-5-10 Et2O/hex) yielded a colorless oil; yield 0.16 g, 36%;  Rf  = 
0.42 (10% EtOAc/hex); IR (thin film) 2924, 1112, 1064 cm-1; 1H NMR (CDCl3, 100 
MHz) δ: 7.57 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.11 (m, 4H), 4.56 (s, 2H), 
3.69 (t, J = 7.1 Hz, 2H), 2.90 (t, J = 7.1 Hz, 2H). 13C NMR (CDCl3, 100 MHz) δ: 142.6 
(s), 135.8 (s), 135.6 (s), 129.8 (s), 129.1 (d), 129.0 (d), 128.8 (d), 127.4 (d), 125.3 (q, J = 
3.7 Hz)*, 72.1 (t), 71.8 (t), 35.9 (t), 21.0 (q). *Due to C-F splitting. 
1-Methyl-4-(2-(octyloxy)pent-4-en-1-yl)benzene 
(2.73): Ester 2.5a (80 mg, 3.05 mmol) was added 
to flame dried 10 mL round bottom flask that was purged with N2 before being dissolved 
in DCM (1.0 M). The reaction was placed in a dewar before being cooled to -78⁰C using 
a dry ice and acetone bath. After cooling for 10 minuted 1.2 eq DIBAL was added 
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dropwise via syringe. The reaction stirred an additional 10 minutes before allyl silane 
(2.5 eq.) was added dropwise via syringe. The reaction stirred for 10 minutes before 
adding TMSOTf (2.5 eq.) dropwise via syringe. The reaction stirred for 1.25 hours and 
was monitored by TLC. The reaction was quenched with saturated aqueous NaHCO3 and 
allowed to warm to RT before being added to DCM. The water was extracted three times 
with DCM, and the combined organic layers were dried over Na2SO4, filtered, and 
concentrated in vacuo. Column chromatography (SiO2, 1-5-10 Et2O/hex) yielded a 
colorless oil; yield 0.048 g, 55%; Rf  = 0.52 (10% EtOAc/hex); IR (thin film): 2923, 
2854, 1640, 1096 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.09 (m, 4H), 5.86 (ddt, J = 18.0, 
9.5, 7.0 Hz, 1H), 5.07 (m, 2H), 3.47 (q, J = 6.0 Hz, 1H), 3.43 (dt, J  = 8.8, 6.5 Hz, 1H), 
3.33 (dt, J = 8.8, 6.5 Hz, 1H), 2.77 (dd, J = 13.7, 6.6 Hz, 1H), 2.69 (dd, 13.7, 6.0 Hz, 1H), 
2.32 (s, 3H), 2.23 (m, 2H), 1,49 (p, J = 6.8 Hz, 2H), 1.24 (m, 10H), 0.88 (t, J = 6.7 Hz, 
3H); 13C NMR (CDCl3, 100 MHz) δ: 136.0 (s), 135.4 (s), 135.2 (d), 129.4 (d), 128.9 (d), 
116.9 (d), 80.5 (d), 69.6 (t), 40.1 (t), 38.2 (t), 31.7 (t), 30.1 (t), 29.4 (t), 29.3 (t), 26.2 (t), 
22.7 (t), 21.0 (q), 14.1 (q) 
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 - SYNTHESIS AND DERIVITIZATION OF QUINOLINE SCAFFOLDS 
FOR THE USE AS SMALL MOLECULE HIV-1 INTEGRASE INHIBITORS 
3.1 Introduction 
3.1.1 The Global Impact of HIV/AIDS – An Introduction to HIV-1 
The initial diagnosis of the Human Immunodeficiency Virus (HIV), formerly 
known as Lymphadenopathy Associated Virus (LAV), was the beginning of one of the 
largest calls for research in present day history. Its discovery in 1981, followed by 
isolation in 1983 and protein sequencing in 1985, led to the foundation of research for 
one of the largest biological puzzles. Although HIV-1 is rarely the cause of death, it 
severely weakens the immune system allowing for other infections, such as pneumonia, 
to become lethal. The secondary infections of those infected with HIV have been the 
cause of death of approximately 35 million people, and 1.8 million new individuals are 
infected every year.80  
The origin of HIV-1 and HIV-2 can be traced back to the common chimpanzee 
and the sooty mangabey, respectively.82 It is thought that the first transfer of HIV-1 to 
humans was through the consumption of the flesh of these primates as they are 
commonly hunted in west equatorial Africa. Now, HIV-1 can be transmitted through the 
transfer of bodily fluids, such as blood transfusions, sexual intercourse, needle sharing, 
and mother to fetus transmission.83 Roughly 25% of those infected with HIV-1 are 
unaware that they have contracted the virus and so continue to spread it. The highest 
concentration of HIV-1 is in Africa, which has some of the highest poverty levels and 
drug usage,84 as well as restricted access to health care and contraceptives.85 
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Figure 3.1 Map of HIV prevalence in adults81 
 
3.1.2 Current Modes of Treatment for HIV-1 
Currently, 59% of individuals with HIV are on some form of antiretroviral 
treatment. The most common type of treatment for HIV-1 is Highly Active Antiretroviral 
Therapy (HAART). HAART was first developed in 1996 and has led to a drastic decline 
of HIV-1 advancing to AIDS and related deaths, increasing the lifespan of an individual 
infected with HIV to approximately 46 years.86 By using a combination of treatments, 
HAART has been able to effectively slow the replication of HIV-1, however, it cannot 
completely halt the virus. The first approved HIV drug, AZT, a nucleotide reverse 
transcriptase inhibitor (NRTI), is one of many types of HIV treatments that a play a role 
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in HAART therapy. Other types of compounds used in HAART therapy include non-
nucleotide reverse transcriptase inhibitors (nNRTI), and integrase strand transfer 
inhibitors (INSTI). Additionally, pharmacokinetic enhancers can be added to increase the 
effectiveness of the other components by manipulating the liver enzymes responsible for 
breaking them down. 
 
Figure 3.2 Common components in HAART HIV-1 treatments 
The reason for the cocktail of drug treatment regimen is due to HIV’s ability to 
mutate during its replication cycle. Because of this, researchers have had to develop 
multiple synthetic drug analogs that can inhibit the HIV-1 virus at various steps in the 
replication process. As shown in Table 3.1, there are several HAART variants on the 
market. Most HIV-1 patients will take several HAART treatments over their lifetime as 
HIV-1 continues to mutate and develop drug resistance.  
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Table 3.1 List of common HAART HIV-1 treatments 
Name NRTI nNRTI INSTI 
Pharmacokinetic 
enhancer 
Triumeq abacavir lamivudine dolutegravir -- 
Juluca -- rilpivirine dolutegravir -- 
Stribild 
tenofovir disoproxil 
fumarate/emtricitabine 
-- 
elvitegravir cobicistat 
Genvoya 
tenofovir 
alafenamide/emtricitabine 
-- 
elvitegravir cobicistat 
Atripla 
tenofovir disoproxil 
fumarate/emtricitabine 
efavirenz 
-- -- 
Complera 
tenofovir disoproxil 
fumarate/emtricitabine 
rilpivirine 
-- -- 
Odefsey 
tenofovir 
alafenamide/emtricitabine 
rilpivirine 
-- -- 
Biktarvy 
tenofovir 
alafenamide/emtricitabine 
-- bictegravir 
-- 
 
3.1.3 HIV-1 Lifecycle and Mechanism of Attack 
Within the lifecycle of HIV-1, there are many steps in which researchers are 
actively studying to better understand the virus. The four main steps in HIV-1 replication 
are: fusion into the host cell wall, reverse transcription of the viral RNA, integration and 
transcription of the viral RNA to DNA, and then finally release and maturation of the 
new HIV-1 virus.87  
There are multiple pharmaceutical drugs that have been used as fusion, entry, 
NRTIs, inhibition/transcription, and maturation inhibitors. However, there are only three 
known FDA-approved IN inhibitors: dolutegravir (DVG), elvitegravir (EVG), and 
raltegravir (RAL). Due to HIV-1’s ability to rapidly mutate, drug resistant strands against 
RAL and EVG have already appeared.88 Fortunately, there have been no reports of 
resistance to DVG, however, it is only likely only a matter of time. 
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Figure 3.3 HIV lifecycle87 
 
3.1.4 HIV-1 Inhibition of the Catalytic Core Domain  
IN is the enzyme responsible for inserting viral DNA (vDNA) into the host cell 
DNA and has two catalytic activities: 3’ processing and DNA strand transfer,89 both of 
which are catalyzed by either Mg2+ or Mn2+.90 The vDNA molecule exists in the form of a 
pre-integration complex (PIC). Once the PIC gains access to the nuclear compartments of 
the host’s cell, the vDNA ends are inserted into the cellular chromosome, which is 
initiated by IN and completed by the host cell DNA.91 IN consists of three structural 
domains: the N-terminal domain (NTD), the catalytic core domain (CCD), and the C-
terminal domain (CTD).92 The NTD folds into a compact three-helical bundle stabilized 
by coordination of a Zn2+ ion by histidine and cystine residues.93 During integration, the 
NTD and the CTD make important interactions with DNA substrates, while the CCD 
harbors the active site for integration of the vDNA.91 
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The active site of HIV IN is key for viral mutations to occur, which is why it is 
essential to explore other inhibition sites on the enzyme.94 HIV IN operates in a 
tetrameric form, where two dimers are separately formed at the CCD interface for vDNA 
interactions.95 Lens epithelium-derived growth factor (LEDGF) and endogenous 
transcriptional coactivator (p75) promote the interaction between dimers within an 
allosteric binding pocket. This interaction has been shown to be a vital factor in HIV 
vDNA integration via the C-terminal integrase binding domain (IBD).96-98 This allosteric 
site has been of interest as a new inhibition site to potentially prevent this LEDGF/p75 
binding interaction and ultimately inhibit vDNA integration.99 Recent studies have shown 
that the use of small molecule inhibitors to interact with the IN dimer interface at the IBD 
binding site enable an immediate multimerization of the enzyme, rendering it unable to 
participate in vDNA integration.100-101 
 
3.1.5 Quinoline Scaffolds as HIV-1 Inhibitors 
Recently, two candidates for IN inhibition have been shown to target the 
LEDGF/p75 binding interactions in the CCD, quinoline scaffolds 3.7102 and 3.8103 
(Figure 3.4).  
 
Figure 3.4 Trisubstituted biaryl quinoline scaffolds with quinoline structure notation 
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Figure 3.5, part A depicts the ribbon representation of the crystal structure for 3.7 
within the integrase (IN) CCD binding pocket. In part B, the amino acids Trp 132 and 
Leu 102 are seen to interact with the aromatic ring in the northern region of the binding 
pocket and the acetic acid residue in the eastern region of the binding pocket of 3.7. An 
understanding of the relevant noncovalent and steric interactions within this binding 
pocket can be assessed through manipulation of the aromatic substitution at the 4-position 
of the quinoline scaffold. To accomplish this, a library of 4-biaryl quinolines will be 
synthesized and a structure activity relationship (SAR) study will be carried out.  
 
Figure 3.5 Ribbon representation of the IN CCD dimer with quinoline 3.7 
 
3.1.6 Synthesis of the Quinoline Scaffold 
Approximately 60% of all FDA approved drugs contain a nitrogen heterocycle. 
The quinoline scaffold is the 4th most common six-membered aromatic nitrogen 
heterocycle and is found in 2% of FDA approved prescription drugs.104 There are several 
synthetic strategies for synthesizing unsubstituted,105 mono-substituted,106 di-
substituted,107-109 and tri-substituted quinolines,110-112 that have been prepared from 
aniline, anthranilic, indole, and isatin derivatives, respectively (Scheme 3.1). Variations 
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of these methods include, but are not limited to: electrophilic,113-114 oxidative,115 iodine-
catalyzed,116 and aza-Wittig cascade reactions.117 
 
Scheme 3.1 A variety of synthetic strategies for the synthesis of quinolines 
 
3.2 Research Hypothesis 
Manipulation of the 4-position in the quinoline scaffold will enhance the 
noncovalent interaction of the allosteric IN site leading to the inhibition of IN. This will 
be accomplished through the development of a route to access a quinoline scaffold that 
can be derivatized at a later stage. The synthesized trisubstituted biaryl quinolines will be 
submitted to a IN multimerization assay to prove the potency of the compounds.  
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3.3 Research Design and Methods 
3.3.1 Precursors for the Quinoline Scaffold 
Biaryl quinolines such as 3.7 and 3.8 have been demonstrated inhibitory activity 
against HIV IN.103 SAR studies revealed that the methyl and acetic acid residue at the 2- 
and 3-positions of the quinoline ring proved essential to inhibition, whereas the 
remaining substitutions at the 4-, 6-, 7-, and 8-positions enhance the potency. The two 
planned precursors to access the quinolines is shown in Scheme 3.2. Commercially 
available quinoline 3.18 will allow for derivatization specifically at the 4-position via a 
Suzuki coupling reaction. Various aryl groups will be installed, which will allow for 
exploration of the noncovalent interactions in the nonpolar pocket that are deemed 
essential for IN inhibition. To be able to study functionalization at the 6-, 7-, and 8- 
positions and probe noncovalent interactions in those regions, quinoline scaffold 3.20 
will be synthesized starting from anthranilic acid derivatives (such as 3.19), which can be 
converted via an isatoic anhydride intermediate.118 The approach to install the acetic acid 
residue also differs in both routes. Starting from quinoline 3.18 requires a Grignard 
reaction to add the two carbons of the side chain as an electrophile whereas the 
anthranilic acid route will intercept quinoline 3.20 and add the side chain via a one-
carbon nucleophile. 
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Scheme 3.2 Synthetic analysis of quinoline scaffold 3.17 
 
3.4 Results and Discussion 
3.4.1 Forward Synthesis of the 4-Substituted Quinolines 
The 4-aryl quinoline derivatives were the initial targets as the route was 
previously developed by the Boehringer Ingelheim process group.119 The route begins 
with commercially available 4-hydroxyquinoline 3.18 and utilizes a late stage 
intermediate 3.20 that can be derivatized using a Suzuki coupling reaction.  
At the beginning of this reaction sequence, bromination of 4-hydroxy-2-methyl 
quinoline 3.17 at the 3-position of the quinoline was successful and selective utilizing 
NBS in the presence of acetic acid at 80 C (92% yield). This was followed by 
chlorination of the alcohol using neat POCl3 to produce 3.18 in 66% yield. With the 
bromine and chlorine installed, the next step was to secure the necessary ethyl oxalate 
chloride at position 3 via a selective halogen-metal exchange. 
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Scheme 3.3 Synthesis of trisubstituted biaryl quinolines 
A Grignard of 3.18 was formed in the presence of isopropyl magnesium chloride 
and a copper (I) bromide dimethylsulfide complex. Although complete conversion of 
3.18 was observed, it was determined that a dehalogenated byproduct 3.30 was also 
forming (Scheme 3.4). Attempts to scale the reaction resulted in an increase in the 
formation of 3.30. Reactions were therefore kept below 1 g to prevent the formation of 
3.30. Due to difficulties in purification, only low yields were obtained (35%). 
 
Scheme 3.4 Grignard addition with byproduct formation 
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Sodium borohydride reduction of the ketone produced α-hydroxy ester 3.19 in 
77% yield and was followed by a Finkelstein trans-halogenation converting the 4-chloro 
to 4-iodo in 63% yield. The use of HCl is to form the protonated quinoline, thereby 
making it a better electrophile for displacement of the chlorine by iodine. Subsequent 
etherification via perchloric acid and t-butylacetate produced 3.20 in 71% yield and 
provided a bench stable intermediate prior to the derivatization step.   
The final two steps involved a Suzuki coupling of commercially available aryl 
boronic acids at the 4-position of 3.20 followed by saponification of the ester to produce 
the acetic acid side chain. Table 3.2 shows a summary of the synthesized biaryl 
quinolines with ortho-, meta-, and para-substitutions. A variety of heterocyclic 
compounds is shown in Table 3.3. Yields for the Suzuki coupling and saponification 
ranged from 38-99% and 11-99%, respectively. No clear trend in yields could be 
determined regarding substrate or the positioning of the group on the ring.  
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Table 3.2 Summary of phenyl-substituted biaryl quinolines yields 
 
Entry R1 
Parab Metab Orthob 
3.25 3.21 3.26 3.22 3.27 3.23 
1 a H 55% 40% -- -- -- -- 
2 b F 67% 76% 83% 35% 85% 54% 
3 c Cl 63% 40% 92% 92% 84% 96% 
4 d CH3 49% 51% 91% 11% 98% 93% 
5 e CF3 51% 99% 68% 51% -- -- 
6 f OCH3 63% 57% 75% 54% 97% 14%  
7 g SCH3 97% 75% 78% 53% 56% 12% 
8 Ha OCF3
b 94% 57% 87% 86% 73% 
13% 
11% 
9 i CN 80% 34% 73% 49% 38% 56%  
10 j COCH3 63% 57% 50% 13% -- -- 
11 k CHO -- -- -- -- 70% 10% 
12 l NHCOCH3 67% 9% -- -- -- -- 
Note: a) 3.23h had two diastereomer that were separated and analyzed individually. b) all yields are of the purified compounds 
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Table 3.3 Summary of heterocyclic and bicyclic biaryl quinoline yields 
 
Entry Quinoline R1 
% Yielda 
3.28 
% Yielda 
3.24 
1 3.24a 
 
59% 77% 
2 3.24b 
 
38% 86% 
3 3.24c 
 
99% 99% 
4 3.24d 
 
59% 59% 
5 3.24e 
 
72% 78% 
6 3.24f 
 
80% 78% 
7 3.24g 
 
52% 84% 
Note: a) all yields are of the purified compounds 
Substrates were analyzed as racemic mixtures, with the chiral center at the apex of 
the acetic acid residue. In addition, ortho- and meta-substituted compounds also formed 
two atropisomers. Atropisomers are stereoisomers with hindered rotation about a sigma 
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bond, where the energy differences due to steric strain or other contributors create a 
barrier of rotation making it possible for the isolation of the individual conformers.120 
Although enantiomers are indistinguishable by NMR, the addition of a rotational barrier 
creates an axis of chirality resulting in diastereomers that can be distinguished by NMR. 
All stereoisomers would be expected to interact differently in the protein binding pocket. 
Atropisomers were observed for the 2-trifluoromethoxy 3.23h-1 and 3.23h-2 derivatives 
which were analyzed separately where 3.23h-1 had an inhibition of 2.69 µM, and 3.23h-2 
showed no activity (Table 3.4). 
 
Scheme 3.5 Synthesis of quinoline atropisomers, and their naming convention 
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3.4.2 Structural Elucidation of Biaryl Quinoline Scaffolds 
Due to the complexity of the biaryl quinolines, all structures were characterized 
by 2D NMR in addition to 1H, 13C, DEPT, and IR. The structural elucidation of para 
derivative 3.21c will be discussed first, as it was used to help understand the more 
complicated ortho and meta derivatives. In the case of the para substituent 3.21c, the 13C 
NMR and DEPT data revealed the presence of 22 unique carbons, including three 
methyls, one methylene (alkyl), nine methines (one alkyl, eight aryl), and nine quaternary 
carbons (one alkyl, eight aryl). COSY confirmed H12 to H14 connectivity on the aromatic 
ring and for the ethyl group. The eastern side of the quinoline scaffold was confirmed by 
HMBC with H21 correlating to carbons 2 and 9 while H18 correlated to carbons 1, 2, 4, 
and 9. Other key correlations included H10 to carbons 3, 14, 15, and H12 to 14, 15, 
providing the western side of the quinoline scaffold. The northern aromatic ring was 
slightly more complicated as COSY crosspeaks could not be identified due to 
overlapping of the 1H aromatic signals. The key correlation showing connectivity of the 
northern region to the quinoline was observed between H7 and carbon 4.  
 77 
 
Figure 3.6 1H and 13C assignments with HMBC and COSY correlations for 3.21c 
 Elucidation became much more difficult when dealing with the formation of  
atropisomers. Most carbon peaks essentially double, which made identifying single 
carbon signals that belong to each isomer much more difficult. It also caused a lot of 
overlapping peaks in the 1H and 13C spectra (atropisomers 3.23c-1 and 3.23c-2 are used 
for example as in Figure 3.7). Therefore, DEPT NMR became essential with the ability to 
distinguish quaternary carbons. When DEPT-135 was used to analyze the spectra, the 
quaternary carbons disappeared. If DEPTq was used, then the quaternary carbons would 
have a 180 phase separation and appear upside down. Also, with the para-derivatives 
already elucidated, 13C NMR chemical shifts similarities were able to be used as a guide 
for both the ortho- and meta-derivatives. An additional resource Structural Determination 
of Organic Compounds by Ernö Pretsch,121 was also heavily consulted to estimate where 
carbon shifts would occur.  
For atropisomers 3.23c-1 and 3.23c-2, COSY was used to identify 3 isolated spin 
systems: the protons of the quinoline scaffold, as well as the ethyl chain, and H9 and H13 
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on the northern ring (H7 and H8 were overlapping). Hydrogens H18 and H21 were again 
key in determining the eastern side of the quinoline scaffold by HMBC with H18 → 
carbons 1, 2, 4, and 11 and H21 → carbons 2 and 11. For the northern aromatic ring, H9 
correlated with carbon 6. The Pretsch book was utilized to determine the location of 
carbons 3, 5, and 6, which were the final assignments necessary to solve the elucidation.  
 
Figure 3.7  Comparison of 3.21c and 3.23c-1 and 3.23c-2 13C NMR spectral regions 
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Table 3.4 contains the structural assignments for 3.21c and 3.23c-1 and 3.23c-2, 
including 1H coupling constants.  
 
 
Figure 3.8 1H and 13C assignments with HMBC and COSY correlations for 3.23c 
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Table 3.4 1H and 13C NMR Data of 3.21c and 3.23c 
Entry 3.21c 3.23c-1 and 3.23c-2a  
c (ppm) m H (ppm) m J (Hz) #H c (ppm) m H (ppm) m J (Hz) #H 
1 172.4 s ------ -- ------ -- 172.50, 171.82 s ------ -- ------  
2 159.4 s ------ -- ------ -- 159.61, 159.55 s ------ -- ------  
3 146.8 s ------ -- ------ -- 146.67, 146.58 s ------ -- ------  
4 145.2 s ------ -- ------ -- 144.36, 144.92 s ------ -- ------  
5 134.7 s ------ -- ------ -- 137.25, 137.14 s ------ -- ------  
6 134.6 s ------ -- ------ -- 134.99, 134.96 s ------ -- ------  
7 132.3 d 7.47 dd 8.8, 2.4 1 133.84, 133.64 d 7.53-7.24 m ------ 1 
8 131.2 d 7.28 m ------ 1 130.18, 129.94 d 7.53-7.24 m ------ 1 
9 129.6 s ------ -- ------ -- 129.88, 129.86 d 7.56 m ------ 1 
10 129.3 d 7.66 ddd 8.3, 6.8, 1.4 1 129.46, 129.37 d 7.64 ddd 8.3, 6.8, 1.4 1 
11 128.8 d 7.53 m ------ 1 129.43, 129.34 s ------ -- ------  
12 128.7 d 8.04 d 8.1 1 128.61, 128.53 d 8.05 d 8.4 1 
13 128.3 d 7.53 m ------ 1 126.66, 126.56 d 7.53-7.24 m ------ 1 
14 126.3 d 7.28 m ------ 1 126.28, 125.95 d 7.17 m ------ 1 
15 126.1 s ------ -- ------ -- 126.11, 126.10 d 7.53-7.24 m ------ 1 
16 125.9 d 7.37 ddd 8.3, 6.8, 1.2 1 125.77, 125.35 s ------ -- ------  
17 76.1 s ------ -- ------ -- 76.27, 75.84 s ------ -- ------  
18 70.8 d 5.10 s ------ 1 71.26, 70.84 d 5.11, 5.08 s  1 
19 61.4 t 4.19 dq 10.8, 7.2 2 61.34, 61.84 t 4.10 m  2 
20 28.1 q 1.00 s ------ 9 28.16, 27.95 q 1.11, 1.05 s ------ 9 
21 24.9 q 2.85 s ------ 3 25.32, 24.97 q 3.00, 2.90 s ------ 3 
22 14.2 q 1.23 t 7.2 3 14.13, 13.99 q 1.22, 1.15 t 7.1  
Note: a) 3.23c was isolated as a 1:0.97 mixture of atropisomers
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Analysis of the atropisomers proved to be quite difficult in some cases where 
other NMR phenomena interfered such as 13C-19F couplings. Coupling of a single carbon 
signal would split two-fold due to the 13C-19F coupling as well as the presence of the 
atropisomer giving a total of 4 peaks per carbon for the ring system with the associated 
fluorine. Therefore, 13C-19F coupling constants became a key tool to determine carbon 
assignments, which can be seen in Figure 3.9.  
 
Figure 3.9 Carbon-fluorine couplings 
 
3.4.3 Multimerization Assay 
Due to the nature of these compounds to interact with IN at the dimer interface in 
the LEDGF/p75 binding pocket, they cause inhibition of the IN-LEDGF/p75 binding and 
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therefore aberrant IN multimerization.122 Quinolines 3.21 – 3.24 were submitted to a 
homogeneous time-resolved fluorescence (HTRF) based assay, which allows for the 
determination of EC50 values for inhibitor-induced formation of higher order HIV-1 IN 
mutimers. The assay involves the use of two recombinant IN enzymes containing either a 
hexahistidine (6xHis) tag or the FLAG epitope at the protein’s N-terminus. Antibodies  
(anti-6xHis-XL665 and anti-FLAG-EuCryptate) that recognize and bind to the respective 
6xHis and FLAG tags are added to measure the time-resolved fluorescence resonance 
energy transfer between the XL665 and EuCryptate fluorophores upon IN 
multimerization. Compounds that induce IN multimerization have an increased 
corresponding Förster resonance energy transfer (FRET) signal. Moreover, titration of a 
test compound into the assay will yield the EC50 value for IN multimerization.
123 The 
data from this assay is presented in the following section. Compounds that have lower 
concentration values have greater multimerization and inhibition capabilities. 
 
3.4.4 Structure Activity Relationships of Quinoline Substrates 
The 4-phenylquinoline (3.21a, R1 = H, entry 1) was used as a standard for the 
relative comparison of the ortho-, meta-, and para-substituted substituents. Looking at the 
para series, substitution of a methyl group at the 4-position (3.21d, R1 = CH3, entry 4) 
caused a 6-fold decrease in EC50 value, indicating significant ability to inhibit IN. 
Alternatively, by substituting the methyl hydrogens for fluorine (3.21e, R1 = CF3, entry 5)  
also lessened the inhibitory capacity of the quinoline 3-fold. Additionally, 4-methoxy 
3.21f and 4-fluoromethoxy 3.21h continued this trend yet to a lesser extent. Insertion of a 
halogen substituent as in 3.21b and 3.21c showed a significant increase in inhibition with 
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the 4-chloro (3.21c) derivative having the best inhibition of the series with an EC50 value 
of 100 nM. 
Table 3.5 SAR for substituted aromatic biaryl quinolines 
 
Entry R1 Para Meta Ortho 
1 H 3.21a 1.32 ± 0.53 -- -- 
2 F 3.21b 0.49 ± 0.04 3.22b 2.11 ± 0.59 3.23b 0.58 ± 0.07 
3 Cl 3.21c 0.10 ± 0.02 3.22c 3.79 ± 0.59 3.23c 0.26 ± 0.04 
4 CH3 3.21d 0.24 ± 0.11 3.22d 0.95 ± 0.29 3.23d 0.51 ± 0.05 
5 CF3 3.21e 0.72 ± 0.06 3.22e 7.33 ± 0.97 -- 
6 OCH3 3.21f 0.23 ± 0.04 3.22f 1.38 ± 0.37 3.23f 8.39 ± 0.92 
7 SCH3 3.21g 0.49 ± 0.01 3.22g 1.00 ± 0.14 3.23g 4.51 ± 0.71 
8 OCF3 3.21h 0.35 ± 0.09 3.22h 3.34 ± 0.19 3.23h-1 
2.23h-2 
2.69 ± 0.85 
No Activity 
9 CN 3.21i 2.97 ± 0.81 3.22i No Activity 3.23i 11.14 ± 
0.85 
10 COCH3 3.21j 1.39 ± 0.48 3.22j 3.21 ± 0.76 -- 
11 CHO -- -- 3.23k 2.12 ± 0.67 
12 NHCOCH3 3.21l 8.41 ± 0.73 -- -- 
Note: aOrtho OCF3 was isolated as separate diastereomers and submitted for SAR analysis individually 
Initially it was thought that electron density at the aromatic ring was a significant 
factor; however, the presence of the chlorine substituent interfered with this trend. This 
led to the consideration of other factors such as size restrictions, steric interactions, and 
substrate-π interactions that may contribute to protein binding affinities and could explain 
this anomaly. Examining the trends again showed that electron density at the aromatic 
ring has a minimal, yet observable, effect on inhibition as compared to the size and steric 
factors. An example where this is apparent is the 4-cyano substituent (3.21j, entry 9) 
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which had a two-fold increase in EC50, which was attributed to the ridged linear geometry 
of the substrate potentially resulting in restricting access to the binding pocket of the 
protein.  
Unfortunately, steric interactions still could not completely explain the increase in 
enhanced potency of 4-chloro (3.21c, entry 3). Further understanding of this anomaly 
from the trend can be explained through stabilization via a chlorine-π interaction. A DFT 
study illustrates the importance of this interaction within the π-system of specific amino 
acid residues such as phenylalanine, histidine, and tryptophan.124 A stabilization factor of 
-2.01 kcal/mol can be attributed to a chlorine-π interaction with Typ-132 as the chlorine 
resides within 4 Å of the aromatic ring (Figure 3.7). The large dashed red line denotes the 
chlorine-π interaction and the small dashed blue lines denote hydrogen bonding between 
His-171 and Thr-174 with the acetic acid side. 
 
Figure 3.10 Ribbon representation of 3.21c with the target IN binding pocket.  
 After analysis of the para-substituents, the ortho- and meta-substituted phenyl 
rings were examined, and a comparison was made with all three groups of substituted 
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biaryl quinolines (Table 3.5). Immediately it was evident that the para-substituents are 
superior when compared to both the ortho and meta derivatives in terms of the lowest 
values for inhibition data. The trend is para<ortho<meta with the exception of the 3-
methoxy and 3-thiomethoxy, which can be attributed to unfavorable steric interactions 
within the protein binding pocket.  
 
Note: meta-CN showed no activity. Ortho-COCH3 was not synthesized. 
Figure 3.11 SAR trends of the phenyl substitutions 
 The heterocyclic and bicyclic systems were also tested for their ability to inhibit 
IN (Table 3.6). Biphenyl 3.24a and carbazole 3.24b showed no activity, which supports 
the hypothesis that larger substrates will exceed the allowable space within the protein 
binding pocket. Additionally, thiofuran 3.24d and pyrimidine 3.24e also showed no 
activity, indicating the necessity of having noncovalent interactions in the para-position 
of the aryl ring as 3.21c. The 2,3-benzo[b][1,4]dioxane derivative 3.24c was the most 
promising with an EC50 value of 80 nM, which naturally aligns with the need for a 
noncovalent interaction at the para-position.  
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Table 3.6 SAR data of heterocyclic biaryl quinoline substrates  
 
Entry Quinoline R1 EC50 Multimerization (µM) 
1 3.24a 
 
No Activity 
2 3.24b 
 
No Activity 
3 3.24c 
 
2.21 ± 0.56 
5 3.24d 
 
No Activity 
6 3.24e 
 
No Activity 
6 3.24f 
 
0.08 ± 0.01 
7 3.24g 
 
3.70 ± 0.90 
 
3.5 Summary and Conclusion 
Although HIV has been extensively studied for the past 40 years, the virus’s 
innate mutative capabilities have been able to produce resistant strands to current 
available treatments. Despite the current advances, HIV has been shown to affect the 
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lives of millions worldwide each year. This chapter presents an eight-step synthesis of 4-
substituted biaryl quinolines that have shown potency against HIV IN. Most steps can be 
completed at large scales (25 g), except for the Grignard addition of ethyl oxalyl chloride, 
which had to be kept below a reaction scale of 1 g to prevent the formation of a 
debrominated side product. Another key aspect is that many steps can be carried through 
without purification. Of the 38 biaryl quinolines synthesized, 4-chlorophenyl 3.21c and 4-
benzodioxane 3.24f had the highest inhibition with EC50 values of 0.10 µM and 0.08µM, 
respectively, via a multimerization assay. Advancements have been made towards a 
synthetic route to achieve functionalization at the 6-, 7-, or 8-positions of the quinoline 
scaffold and is a focus of continued research in the Pigza research group.  
 
3.6 Experimental 
3.6.1 General Methods 
3.6.1.1 Experimental Techniques 
Unless otherwise noted, all reactions were carried out using flame-dried glassware 
and standard syringe, cannula, and septa techniques, when necessary.67 Tetrahydrofuran 
(THF), diethyl ether (Et2O), hexanes, dichloromethane (CH2Cl2), and toluene (PhCH3) 
were dried by passage through a column of activated alumina on an mBraun SPS.68 
Triethylamine (TEA), N,N-dimethylformamide (DMF), and acetonitrile (ACN) were 
dried by passage through a column of activated alumina on an Innovative Technologies 
system. Trimethylsilyl chloride and Hunig’s base were distilled from calcium hydride 
under argon. Pyridine was distilled from potassium hydroxide under nitrogen. 2-methyl-
4-hydroxyquinoline was purchased from Combi-Blocks in San Diego, CA. All boronic 
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acids were purchased from either Combi-Blocks or Oakwood Chemicals in Georgia. 
Analytical thin layer chromatography was performed using Sorbent Technologies 250 
m glass-backed UV254 silica gel plates. The plates were first visualized by fluorescence 
upon 254 nm irradiation then by iodine chamber. The plates were then dipped in one of 
the following stains followed by heating: p-anisaldehyde, phosphomolybdic acid, 
vanillin, ceric ammonium molybdate, potassium iodoplatinate, ninhydrin, or bromocresol 
green. Flash column chromatography was performed using Sorbent Technologies 40-63 
µm, pore size 60 Å silica gel with solvent systems indicated. Solvent removal was 
completed using a Buchi R3 rotary evaporator with a V900 diaphragm pump (~10 
mmHg). All yields refer to isolated material that is chromatographically (TLC or HPLC) 
and spectroscopically (1H NMR) homogenous. 
 
3.6.1.2 Characterization 
All melting points were taken with a Thomas Hoover melting point apparatus and 
are uncorrected. Infrared spectra were recorded on a Nicolet Nexus 470 FTIR 
spectrometer as neat liquids, oils, solids or as thin films formed from evaporation of 
NMR solvent over the ATR plate. HPLC were recorded on an Agilent 1260 Infinity using 
a Poroshell 120 EC-C18 (3.0 x 50 mm, 2.7 micron) column with a binary gradient of 
0.1% TFA in H2O (A) and 0.1% TFA in CH3CN (B): [0 min: A (95%), B (5%); 7 min: A 
(5%), B (95%); 8 min: A (5%), B (95%)] monitoring 214, 254, and 280 nm. All final 
compounds were demonstrated to have ≥ 90% purity by HPLC. Low-resolution mass 
spectra were recorded on a ThermoFinnigan LXQ ESI-LCMS by use of chemical 
ionization (CI). High-resolution mass spectra were recorded at the Old Dominion 
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University College of Science Major Instrumentation Center (COSMIC) on a Bruker 12 
Tesla APEX-Qe FTICR-MS with an Apollo II ion source Combustion analysis was 
performed at Atlanitic Microlabs on samples taken from the bulk of the material. 
 
3.6.1.3 NMR Parameters 
Proton nuclear magnetic resonance spectra were recorded on a Bruker UltraShield 
Plus 400 MHz spectrometer and are recorded in parts per million from internal 
chloroform (7.26 ppm), methanol, benzene, or dimethylsulfoxide on the  scale and are 
reported as follows: chemical shift [multiplicity (s=singlet, d=doublet, t=triplet, 
q=quartet, qu=quintet, m=multiplet, or derivative thereof), coupling constant(s) in hertz, 
integration, interpretation].69 13C NMR data were recorded on a Bruker UltraShield Plus 
100 MHz spectrometer and are reported as follows: chemical shift (multiplicity as 
determined from DEPT (CH, CH3 up and CH2 down) and/or HSQC experiments). 
 
3.6.2 Synthesis of Intermediates 
Supporting information for substrates 3.21a-l, 3.24a,b,e-g, 3.25a-l, and 3.28a,b,e-
g can be found at the provided references.125-126 
 
3.6.2.1 General Procedure for the Preparation of 4-Aryl Quinolines (3.25-3.28):  
To a 0.5-2.0 mL microwave vial was added ethyl 2-(tert-butoxy)-2-(4-iodo-2-
methylquinolin-3-yl)acetate (100 mg, 0.250 mmol), boronic acid (0.50 mmol), potassium 
carbonate (0.70 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.05 mmol). The 
vial was immediately sealed then evacuated and charged with nitrogen three times. 
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Dimethylformamide (800 µL) and water (80 µL) were then added via syringe. The 
reaction was heated to 90 ºC for a total of 3-16 hours and were monitored via HPLC and 
TLC. The reaction was cooled to ambient temperature then diluted with water (1 mL) and 
ethyl acetate (2 mL). The aqueous phase was removed, and the organic phase was filtered 
through a Celite® plug. The filtrate was washed with water (five 1 mL portions), dried 
over magnesium sulfate, gravity filtered, and concentrated to afford a crude oil. The 
residue was chromatographed over 12 g of silica gel eluted with hexanes-acetone 
(9:1→4:1→2:1). Product rich fractions were pooled and evaporated to isolate the 4-aryl 
quinoline products. 
Ethyl 2-(tert-butoxy)-2-(4-(3-fluorophenyl)-2-methylquinolin-3-
yl)acetate (3.26b): The product was isolated as a 1:0.78 mixture of 
atropisomers using the peaks at 2.86 and 2.85 ppm. Orange-red oil, 
yield = 76.8 mg, 83%. IR (thin film) 1751 cm-1; 1H NMR (CDCl3, 
400 MHz) δ: 8.05 (d, J = 8.4 Hz, 1H), 7.67 (m, 1H), 7.49 (m, 1H), 7.32 (m, 1H), 7.32 (m, 
1H), 7.32 (m, 1H), 7.32 (m, 1H), 7.09 (m, 1H), 5.12 (minor), 5.10 (major) (s, 1H), 4.19 
(m, 2H), 2.86 (major), 2.85 (minor) (s, 3H), 1.23 (q, J = 6.4 Hz, 3H), 1.00 (s, 9H); 13C 
NMR (CDCl3, 100 MHz) δ: [172.40, 172.17] (s), [163.86, 161.40] (d, J = 248.0 Hz)*, 
[159.44, 159.43] (s), 146.70 (s), [145.16, 145.10] (s), [138.46, 138.38] (d, J – 7.7 Hz)*, 
[133.83, 133.64] (d), [132.15, 132.02] (d, J = 14.0 Hz)*, [130.27, 130.13] (d, J = 8.4 
Hz)*, [129.51, 129.49] (s), [128.60, 128.47] (d, J = 12.5 Hz), [126.68, 125.61, ] (d, J = 
108.1), [126.38, 126.06] (d, J = 31.5 Hz), [125.61, 125.58] (s), [115.63, 115.42] (d, J = 
4.5 Hz), [117.13, 116.92] (d), [76.15, 76.11] (s), [70.77, 70.76] (d), [61.51, 61.43] (t), 
28.06 (q), [24.82, 24.80] (q), [14.13, 14.10] (q). *Due to C-F coupling 
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Ethyl 2-(tert-butoxy)-2-(4-(3-chlorophenyl)-2-methylquinolin-3-
yl)acetate (3.26c): The product was isolated as a 1:0.80 mixture of 
atropisomers using the peaks at 2.86 and 2.84 ppm. Orange-red oil, 
yield = 85.1 mg, 92%. IR (thin film) 1640 cm-1; 1H NMR (CDCl3, 
400 MHz) δ: 8.04 (d, J = 7.2 Hz, 1H), 7.67 (m,1H), 7.52 (m, 1H), 7.49 (m, 1H), 7.44 (m, 
1H), 7.38 (m, 1H) 7.38 (m, 1H), 7.30 (m, 1H), 5.07 (minor), 5.06 (major) (s, 1H), 4.19 
(m, 2H), 2.86 (major), 2.85 (minor) (s, 3H), 1.23 (dt, J = 16.7, 7.2 Hz, 3H), 1.01 (minor), 
1.00 (major) (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.39, 172.06] (s), 159.51 (s), 
146.75 (s), 145.01 (s), 138.10 (s), [134.58, 134.11] (s), 131.07 (d), [129.85, 129.79] (d), 
[129.55, 129.48] (s), [129.42, 129.28] (d), 129.03 (d), [128.65, 128.62] (d), 127.85 (d), 
126.34 (d), [126.07, 126.01] (d), [125.97, 125.88] (s), 76.13 (s), 70.76 (d), [61.52, 61.42] 
(t), [28.07, 28.03] (q), [24.90, 24.83] (q). 
Ethyl 4,6-dihydroxy-2-methylquinoline-3-carboxylate (3.26d): 
The product was isolated as a 1:0.91 mixture of atropisomers using 
the peaks at 5.16 and 5.15 ppm. Yellow Oil, yield = 83.4 mg, 91%; 
IR (thin film) 1749 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.04 (d, J = 
8.4 Hz, 1H), 7.64 (m, 1H), 7.48-7.26 (m, 4H), 7.15-7.04 (m, 2H), 5.16 major, 5.15 minor 
(s, 1H), 4.15 (m, 2H), 2.86 major, 2.85 minor (s, 3H), 2.43 major, 2.42 minor (s, 3H), 
1.24 major, 1.21 minor (t, J = 7.1 Hz, 3H), 0.99 major, 0.98 minor (s, 9H); 13C NMR 
(CDCl3, 100 MHz) δ: [172.64, 172.51] (s), [159.47, 159.44] (s), [146.93, 146.65] (s), 
138.04 (s), 137.58 (s), [136.09, 136.06] (s), 131.38 (d), 130.47 (d), 129.70 (s), [129.28, 
129.23] (d), [129.19, 129.09] (d), [128.34, 128.32] (d), [127.85, 127.75] (d), [126.86, 
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126.82] (d), [126.41, 126.35] (s),  125.72 (d), 76.03 (s), [70.87, 70.82] (d), [61.37, 61.20] 
(t), [28.10, 28.01] (q), [24.75, 24.69] (q), [21.53, 21.42] (q), [14.23, 14.13] (q). 
Ethyl 2-(tert-butoxy)-2-(2-methyl-4-(3-
(trifluoromethyl)phenyl)quinolin-3-yl)acetate (3.26e): The product 
was isolated as an 1:0.75 mixture of atropisomers using the peaks at 
2.89 and 2.88 ppm. Red-orange oil, yield = 70.9 mg, 68%. IR (thin 
film) 1752 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.07 (d, J = 8.4 Hz, 1H), 7.83 (m, 1H), 
7.77-7.60 (m, 3H), 7.55 (m, 1H), 7.38 (m, 1H), 7.25 (m, 1H), 5.02 (major), 5.01 (minor), 
(s, 1H), 4.18 (m, 2H), 2.89 (major), 2.88 (minor) (s, 3H), 1.22 (td, J = 7.1, 4.4 Hz, 3H), 
0.99 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ; [172.26, 171.92] (s), [159.47, 159.39] (s), 
[146.65, 146.63] (s), [145.06, 145.01] (s), [137.19, 137.12] (s), [134.24, 134.09] (d), 
[132.24, 132.04] (d), [131.0, 130.6] (q, J = 33.2 Hz)*, [129.79, 128.85] (q, J = 37.2 Hz)*, 
129.75 (s), [128.57, 128.54] (d), [127.87, 126.59] (q, J = 131.5 Hz)*, 125.93 (s), [125.37, 
125.24] (q, J = 9.6 Hz)*, [76.74, 76.14] (s), [70.71, 70.63] (d), [61.60, 61.47] (t), [27.98, 
27.95] (q), [24.74, 24.70] (q) [14.11, 13.91] (q). *Due to C-F coupling. 
Ethyl 2-(tert-butoxy)-2-(4-(3-methoxyphenyl)-2-methylquinolin-
3-yl)acetate (3.26f): The product was isolated as an 1:0.72 mixture 
of atropisomers using the peaks at 0.98 and 0.96 ppm. Orange Oil, 
yield = 71.5 mg, 75%; IR (thin film) 1749 cm-1; 1H NMR (CDCl3, 
400 MHz) δ: 8.45 (d, J = 8.4 Hz, 1H), 7.65 (m, 1H), 7.45 (m, 4H), 7.37 (m, 1H), 7.06 (m, 
1H), 5.20 (major), 5.19 (minor) (s, 1H), 4.19 (q, J = 7.2 Hz, 2H), 3.84 (major) 3.82 
(minor) (s, 3H), 2.85 (s, 3H), 1.22 (dt, J = 7.2, 5.4 Hz, 3H), 1.01 (minor), 1.00 (major) (s, 
9H); 13C NMR (CDCl3, 100 MHz) δ:[172.62, 172.57] (s), [159.57, 159.45, 159.43, 
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159.06] (s), [146.64, 146.63, 146.58, 146.50] (s), [137.45, 137.44] (s), [132.15, 132.06] 
(s), 129.93 (s), [129.61, 129.53, 129.50] (d), [129.28, 129.06] (d), [128.60, 128.48, 
128.35, 128.33] (d), [126.78, 126.75, 125.83, 125.80] (d), [126.78, 126.75] (d), 126.20 
(s), [125.83, 125.80] (d), [123.15, 122.22] (d), [116.31, 115.36] (d), [114.28, 114.13] (d), 
76.07 (s), [70.89, 70.83] (d), [61.42, 61.35] (t), [55.35, 55.28] (q), [28.12, 28.10] (q), 
[24.72, 24.71] (q), [14.18, 14.13] (q). 
Ethyl 2-(tert-butoxy)-2-(2-methyl-4-(3-
(methylthio)phenyl)quinolin-3-yl)acetate (3.26g): The product 
was isolated as a 1:0.76 mixture of atropisomers using the peaks at 
5.16 and 5.14 ppm. Yellow Oil, yield = 77.3 mg, 78%; IR (thin 
film) 1748 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.04 (d, J = 8.5 Hz, 1H), 7.65 (m, 1H), 
7.49-7.22 (m, 5H), 7.20-7.05 (m, 1H), [5.16, 5.14] (s, 1H), 4.15 (m, 2H), [2.85, 2.84] (s, 
3H), [2.50, 2.47] (s, 3H), 1.23 (m, 3H), [1.00, 0.99] (s, 9H); 13C NMR (CDCl3, 100 MHz) 
δ: [172.50, 172.49] (s), 159.43 (s), [146.85, 146.72] (s), [139.30, 138.64] (s), [136.92, 
136.80] (s), [131.39, 130.48] (d), [129.54, 129.50] (s), [129.30, 129.17] (d), [129.09, 
129.06] (d), [128.48, 128.40] (d), [128.31, 128.20] (d), [126.84, 126.66] (d), [126.36, 
126.27] (d), [126.40, 126.14] (s),  [125.84, 125.68] (d), [76.11, 76.08] (s), [70.87, 70.84] 
(d), [61.47, 61.36] (t), [28.10, 28.01] (q), [24.83, 24.78] (q), [21.53, 21.42] (q), [14.22, 
14.13] (q). 
Ethyl-2-(tert-butoxy)-2-(2-methyl-4-(3-
(trifluoromethoxy)phenyl)quinolin-3-yl)acetate (3.26h): The 
product was isolated as an 1:0.72 of atropisomers using the peaks at 
0.98 and 0.96 ppm. Orange oil, yield = 78.1, 87%. IR (thin film) 
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1753, 1723 cm-1. 1H NMR (CDCl3, 400 MHz) δ: 8.06 (d, J = 8.4 Hz, 1H), 7.68 (m, 1H), 
7.59 (m, 1H), 7.48 (m, 1H), 7.39 (m, 2H), 7.28 (m, 2H), 5.08 (major), 5.07 (minor) (s, 
1H), 4.19 (m, 2H), 2.85 (s, 3H), 1.22 (dt, J = 7.1, 5.7 Hz), 0.98 (minor), 0.96 (major) (s, 
9H); 13C NMR (CDCl3, 100 MHz) δ: [172.34, 172.16] (s), [159.47, 159.42] (s), [149.29, 
148.81] (q, J = 2.2 Hz)*, [146.76, 146.74] (s), 144.69 (s), [138.27, 138.25] (s), [132.15, 
132.06, 131.97, 191.95] (s), 130.09 (d), [129.52, 129.44] (d), [128.62, 128.47] (d), 
[126.22, 126.12] (d), [125.80, 125.75] (d), 123.63 (d), 122.63 (d), 121.79 (s), [121.19, 
121.03] (d), [76.16, 76.11] (s), [70.73, 70.58] (d), [61.58, 61.47] (t), [27.95, 27.92] (q), 
[24.81, 24.79] (q), [14.14, 13.97] (q). *Due to C-F coupling 
Ethyl 2-(tert-butoxy)-2-(4-(3-cyanophenyl)-2-methylquinolin-3-
yl)acetate (3.26i): The product was isolated as an 1:0.79 mixture of 
atropisomers using the peaks at 4.99 and 4.97 ppm. Orange-red oil. 
Yield = 68.8 mg, 73%. 1H NMR (CDCl3, 400 MHz) δ: 8.07 (d, J = 
8.3 Hz, 1H), 7.84 (m, 1H), 7.84 (m, 1H), 7.68 (dt, J = 7.7, 1.4 Hz, 1H), 7.66 (m, 1H), 
7.61 (m, 1H), 7.40 (m, 1H), 7.17 (m, 1H), 4.99 (minor), 4.97 (major) (s, 1H), 4.17 (m, 
2H), 2.88 (major), 2.27 (minor) (s, 3H), 1.25 (dt, J = 14.4, 7.2 Hz, 3H), 1.00 (s, 9H); 13C 
NMR (CDCl3, 100 MHz) δ: [172.14, 171.48] (s), [159.34, 159.26] (s), [146.73, 146.71] 
(s), [144.04, 143.98] (s), [137.80, 137.77] (s), [135.40, 133.98] (d), 134.52 (d), 133.12 
(s), 129.68 (s) 129.43 (d), [128.94, 128.75] (d), [126.42, 126.36] (d), [125.88, 125.85] 
(d), [118.28, 118.19] (s), [112.91, 112.44] (s), [76.26, 76.22] (s), [70.70, 70.66] (d), 
[61.68, 61.57] (t), [28.03, 28.01] (d), [24.85, 24.81] (q), [14.15, 14.14] (q). 
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Ethyl 2-(4-(3-acetylphenyl)-2-methylquinolin-3-yl)-2-(tert-
butoxy)acetate (3.26j): The product was isolated as an 1:0.81 
mixture of atropisomers using the peaks at 2.64 and 2.61 ppm. 
Orange-red oil. Yield = 49.1 mg, 50%. IR (thin film) 1749, 1684 cm-
1; 1H NMR (CDCl3, 400 MHz) δ: 8.15 (m, 1H), 8.06 (d, J = 8.3, 1H), 7.91 (m, 1H), 7.66 
(m, 1H), 7.66 (m, 1H), 7.55 (m, 1H), 7.37 (m, 1H), 7.23 (m, 1H), 5.05 (major), 
5.01(minor) (s, 1H), 4.17 (m, 2H), 2.87 (major), 2.86 (minor) (s, 3H), 2.64 (major), 2.61 
(minor) (s, 3H),  1.24 (dt, J = 12.5, 7.2 Hz, 3H), 0.98 (minor), 0.97 (major) (s, 9H); 13C 
NMR (CDCl3, 100 MHz) δ: [197.60, 197.43] (s), [172.32, 172.30] (s), [159.45, 159.38] 
(s), 146.64 (s), 145.60 (s), 138.66 (s), 137.20 (s), [136.81, 136.78] (s), [135.40, 135.24] 
(d), [132.16, 132.06] (d), [129.76, 129.71] (s), [129.56, 129.52] (d), [128.90, 128.63] (d), 
[128.52, 128.40] (d), [128.36, 128.28] (d), [126.33, 126.11] (d), 115.01 (d), [76.18, 
76.13] (s), 70.77 (d), [61.68, 61.48] (t), [28.06, 28.01] (q), 26.72 (q), 24.33 (q), 14.14 (q). 
Ethyl 2-(tert-butoxy)-2-(4-(2-fluorophenyl)-2-methylquinolin-3-
yl)acetate (3.27b): The product was isolated as an 1:0.66 mixture of 
atropisomers using the peaks at 2.95 and 2.86 ppm. Orange Oil, yield 
= 74.0 mg, 80%. IR (thin film) 1749 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 8.05 (d, J = 8.4 Hz, 1H), 7.66 (ddt, J = 8.4, 6.7, 1.6 Hz, 1H), 7.58-7.43 (m, 2H), 
7.42-7.16 (m, 4H), 5.14 major, 5.13 minor (s, 1H), 4.13 (m, 2H), 2.95 minor, 2.86 major 
(s, 3H), 1.23 major, 1.13 minor (t, J = 7.1 Hz, 3H), 1.08 minor, 1.01 major (s, 9H); 13C 
NMR (CDCl3, 100 MHz) δ: [172.40, 171.78] (s), [161.19, 158.72] (d, J = 125.2 Hz)*, 
[159.71, 159.38] (s), [146.71 146.48] (s), [141.11, 140.92] (s), [132.86, 132.83] (d), 
[131.04, 130.31] (d), [130.94, 130.71,] (d, J = 8.1 Hz)*, [130.37, 130.31] (s), [129.43, 
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129.39] (d), [128.67, 128.61] (d), [126.29, 125.76] (s), [126.05, 125.99] (d, J = 18.6 
Hz)*, [124.24, 123.87] (d, J = 3.6 Hz)*, [123.79, 123.63] (s), [115.99, 115.88] (d, J = 
21.5 Hz)*, [76.19, 75.88] (s), [71.20, 70.80] (d), [61.42, 61.22] (t), [28.09, 27.82] (q), 
[25.17, 24.81] (q), [14.13, 13.82] (q). *Due to C-F coupling. 
Ethyl 2-(tert-butoxy)-2-(4-(2-chlorophenyl)-2-methylquinolin-3-
yl)acetate (3.27c): The product was isolated as an 1:0.97 mixture of 
atropisomers using the peaks at 5.11 and 5.08 ppm. Orange Oil, yield 
= 80.8 mg, 84% IR (thin film) 1748 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 8.05 (d, J = 8.4 Hz, 1H), 7.64 (td, J = 6.8, 1.2 Hz, 1H), 7.61-7.28 (m, 5H), 7.28-
7.10 (m, 1H), 5.11 major, 5.08 minor (s, 1H), 4.10 (m, 2H), 3.00 major, 2.90 minor (s, 
3H), 1.22 major, 1.15 minor (t, J = 7.1 Hz, 3H), 1.11 major, 1.05 minor (s, 9H); 13C 
NMR (CDCl3, 100 MHz) δ: [172.50, 171.82] (s), [159.61, 159.55] (s), [146.67, 146.58] 
(s), [144.36, 144.92] (s), [137.25, 137.14] (s), [134.99, 134.96] (s), [133.84, 133.64] (d), 
[130.18, 129.94] (d), [129.88, 129.86] (d), [129.46, 129.37] (d), [129.43, 129.34] (s), 
[128.61, 128.53] (d), [126.66, 126.56] (d), [126.28, 125.95] (d), [126.11, 126.10] (d), 
[125.77, 127.35] (d), [76.27, 75.84] (s), [71.26, 70.84] (d), [61.34, 61.18] (t), [28.16, 
27.95] (q), [25.32, 24.97] (q), [14.13, 13.99] (q). 
Ethyl 2-(tert-butoxy)-2-(2-methyl-4-(o-tolyl)quinolin-3-yl)acetate 
(3.27d): The product was isolated as an 1:0.78 mixture of 
atropisomers using the peaks at 5.14 and 5.12 ppm. Yellow Oil, yield 
= 89.8 mg, 98%. IR (thin film) 1750 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 8.07 (d, J = 8.4 Hz, 1H), 7.63 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.48-7.28 (m, 3H), 
7.25-6.98 (m, 3H), 5.14 major, 5.12 minor (s, 1H), 4.14 (m, 2H), 2.93 minor, 2.89 major 
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(s, 3H), 1.97 minor, 1.90 major (s, 3H), 1.22 major, 1.15 minor (t, J = 7.1 Hz, 3H), 1.11 
minor, 1.00 major (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.85, 172.48] (s), [159.94, 
159.91] (s), [147.29, 146.65] (s), [146.38, 146.27] (s), [137.86, 137.41] (s), [135.68, 
135.37] (s), [130.38, 130.31] (d), [129.55, 129.44] (d), [129.49, 129.33] (s), [128.79, 
128.69] (d), [128.31, 128.15] (d), 126.83 (d), [126.54, 126.39] (d), [126.17, 125.81] (s), 
[126.13, 126.08] (d), [125.71, 125.54] (d), [76.37, 75.65] (s), [71.26, 70.69] (d), [61.29, 
61.20] (t), [28.44, 27.06] (q), [24.77, 24.53] (q), [20.37, 19.85] (q), [14.11, 14.01] (q). 
Ethyl 2-(tert-butoxy)-2-(4-(2-methoxyphenyl)-2-methylquinolin-
3-yl)acetate (3.27f): The product was isolated as an 1:0.84 mixture 
of atropisomers using the peaks at 5.16 and 5.09 ppm. Yellow oil, 
yield = 92.5 mg, 97% IR (thin film) 1744 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.03 (dd, 
J = 8.4, 5.4 Hz, 1H), 7.61 (m, 1H), 7.50 (m, 1H), 7.29 (m, 3H), 7.10 (t, J = 7.4 Hz, 1H), 
7.04 (t, J = 7.8 Hz, 1H), 5.16 major, 5.14 minor (s, 1H), 4.15 (m, 2H), 3.60 minor, 3.58 
major (s, 3H), 2.96 minor, 2.85 major (s, 3H), 1.21 major, 1.20 minor (t, J = 7.1 Hz, 3H), 
1.02 minor, 0.99 major (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.65, 171.72] (s), 
[159.82, 159.50] (s), [157.62, 156.44] (s), [146.94, 146.40] (s), [144.29, 143.93] (s), 
[132.28, 131.14] (d), [130.29, 130.22] (d), [129.97, 129.69] (s), [129.05, 128.95] (d), 
[128.44, 128.40] (d), [126.66, 126.47] (d), [126.43, 126.23] (s), 125.54 (d), [124.85, 
124.66] (s), [120.44, 120.24] (d), [110.84, 110.54] (d), [76.23, 75.67] (s), [71.73, 70.94] 
(d), [61.25, 60.96] (t), [55.04, 54.83] (q), [28.18, 27.75] (q), [25.39, 24.80] (q), [14.13, 
14.09] (q). 
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Ethyl 2-(tert-butoxy)-2-(2-methyl-4-(2-
(methylthio)phenyl)quinolin-3-yl)acetate (3.27g): The product was 
isolated as an 1:0.84 mixture of atropisomers using the peaks at 5.16 
and 5.09 ppm. Yellow-orange oil, yield = 55.5 mg, 56%. IR (thin 
film) 1743 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.03 (d, J = 8.4 Hz, 1H), 7.63 (ddt, J = 
8.2, 6.8, 1.4 Hz, 1H), 7.50 (tdd, J = 8.0, 3.5, 1.6 Hz, 1H), 7.42-7.2 (m, 4H), 7.13 (m, 1H), 
5.09 minor, 5.08 major (s, 1H), 4.13 (m, 2H), 2.98 minor, 2.90  major (s, 3H), 2.29 
minor, 2.28 major (s, 3H), 1.21 major, 1.16 minor (t, J = 7.1 Hz, 3H), 1.09 minor, 1.05 
major (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.69, 171.77] (s), [159.96, 159.82] (s), 
[146.80, 146.64] (s), [145.37, 144.38] (s), [139.86, 138.75] (s), 131.43 (d), [129.60, 
129.29] (d), [129.52, 129.19] (s), [129.28, 129.12] (d), [128.68, 128.58] (d), 126.65 (d), 
126.22 (d), [125.84, 125.58] (s), [125.79, 125.77] (d), [76.32, 75.76] (s), [71.55, 70.88] 
(d), [61.19, 61.04] (t), [28.29, 27.94] (q), [25.46, 25.01] (q), [16.04, 15.41] (q), [14.10, 
14.02] (q). 
Ethyl 2-(tert-butoxy)-2-(2-methyl-4-(2-
(trifluoromethoxy)phenyl)quinolin-3-yl)acetate (3.27h): The 
product was isolated as an 1:0.84 mixture of atropisomers using the 
peaks at 5.07 and 5.01 ppm. Orange oil, yield = 78.8 mg, 73% IR (thin film) 1749 cm-1; 
1H NMR (CDCl3, 400 MHz) δ: 8.05 major, 8.04 minor (d, J = 8.4 Hz, 1H), 7.65 (tt, J = 
6.9, 1.5 Hz, 1H), 7.54-7.23 (m, 4H), 7.19, 7.18 (d, J = 8.2 Hz, 1H), 5.07 minor, 5.01 
major (s, 1H), 4.11 (m, 2H), 2.94 major, 2.90 minor (s, 3H), 1.21 minor, 1.16 major (t, J 
= 7.1 Hz, 3H), 1.04 minor, 1.03 minor (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.23, 
171.73] (s), [159.45, 159.37] (s), 147.83 (s), [146.74, 146.49] (s), 141.62 (s), 133.45 (d), 
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132.08 (d), [130.40, 130.36] (d), [129.99, 129.90] (s), [129.37, 129.35] (d), 128.94 (d), 
[128.58, 128.53] (d) [126.08, 125.70] (s), [126.04, 125.98, 125.92, 125.86] (q, J = 5.6 
Hz)*, 125.47 (d), [119.62, 117.30] (d), [126.73, 126.54] (d), [126.20, 125.93] (d), [76.22, 
75.84] (s), [71.25, 70.91] (d), [61.34, 61.23] (t), [28.12, 27.76] (q), [25.15, 25.00] (q), 
[14.67, 13.79] (q). *Due to C-F Splitting 
Ethyl 2-(tert-butoxy)-2-(4-(2-cyanophenyl)-2-methylquinolin-3-
yl)acetate (3.27i): The product was isolated as an 1:0.67 mixture of 
atropisomers using the peaks at 5.10  and 4.99. Orange oil, yield = 
35.8 mg, 38% IR (thin film) 1748 cm-1; 1H NMR (CDCl3, 400 MHz) 
δ: 8.07 minor, 8.06 major (d, J = 8.4 Hz, 1H), 7.90-7.83 (m, 1H), 7.80-7.59 (m, 3H), 
7.45-7.29 (m, 2H), 7.12 minor, 7.03 major (dd, J = 8.4, 0.8, 1H), 5.10 minor, 4.99 major 
(s, 1H), 4.15 (m, 2H), 2.99 major, 2.91 minor (s, 3H), 1.23 major, 1.17 minor (t, J = 7.1 
Hz, 3H), 1.12 major, 1.05 minor (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.17, 
171.63] (s), [159.25, 159.62] (s), [146.76, 146.73] (s), [143.12, 142.42] (s), [140.72, 
139.98] (s), [132.85, 132.45] (d), [132.44, 132.21] (d), 129.92 (d), [129.74, 129.70] (d), 
129.61 (s), [129.16, 128.97] (d), [128.86, 128.77] (d), [126.59, 126.56] (d), [125.41, 
125.26] (d), [177.54, 117.16] (s), [115.28, 113.90] (s), [76.75, 76.06] (s), [70.81, 70.67] 
(d), [61.52, 61.39] (t), [27.92, 27.91] (q), [25.12, 24.960] (q), [14.11, 14.06] (q). 
Ethyl 2-(tert-butoxy)-2-(4-(2-formylphenyl)-2-methylquinolin-3-
yl)acetate (3.27k): The product was isolated as an 1:0.39 mixture of 
atropisomers using the peaks at 5.08 and 4.98 ppm. Orange oil, yield 
= 66.4 mg, 70%. IR (thin film) 1751, 1698 cm-1; 1H NMR (CDCl3, 
400 MHz) δ: 9.42 (s, 1H), 8.21 major, 8.17 minor (dd, J = 7.6, 1.2 Hz, 1H), 8.07 (d, J = 
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8.4 Hz, 1H), 7.85-7.56 (m, 3H), 7.41-7.30 (m, 2H), 7.07 (d, J = 8.3 Hz, 1H), 5.06 minor, 
4.98 major (s, 1H), 4.27-3.98 (m, 2H), 2.94 major, 2.91 minor (s, 3H), 1.24 major, 1.10 
minor (t, J = 7.1 Hz, 3H), 1.08 major, 0.97 minor (s, 9H); 13C NMR (CDCl3, 100 MHz) 
δ: [191.07, 190.58] (d), [172.29, 171.77] (s), [159.57, 159.22] (s), [146.38, 146.22] (s), 
[143.04, 142.44] (s), [139.96, 139.32] (s), [135.50, 134.22] (s), [133.82, 133.50] (d), 
[130.36, 130.13] (s), [130.29, 130.22] (d), [129.83, 129.72] (d), [129.44, 129.36] (d), 
[128.81, 128.69] (d), [127.40, 127.37] (d), [126.98, 126.84] (s), [126.73, 126.54] (d), 
[126.20, 125.93] (d), [76.19, 75.95] (s), [70.95, 70.84] (d), [61.47, 61.38] (t), [28.18, 
27.96] (q), [25.02, 24.89] (q), [14.10, 13.96] (q). 
Ethyl 4,6-dihydroxy-2-methylquinoline-3-carboxylate (3.28c): 
Orange oil, yield = 85.1 mg, 99% 1H NMR (CDCl3, 400 MHz) δ: 
8.02 (d, J = 8.2 Hz, 1H), 7.49 (m, 1H), 7.49 (m, 1H), 7.49 (m, 1H), 
7.37 (m, 1H), 7.37 (m, 1H), 6.62 (s, 1H), 5.45 (s, 1H), 4.22 (dq, J = 
10.8, 7.2 Hz, 1H), 4.17 (dq, J = 10.8, 7.2 Hz, 1H), 2.82 (s, 3H), 1.22 (t, J = 7.1 Hz, 3H), 
1.02 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 172.5 (s), 159.3 (s), 146.7 (s), 143.3 (d), 
132.2 (s), 130.8 (d), 129.3 (d), 128.6 (s), 128.4 (d), 126.3 (d), 125.9 (d), 119.8 (s), 113.0 
(d), 76.1 (s), 70.7 (d), 61.4 (t), 28.0 (q), 24.8 (q), 14.2 (q). 
Ethyl 2-(tert-butoxy)-2-(2-methyl-4-(thiophen-2-yl)quinolin-3-
yl)acetate (3.28d): The product was isolated as an 1:0.13 mixture of 
atropisomers using the peaks at 2.85 and 2.83. Red-orange oil, yield 
= 47.4 mg, 59%. 1H NMR (CDCl3, 400 MHz) δ: 8.10 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 
8.3 Hz, 1H), 7.67 (m, 1H), 7.67 (m, 1H), 7.54 (m, 1H), 7.46 (m, 1H), 7.33 (m, 1H), 5.93 
(s, 1H), 4.18 (m, 2H), 2.85 (minor), 2.83 (major) (s, 3H), 1.28 (minor), 1.25 (major) (s, 
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9H), 1.18 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ: 171.30 (s), 158.78 (s), 
146.68 (s), 137.23 (s), 136.85 (s), [133.83, 133.63] (d), 133.18 (d), 133.02 (s), [132.15, 
131.97] (d), 130.09 (d), 129.38 (s), [128.78, 128.70] (d), [128.57, 128.45] (d), 127.46 (d), 
80.26 (s), [70.79, 70.36] (d), [61.56, 61.38] (t), [28.34, 28.11] (q), 24.69 (q), 14.08 (q). 
 
3.6.2.2 General Procedure for Ethyl Ester Hydrolysis (3.21-3.24) 
To a solution of ethyl ester quinoline (1.0 equiv) and ethanol (3.5 mL) was added aqueous 
50% sodium hydroxide (3 equiv). The reaction was heated to 60 ºC and was stirred until 
100% conversion was observed by HPLC. The solution was cooled to ambient temperature 
and was neutralized with 1N HCl to pH 5. The solution was extracted with chloroform-d6 
(two 0.5-mL portions) and the combined organic phase was dried over magnesium sulfate, 
filtered, and examined via 1H-NMR. Carboxylic acid products requiring purification were 
chromatographed over 4 g of silica gel eluted with 0-5-10% dichloromethane-methanol. 
Product rich fractions were pooled and evaporated to afford desired acids (3.21-3.24). 
2-(tert-Butoxy)-2-(4-(3-fluorophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.22b): The product was isolated as an indistinguishable mixture 
of atropisomers. White solid, yield = 24.1 mg, 35%. mp 110-115ºC; IR 
(thin film) 1730 cm-1; 1H NMR (MeOH-d4, 400 MHz) δ: 8.06 (d, J = 
8.4 Hz, 1H), 7.68 (t, J = 6.9 Hz, 1H), 7.61-7.18 (m, 5H), 7.09 (m, 1H), 5.24 (s, 1H), 2.84 
(s, 3H), 1.00 (s, 9H); 13C NMR (MeOH-d4, 100 MHz) δ: 177.26 (s), [158.95, 157.20] (s), 
[146.05, 144.62] (s), 137.05 (s), 132.68 (s), [132.13, 132.08, 132.06, 132.03] (d),* 
[131.83, 131.51, 131.65] (s),* [130.11, 129.78] (s) 129.87 (d), 129.87 (s), [129.15, 
129.00] (d), [128.63, 128.17] (d), 126.71 (d), [125.36, 125.35, 125.30] (s),* 119.04 (d), 
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116.20 (d), 116.16 (d) [75.71, 75.60] (s), 72.83 (d), [27.91, 27.79] (q), 24.66 (q); Exact 
mass calcd for C23H22FNO4 [M+H]
+, 368.165648. Found 368.165782.*C-F coupling 
could not be determined for this sample, and so all peaks were reported.  
2-(tert-Butoxy)-2-(4-(3-chlorophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.22c): The product was isolated as an 1.0:0.9 mixture of 
atropisomers using the peaks at 5.20 and 5.17 ppm ppm; Yellow oil, 
yield = 67.5 mg, 92%. IR (thin film) 1640 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 10.00 (s, 1H, OH) 8.13 (d, J = 8.4 Hz, 1H), 7.78 (s,1H), 7.69-7.61 (m, 2H), 
7.54-7.46 (m, 2H), 7.43-7.30 (m, 2H), 7.22 (d, J = 7.3 Hz, 1H), 5.2 major, 5.17 minor (s, 
1H), 2.94 major, 2.90 minor (s, 3H), 0.99 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: 173.7 
(s), [158.9, 158.8] (s), [146.6, 146.5] (s), [145.5, 145.4] (s), [137.6, 137.5] (s), 134.0 (s), 
131.2 (d), [130.3, 129.9] (s), [130.2, 129.2] (d), [130.1, 130.0] (d), [129.6, 129.5] (d), 
[129.0, 128.9] (d), 127.9 (d), [127.4, 127.3] (d), [126.6, 126.5] (d), 126.4 (d), [126.1, 
125.9] (s), [77.2, 76.9] (s), 70.7 (d), [28.14, 28.07] (q), [23.8, 23.7] (q). Exact mass calcd 
for C22H22ClNO3 [M+H]
+, 384.136098. Found 384.136358. 
2-(tert-Butoxy)-2-(2-methyl-4-(m-tolyl)quinolin-3-yl)acetic acid 
(3.22d): The product was isolated as a 1:0.79 mixture of atropisomers 
using the peaks at 5.33 and 5.32 ppm. Yellow oil, yield = 8.3 mg, 11%. 
IR (thin film) 1726 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.06 (d, J = 
8.4 Hz, 1H), 7.67 (ddt, J = 2.2, 6.6, 8.4 Hz, 1H), 7.52-7.30 (m, 5H), 7.15-7.08 (m, 1H), 
[5.33, 5.32] (s, 1H), 2.84 (s, 3H), 2.44 (s, 3H), [1.01, 1.00] (s, 9H); Exact mass calcd for 
C23H25NO3 [M+H]
+, 364.190720. Found 364.190736. 
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 2-(tert-Butoxy)-2-(2-methyl-4-(3-(trifluoromethyl)phenyl)quinolin-
3-yl)acetic acid (3.22e): The product was isolated as a 1:0.73 mixture 
of atropisomers using the peaks at 4.99 and 4.92 ppm. Yellow oil, yield 
= 36.1 mg, 51%. 1H NMR (MeOH-d4, 400 MHz) δ: 8.18 (d, J = 7.6 
Hz, 1H), 7.99 (dd, J = 2.7, 8.0 Hz, 1H), 7.87 (t, J = 7.2 Hz, 1H), 7.78 (d, J = 7.0 Hz, 1H), 
7.68 (m, 1H), 7.65 (m, 1H), 7.43 (m, 1H), 7.32 (m, 1H), 4.99 minor, 4.91 major (s, 1H), 
2.92 (s, 3H), 0.93 (s, 9H); 13C NMR (MeOH-d4, 100 MHz) δ: [177.65, 177.42] (s), 
[160.20, 160.13] (s), 145.62 (s), [144.59, 144.55] (s), 137.49 (s), [135.14, 134.04] (d), 
[133.88, 133.82] (s), [132.36, 132.41,] (q, J = 3.5 Hz)*, [130.71, 130.39] (s), 129.85 (d), 
129.61 (s), [129.06, 128.77] (q, J = 21.5 Hz)*, [128.16, 128.07,] (q, J = 5.4 Hz)*, 
[126.93, 126.66] (q, J = 3.7 Hz)*, [126.06, 125.99] (s), [125.95, 125.66] (d), [124.89, 
124.66] (q, J = 3.7 Hz)*, [74.81, 74.75] (s), [72.16, 72.03] (d), [27.20, 27.16] (q), 20.46 
(q). *Due to C-F coupling. 
2-(tert-Butoxy)-2-(4-(3-methoxyphenyl)-2-methylquinolin-3-
yl)acetic acid (3.22f):  The product was isolated as a 1:0.72 mixture of 
atropisomers using the peaks at 3.84 and 3.83 ppm. Yellow oil, yield = 
33.7 mg, 54%. 1H NMR (CDCl3, 400 MHz) δ: 8.22 (m, 1H), 7.71 (t, J 
= 7.6 Hz, 1H), 7.45 (m, 3H), 7.29 (m, 1H), 7.08 (dtd, J = 0.8, 3.5, 8.3 Hz, 1H), 6.90 (m, 
1H), 5.33 minor, 5.32 major (s, 1H), 3.84 minor, 3.83 major (s, 3H), 2.91 (s, 3H), 1.02 
minor, 1.01 major (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.35, 172.25] (s), [159.81, 
159.04], [158.31, 158.18] (s), 149.11 (s), [136.52, 136.44] (s), [132.17, 132.12] (d),  
[130.37, 130.12] (d), 129.09 (s), [128.62, 128.50] (d), 126.93 (d), 126.68 (d), 126.15 (s), 
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[123.58, 121.69] (d), 115.86 (s), 115.34 (d), [115.60, 114.49] (d), [77.90, 77.72] (s), 
[70.68, 70.50] (d), [55.43, 55.21] (q), 28.13 (q), 23.79 (q). 
2-(tert-Butoxy)-2-(2-methyl-4-(3-(methylthio)phenyl)quinolin-3-
yl)acetic acid (3.22g): The product was isolated as a 1:0.78 mixture of 
atropisomers using the peaks at 5.30 and 5.27 ppm. Yellow oil, yield = 
34.4 mg, 53%. IR (thin film) 1729 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 
8.13 (m, H), 7.66 (m, 1H), 7.52-7.29 (m, 5H), 7.16-7.02 (m, 1H), 5.31 minor, 5.28 major 
(s, 1H), 2.89 (s, 3H), 2.48 major, 2.44 minor (s, 3H), 1.02 major, 1.00 minor (s, 9H); 13C 
NMR (CDCl3, 100 MHz) δ: [173.01, 172.81] (s), [158.48, 158.45] (s), [148.92, 148.90] 
(s), [145.89, 145.82] (s), [138.64, 137.55] (s), [136.30, 135.39] (s), 131.74 (d), [129.97, 
129.95] (d), [129.57, 128.74] (s), 129.30 (s), [128.27, 128.08] (d), [127.83, 127.78] (d), 
[127.67, 127.59] (d), [126.72, 126.64] (d), 126.10 (s), 125.75 (d), [77.56, 77.42] (s), 
70.69 (d), [28.75, 28.06] (q), [24.01, 23.81] (q), [21.57, 21.42] (q); Exact mass calcd for 
C23H25NO3S [M+H]
+, 396.162791. Found 396.163160. 
2-(tert-Butoxy)-2-(2-methyl-4-(3-
(trifluoromethoxy)phenyl)quinolin-3-yl)acetic acid (2.22h): The 
product was isolated as a 1:0.53 mixture of atropisomers using the 
peaks at 5.20 and 5.19 ppm. Yellow oil, yield = 63.1 mg, 86%. 1H 
NMR (CDCl3, 400 MHz) δ: 8.69 (s, 1H, O-H), 7.87 (tt, J = 7.1, 1.4 Hz, 1H), 7.73-7.52 
(m, 4H), 7.52-7.42 (m, 2H), 7.22 (s, 1H), 5.20 (minor), 5.19 (major) (s, 1H), 3.14 (minor) 
3.11 (major) (s, 3H), 0.99 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [172.33, 172.14] (s), 
158.65 (s), 149.59 (s), 148.84 (s), 135.86 (s), 132.56 (q)*, [132.28, 132.18,] (s), 132.01 
(s), 131.51 (s), 131.06 (d), [129.92, 129.33] (d), [128.66, 128.54] (d), [126.78, 126.67] 
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(d), 126.27 (s), 123.46 (d), 122.42 (d), [77.59, 77.44] (s), [70.04, 69.98] (d), [27.90, 
27.85] (q), 21.47 (q); Exact mass calcd for C23H22F3NO4 [M+H]
+, 434.157369. Found 
434.157945. * C-F coupling could not be determined for this sample, and so all peaks 
were reported. 
2-(tert-Butoxy)-2-(4-(3-cyanophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.22i): The product was isolated as a 1:0.95 mixture of 
atropisomers using the peaks at 5.06 and 4.97 ppm. Yellow oil, yield = 
31.4 mg, 49%. 1H NMR (MeOH-d4, 400 MHz) δ: 8.16-7.90 (m, 3H), 
7.71-7.29 (m, 5H), 5.06 major, 4.97 minor (s, 1H), 2.90 minor, 2.87 major (s, 3H), 0.92 
minor, 0.89 major (s, 9H); 13C NMR (MeOH-d4, 100 MHz) δ:178.09 (s), 160.13 (s), 
[146.45, 145.61] (s), [145.55, 145.48] (s), [137.11, 136.73] (s), [135.93, 135.73] (s), 
[133.88, 133.81] (s), 133.04 (d), 132.83 (s), 131.30 (d), [128.91, 128.75] (d), [128.53, 
128.30] (d), [127.46,127.12] (d), 126.77 (d), 126.55 (d), 126.40 (s), [125.73, 125.49] (d), 
74.75 (s), [72.40, 72.32] (d), [27.33, 27.25] (q), [23.44, 23.39] (q); Exact mass calcd for 
C23H22N2O4•H2O [M+Na]+, 415.162828. Found 415.163184. 
2-(tert-Butoxy)-2-(4-(2-fluorophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.23b): The product was isolated as a 1:0.56 mixture of 
atropisomers using the peaks at 2.93 and 2.85 ppm. White solid, 35.9 
mg, 54%. mp 140-144 ºC; IR (thin film) 1722 cm-1; 1H NMR (CDCl3, 
400 MHz) δ: 8.02 (d, J = 8.4 Hz, 1H), 7.80-7.71 (m, 1H), 7.71-7.57 (m, 2H), 7.52-7.22 
(m, 4H), 5.23 minor, 5.21 major (s, 1H), 2.93 minor 2.85 major (s, 3H), 1.08 minor, 0.99 
major (s, 9H); 13C NMR (CD3OD, 100 MHz) δ: [174.14, 173.50] (s), [161.69, 159.27] (d, 
J  = 119.4 Hz)*, 158.99 (s), [145.38, 142.68] (d, J = 272.8 Hz) *, [132.50, 132.47] (d), 
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[131.49, 131.41] (d), 131.27 (d), [131.00, 130.91] (d), 130.85 (d), [129.95, 129.92] (d), [ 
126.61, 126.50] (d, J = 1.4 Hz)*, [125.87, 125.70] (d), 125.77 (s), [124.39, 123.94] (d, J 
= 3.7 Hz)*, 123.63 (s), [123.06, 123.90] (s), [115.80, 115.71] (d, J = 21.5 Hz)*, [76.15, 
75.77] (s), [70.57, 70.34] (d), [26.97, 26.77] (q), [23.12, 22.77] (q).Exact mass calcd for 
C23H22FNO4 [M+H]
+, 368.165648. Found 368.165878. 
2-(tert-Butoxy)-2-(4-(2-chlorophenyl)-2-methylquinolin-3-yl)acetic 
acid (3.23c): The product was isolated as a 1:0.97 mixture of 
atropisomers using the peaks at 5.34 and 5.19 ppm. White solid, 66.9 
mg, 96%. mp 109-115 ºC; IR (thin film) 1729 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.13 
(d, J = 8.5 Hz, 1H), 7.73-7.62 (m, 2H), 7.81-7.50 (m, 1H), 7.50-7.32(m, 3H), 7.22-7.15 
(m, 1H), 5.34 major, 5.19 minor (s, 1H), 3.04 major, 2.93 minor (s, 3H), 1.16 major, 1.08 
minor (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [173.68, 172.97] (s), [159.35, 158.43] (s), 
[145.98, 145.54] (s), [145.24, 145.08] (s), [135.64, 134.64] (s), [134.57, 133.53] (s), 
133.35 (d), [132.18, 132.08] (d), [130.57, 130.33] (d), 130.04 (s), [129.82, 129.72] (d), 
[128.59, 128.47] (d), [127.84, 127.70] (d), [126.95, 126.66] (d), [126.41, 125.89] (d), 
[126.24, 125.41] (s), 76.51 (s), [70.72, 70.39] (d), [28.04, 27.80] (q), [24.32, 24.09] (q); 
Exact mass calcd for C22H22ClNO3 [M+H]
+, 384.136098. Found 384.136256. 
2-(tert-Butoxy)-2-(2-methyl-4-(o-tolyl)quinolin-3-yl)acetic acid 
(3.23d): The product was isolated as a 1:1 mixture of atropisomers 
using the peaks at 5.34 and 5.24 ppm. White solid, yield = 75.8 mg, 
93% mp 220-226 C; 1H NMR (CDCl3, 400 MHz) δ: 8.13 (d, J = 8.4 
Hz, 1H), 7.64 (m, 1H), 7.50-7.28 (m, 4H), 7.24 (m, 2H) 5.34, 5.24  (s, 1H), 2.92, 2.90 (s, 
3H), 2.06, 1.91 (s, 3H), 1.15, 1.05 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [173.97, 
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173.33] (s), [159.25, 159.01] (s), [148.92, 148.33] (s), [145.29, 144.92] (s), 136.12 (s) 
[135.23, 134.67] (s), [130.94, 130.62] (d), [130.38, 130.11] (d), 129.95 (s) [128.92, 
128.86] (d), [127.15, 126.98] (d), [126.68, 126.62] (d), [126.55, 126.42] (d), 126.40 (s), 
125.41 (d), 120.28 (d), 76.64 (s), [71.05, 70.62] (d), [28.38, 27.98] (q), [23.89, 23.65] (q), 
[20.44, 20.05] (q); Exact mass calcd for C23H25NO3 [M+H]
+, 364.190720. Found 
364.191025. 
2-(tert-Butoxy)-2-(4-(2-methoxyphenyl)-2-methylquinolin-3-
yl)acetic acid (3.23f): The product was isolated as a 1:0.38 mixture of 
atropisomers using the peaks at 3.67 and 3.61 ppm. Yellow solid, yield 
= 12.1 mg, 14%. mp 115-120 ºC; 1H NMR (CDCl3, 400 MHz) δ: 8.37 (m, 1H), 7.72 (m, 
1H), 7.62-7.49 (m, 2H), 7.42 (m, 1H), 7.34 (m, 1H), 7.22-7.03 (m, 2H), 5.28 major, 5.08 
minor (s, 1H), 3.67 minor, 3.61 major (s, 3H), 3.07 minor, 3.02 major (s, 3H), 1.02 
minor, 1.01 major (s, 9H); Exact mass calcd for C23H25NO4 [M+H]
+, 380.185635. Found 
380.185964. 
2-(tert-Butoxy)-2-(2-methyl-4-(2-(methylthio)phenyl)quinolin-3-
yl)acetic acid (2.23g): The product was isolated as a 1:0.64 mixture of 
atropisomers using the peaks at 1.10 and 1.03 ppm. Yellow oil, yield = 
5.6 mg, 12%. IR (thin film) 1734 cm-1; 1H NMR (CDCl3, 400 MHz) 
δ:7.97 minor, 7.96 major (d, J = 8.0 Hz, 1H), 7.72 (m, 1H), 7.60-7.10 (m, 6H), 5.14 
minor, 5.19 major (s, 1H), 2.99 minor 2.89 major (s, 3H), 2.32 major, 2.31 minor (s, 3H), 
1.10 minor, 1.03 major (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [175.06, 173.60] (s), 
[159.66, 159.54] (s), [147.03, 146.41] (s), [145.04, 144.92] (s), 138.83 (s) [134.77, 
133.54] (s), 131.10 (d), [129.69, 129.62] (d), 129.44 (d) [129.19, 129.12] (d), [126.88, 
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126.43] (d), [126.35, 126.30] (d), [126.23, 125.83] (d), [124.49, 124.20] (d), [76.17, 
75.49] (s), [71.07, 70.71] (d), [27.21, 27.09] (q), [23.61, 22.99] (q), [14.23, 14.27] (q); 
Exact mass calcd for C23H25NO3S [M+H]
+, 396.162791. Found 396.163143. 
2-(tert-Butoxy)-2-(2-methyl-4-(2-
(trifluoromethoxy)phenyl)quinolin-3-yl)acetic acid (3.23h): The 
product was isolated as a 1:0.94 mixture of atropisomers using the 
peaks at 5.25 and 5.15 ppm. Colorless oil; IR (thin film) 2904, 1704 
cm-1; 1H NMR (CDCl3, 400 MHz) δ: 8.10 (d, J = 8.4 Hz, 1H), 7.40-7.30 (m, 6H), 7.19 (t, 
J = 9.1 Hz, 1H), 5.25 major, 5.15 minor (s, 1H), 2.99 major, 2.92 minor (s, 3H), 1.07 
major, 1.00 minor (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [173.88, 173.25] (s), [159.49, 
158.77] (s), [147.78, 146.72] (s), [146.32, 145.67] (s), [143.05, 142.07] (s), 133.94 (d), 
131.64 (d), [130.36, 130.07] (s) [130.44, 130.25] (d), [129.82, 129.75] (d), 128.57 (s), 
[128.02, 127.84] (d), [126.11, 126.07] (d), [126.36, 125.92] (q, J = 11.6 Hz)*, [125.67, 
125.76] (d), 116.61 (d), 76.30 (s), [71.21, 70.99] (d), [28.13, 27.83] (q), [24.45, 24.29] 
(q); Exact mass calcd for C23H22F3NO4 [M+H]
+, 434.157369. Found 434.157785. *Due 
to C-F coupling 
2-(tert-Butoxy)-2-(4-(2-cyanophenyl)-2-methylquinolin-3-yl)acetic 
acid (2.23i): The product was isolated as a 1:0.63 mixture of 
atropisomers using the peaks at 5.30 and 5.06 ppm. White solid, yield 
= 18.6 mg, 56 %. mp >260 ºC; IR (thin film) 2904, 1704 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 8.14 (t, J = 7.7 Hz, 1H), 7.93-7.82 (m, 2H), 7.79-7.56 (m, 3H), 7.40 (m, 1H), 
7.18-7.06 (m, 1H), 5.37 major, 5.06 minor (s, 1H), 3.04 major 2.91 minor (s, 3H), 1.17 
major, 1.06 minor (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [173.41, 172.83] (s), [158.84, 
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156.73] (s), [146.16, 145.84] (s), [143.96, 143.81] (s), [140.39, 139.30] (s), [132.98, 
132.94] (d), [132.61, 132.52] (d), [132.18, 132.09] (d), [130.26,129.45] (d), 130.14 (s), 
129.93 (d), [128.24, 128.09] (d), [127.07, 126.97] (d), [126.41, 125.33] (s), [125.54, 
125.11] (d), [117.91, 117.24] (s), [115.04, 113.65] (s), [77.72, 77.57] (s), [70.66, 69.96] 
(d), [28.07, 27.62] (q), [24.25, 24.09] (q); Exact mass calcd for C23H22N2O3 [M+H]
+, 
375.170319. Found exact mass not observed. 
2-(tert-Butoxy)-2-(4-(2-formylphenyl)-2-methylquinolin-3-yl)acetic 
acid (3.23k): The product was isolated as a 1:0.51 mixture of 
atropisomers using the peaks at 9.50 and 9.48. Black oil, yield = 6.2 
mg, 10%. IR (thin film) 2904, 1704 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 9.50 major, 
9.48 minor (s, 1H), 8.18 (t, J = 7.8 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.82-7.59 (m, 3H), 
7.39-7.26 (m, 2H), 7.08 (t, J = 8.4 Hz, 1H), 5.12, 5.10 (s, 1H), 3.00 major, 2.95 minor (s, 
3H), 1.08 major, 0.97 minor (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [191.08, 190.45] 
(s), [174.05, 173.60] (s), [159.57, 158.95] (s), [145.11, 144.10](s), [139.24, 138.35] (s), 
[135.35, 133.99] (s), 133.46 (d), 131.51 (s), 130.00 (d), [129.71, 129.47] (d), [127.96, 
127.73] (d), [127.63, 127.05] (d), [126.93, 126.87] (d), [126.19, 12595] (d), [76.74, 
76.47] (s), [70.88, 70.77] (d), [28.17, 28.04] (q), [23.68, 23.36] (q); Exact mass calcd for 
C23H23NO4 [M+H]
+, 378.169985. Found 378.170217. 
2-(tert-Butoxy)-2-(4-(furan-3-yl)-2-methylquinolin-3-yl)acetic acid 
(3.24c): Yellow solid, yield = 77.8 mg, 99% mp >260 ºC; IR (thin film) 
3352, 1595 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.93 (d, J =  8.4 Hz, 
1H), 7.79 (d, J = 9.0 Hz, 1H), 7.78 (s, 1H), 7.69-7.50 (m, 3H), 7.44 (t, J 
= 7.8 Hz, 1H), 5.35 (s, 1H), 2.86 (s, 3H), 0.97 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ 
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177.99 (s), 169.06 (d), 159.97 (s), 145.43 (s), 143.03 (d), 138.35 (s), 134.84 (s), [132.44, 
132.41] (d), [131.72, 131.62] (d), [128.63, 128.54] (d), 126.74 (d), 126.50 (s), [125.91, 
125.59] (d), 119.90 (s), 74.75 (s), 72.14 (d), 27.22 (q), 23.38 (q). 
2-(tert-Butoxy)-2-(2-methyl-4-(thiophen-2-yl)quinolin-3-yl)acetic 
acid (3.24d): The product was isolated as an 1:0.42 mixture of 
atropisomers using the peaks at 6.02 and 5.32 ppm. Red-orange solid, 
yield = 25.9 mg, 59%. mp >260 C: IR (thin film) 1732 cm-1; 1H NMR (CDCl3, 400 
MHz) δ: 8.09 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.3 Hz, 1H), 7.72-7.56 (m, 2H), 7.54 (m, 
1H) 7.49-7.38 (m, 2H), 6.02 (major), 5.32 (minor) (s, 1H), 2.88 (minor), 2.83 (major) (s, 
3H), 1.25 (s, 9H); 13C NMR (CDCl3, 100 MHz) δ: [173.15, 173.38] (s), [157.97, 156.24] 
(s), 137.16 (s), 134.19 (s), 133.35 (s), [132.24, 132.21, 132.16, 132.06] (d), 131.10 (d), 
130.89 (s), 129.57 (d), [128.66, 128.59] (s), 128.11 (d), 127.38 (d), 127.01 (d), 123.46 
(d), [77.58, 76.91] (s), [80.26, 70.52] (d), [28.37, 28.12] (q), [23.72, 20.57] (q); Exact 
mass calcd for C20H21NO3S [M+H]
+, 356.131491. Found 356.131781. 
 
3.6.2.3 Recombinant Proteins and IN Multimerization Assay. 
Recombinant wild type HIV-1 IN proteins containing either a N-terminal 6xHis 
or a FLAG tag were expressed in E. coli and purified as previously described.8 The 
HTRF-based assay used to monitor the inhibitor induced aberrant multimerization of IN 
was performed as previously reported.i,ii Briefly, two separate preparations of His-tagged 
and FLAG-tagged IN proteins were mixed in presence of increasing concentration of the 
test compounds and incubated for 2.5 h at room temperature. Anti-His6-XL665 and anti-
FLAG-EuCryptate antibodies (Cisbio, Inc., Bedford, MA) were then added to the 
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reaction and incubated at room temperature for 3 h. The IN multimerization HTRF signal 
was recorded using a PerkinElmer EnSpire multimode plate reader and dose-response 
curves were fitted using Origin software (v9.4). 
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 – A Foray into Organocatalyzed Carbon-Carbon Bond Forming Reactions 
4.1 Introduction 
4.1.1 Catalysis in Chemistry 
Over 80% of industrial chemical manufacturing processes make use of catalysts 
to increase the rate of a desired reaction.127 A catalyst is a substance that decreases the 
activation energy of a reaction, reduces the overall reaction time, and regenerates at the 
end of the reaction. Catalysts can be classified according to the phases in which the 
catalysts, reactants, and products are present and includes homogeneous, heterogeneous, 
or biological. Traditionally, catalysts have included a transition metal which undergoes a 
redox cycle to synthesize the desired product while also regenerating the catalyst. 
Common transition metal catalysts include palladium, platinum, iridium, and rhodium, 
which are also some of the most expensive metals within the periodic table. The most 
common catalysts used in industry utilize these precious metals for their inherent 
activity.127-129 As these catalysts can be extremely difficult to use, are toxic, and are 
typically non-recoverable, chemists have been developing other catalytic pathways from 
the traditional redox cycle, which are of great interest to the synthetic community. 
 
4.1.2 Rise of Organocatalysis 
New advancements in organic synthesis have led to exchanging these precious 
metal catalysts for organocatalysts. While documented examples have been sporadic over 
the last century using small molecules as organocatalysts, it was not until the late 1990’s 
that the field of organocatalysis was born from a small number of inspiring articles.130 
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Approximately 1,500 manuscripts were prepared on the subject between 1998 and 2008, 
which has led to developing one of the main branches of enantioselective synthesis.  
 
Figure 4.1 Some examples of organocatalysts 
There are 5 main binding types of organocatalysts (Figure 4.1): enamine catalysis, 
hydrogen-bonding catalysis, iminium catalysis, singly occupied molecular orbital 
(SOMO) catalysis, and chiral anion catalysis.131 These catalysts have many benefits over 
their predecessors in that they are stable in air and water, inexpensive and easy to 
prepare, do not require the use of a glove box, and are non-toxic.  
 
4.1.3 Hydrogen Bonding and Chiral Anion Organocatalysts 
Of the previously listed catalysts, squaramide and thiourea catalysts can both be 
used as hydrogen bonding catalysts, as well as chiral anion catalysts. They typically 
contain an acidifying group on one arm, a chiral diamine controller on the other, and a 
central squarate or thiourea group where the hydrogen bond donating (HBD) site is 
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located (Figure 4.3). The acidifying group contains an aromatic ring with electron 
withdrawing substituents such as a trifluoromethyl. The purpose of the acidifying group 
is to decrease the pKa value of the hydrogens in the HBD site leading to an increased 
bonding capacity. The chiral diamine controller changes the size and shape of the 
catalytic pocket and acts as a base in the reaction to deprotonate and place the 
nucleophile for a selective addition. The center of the catalyst will contain either a 
squarate or thiourea group with two nitrogens bearing acidic protons. These protons will 
act as a HBD which will lock in a substrate allowing for selective addition to occur 
through the assistance of the chiral diamine controller.  
 
Figure 4.2 General structure of squaramide and thiourea organocatalysts 
Thiourea organocatalysts were initially used by Jacobson as HBD catalysts for an 
asymmetric variant of the Strecker reaction.132 Additionally, Jacobson showed the 
versatility of thiourea catalysts by successfully and enantioselectively coupling imines 
with silyl enol ethers via a Mannich reaction.133 This led the way for the use of HBD 
catalysis in the following reactions: Michael addition,134-136 Henry reaction,137 and 
addition to oxonium ions.138 
In 2008, Rawal published the first paper using a new class of HBD catalysts with 
a squarate center.139 This new type of organocatalyst quickly became popular in 
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enantioselective organic reactions such as the Michael addition,140-144 Friedel-Crafts,145-
146 and Morita-Baylis-Hillman.147 A summary of these reaction types can be seen in 
Scheme 4.1. 
 
Scheme 4.1 Examples of squaramide catalyzed organic reactions 
 
4.1.4 Structure Activity Relationships of Thiourea and Squaramide Subunits 
Recently, squaramide organocatalysts have surpassed the use of thiourea in terms 
of the number of citations. Delving into the structure activity relationships between the 
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two systems, it is obvious why squaramides have preference and superior conversion 
rates and enantioselectivities over their thiourea counterparts. Activation by the catalysts 
depends on the central nitrogen being in alignment. While both thiourea and the squarate 
centers have planes of rotation, thiourea substituents have lower energy conformers that 
rotate the S-C-N-H system out of the desired alignment (Figure 4.4).148 Substrate 4.7a is 
predicted to be 1.5 kcal more stable than 4.7c due to the weak N-H-S bond and 4.7b is 
slightly more stable than 4.7c by 0.8 kcal due to its intramolecular hydrogen bonding. 
Additionally, with these intramolecular HBD interactions present, it leads to an increase 
in the pKa and decrease in the efficiency of the catalyst. Squaramide catalysts also have 
the potential to rotate and exploit alternative intramolecular HBD interactions. However, 
with the rigidity of the squarate center, it makes the distance much greater, and less 
favorable to access these non-favorable conformers. 
 
Figure 4.3 Competing conformations of thiourea catalysts  
 With these considerations in mind, it is not surprising that squaramides typically 
have pKa values 0.13-1.97 lower than their thiourea counterparts in DMSO.
149-150 
Ultimately the difference in pKa is strongly dependent on the parent structure and the two 
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groups attached to the nitrogens. Manipulation of the acidifying group can greatly affect 
the pKa as shown in Figure 4.5, more so than the chiral diamine group. 
 
Figure 4.4 Comparison of pKa values of common squaramide organocatalysts 
 Although catalyst 4.18 has the highest pKa, it cannot be assumed that it has the 
worst activity. In fact, Rawal used a benzyl acidifying group in his initial work with 
squaramide organocatalysts for the addition of β-diketones to β-nitrostyrenes,139 as well 
as Pedrosa for the synthesis of chromenes and spirochromanes151 and both achieved 
excellent conversions and enantioselectivity. There are other stabilization factors to 
consider, including noncovalent interactions between the substrate and catalyst, which 
factor into the choice of catalyst. 
 
4.2 Research Hypothesis 
Manipulation of noncovalent interactions can be used as a tool to guide the 
development of thiourea and squaramide organocatalysts. This project will have three 
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components: 1) computational calculation of organocatalyst-substrate binding to better 
understand the important noncovalent interactions, 2) the synthesis of new 
organocatalysts utilizing this knowledge, and 3) exploration of new reactions that can be 
catalyzed through the use of organocatalysts. While the results in the first two areas are 
very preliminary and will not be discussed here, the results of the third area and a new 
organocatalyzed reaction will be described.  
 
4.3 Research Design and Methods 
4.3.1 Probing New Organocatalyzed Reactions 
Since organocatalysis is a new area of research in the group, the first task will be 
to screen a known Michael addition using purchased squaramide and thiourea 
organocatalysts.136, 139-140, 152 All reactions will be completed by adding the substrate to a 
4 mL vial and dissolving in CDCl3. The use of CDCl3 will allow the reaction progress to 
be monitored by 1H NMR and spectra will be taken at regular intervals. The nucleophile 
will then be added to the vial followed by the catalyst. The reactions will then be 
transferred to NMR tubes and left to react. 
 
4.4 Results and Discussion 
4.4.1 Reaction Screen for Enantioselective Additions 
Initial screening with β-nitrostyrenes were chosen due to their prevalence in the 
literature in Michael additions (Table 4.6, entry 1-5). Both addition of diketones139 and 
pyrazolinones135, 141, 152-153 were of interest as they had been done before and gave 
important information into the design and work up of these enantioselective additions 
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(entries 1 and 2). To extend the substrate scope for the pyrazolinones, a tosyl substitution 
on the nitrogen was attempted using squaramide 4.34b (Table 4.6, entry 3). 
Disappointingly, conversion rates were extremely slow, and the product was unable to be 
purified by column chromatography. 
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Table 4.1 Reaction screening for enantioselective Michael addition to β-nitrostyrene 
Entry Electrophile Nucleophile Time (hr) Conversiona (%) Yieldb (%) % eec Substrate Product 
1 
 
4.8a 
 
4.22 
24 86 -- -- 4.27a 
 
2 
 
4.23 
24 100 95 77 4.27b 
 
3 
 
4.24 
72 
24 
66.7 
8 
-- -- 4.27c 
 
4 
NO2Me 
4.25 
24 0 -- -- 4.27d No product 
5  
4.26 
8 100% 77 77 4.28a 
 
Note: a) conversion is based on 1H NMR integration of product relative to any remaining starting material. b) yields are of pure products after chromatography.c) Enantioselectivities were determined by 
chiral HPLC as compared to the racemic entry. 
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The final nucleophile that was tried with β-nitrostyrene was a masked acyl 
cyanide (MAC), which has been used previously in the enantioselective addition to 
imines and enones using a quinine-based squaramide organocatalysts (Scheme 4.2).142, 154 
MAC reagents are unique acyl anion equivalents that can be unmasked at a later stage as 
the ester, amide, or carboxylic acid, for example.155 
 
Scheme 4.2 Enantioselective addition of MAC to π-bonds 
The addition of MAC 4.26 to β-nitrostyrene 4.8a fully converted to product 4.28a 
within 8 hours with a yield of 77% and 77 % ee. The addition of MAC to β-nitrostyrene 
surprisingly has not been accomplished prior. The results leading from this reaction will 
be discussed further in the following section. 
 
4.4.2 Enantioselective Addition of Masked Acyl Cyanides to β-Nitrostyrenes 
4.4.2.1 Synthesis of β-Nitrostyrenes to Fulfill Substrate Scope 
To explore the scope of the reaction, multiple β-nitrostyrenes substrates were 
synthesized using one of three condensation reactions followed by an E2 elimination. The 
second step either utilized NaOH as the base in cold temperatures156 or refluxing with 
ammonium acetate.157-158 Initially, reactions were tried with NaOH as the base. However, 
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it was found that the E2 elimination was not occurring if the reaction temperature became 
too warm, leaving behind the initial condensation adduct 4.34. Even with the careful 
addition, the reactions were typically low yielding (10-40%), and some substrates that 
were tried at lower temperatures also did not progress beyond alcohol 4.34. Ammonium 
acetate was also tried, with and without acetic acid, which led to the synthesis of pure 
material, however there was not an improvement in the yields.  
 
Scheme 4.3 Synthesis of β-nitrostyrenes with byproduct formation 
Regardless of the low yields, a range of β-nitrostyrenes were synthesized (Figure 
4.8) with both electron withdrawing (4.8c, 4.8d, and 4.8g) and electron donating groups 
(4.8b, 4.6e, and 4.8f),  as well as heteroaromatic derivatives (4.8h – 4.8j) and one alkyl 
variant (4.8k). This provided a broad substrate scope for the ensuing Michael addition. 
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Figure 4.5 Substrate scope of β-nitrostyrenes via aldehyde condensation with 
nitromethane 
 
4.4.2.2 Enantioselective Addition of Masked Acyl Cyanide to β-Nitrostyrenes 
The addition of MAC to β-nitrostyrenes started with an organocatalyst screen 
using nitrostyrene 4.8a as the model system. No background reaction was observed 
without the presence of a catalyst. Each catalyst contained a thiourea or squaramide 
center with an array of acidifying groups and chiral diamine controllers. MAC 4.26 and 
β-nitrostyrene 4.8a were dissolved in CDCl3 and cooled to 0 C before catalyst was 
added. Monitoring the reaction by TLC was difficult as the starting material and product 
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had similar Rf values. The best solvent system that was determined was using 1:4 DCM 
in hexanes and running the plate 3 times to see separation. Also, a PAA stain could be 
used to differentiate between both UV active products as it only stained the desired 
product. It was much easier to monitor the reactions via 1H NMR. Therefore, 1H NMR 
was taken at 1, 4, 8, and 24 hour increments. Table 4.8 is a summary of the results. It 
became apparent that the catalysts containing the squarate centers (entries 1-6) were 
superior to the thioureas (entries 7-14), which is most likely due to the more acidic 
protons binding the substrates within the catalytic pocket and the more rigid structure of 
squaramides (Figure 4.6).149-150, 159 Additionally, one urea was screened which showed no 
reaction at all (entry 15). 
 
Figure 4.6 pKa comparison of organocatalysts 
Looking more closely at the differences of the catalytic systems, it was found that 
the reaction favored the chiral cyclohexyl diamines with a slight amount of bulk situated 
off the basic amine for both the squarate and thiourea series (entries 5, 6, 9, and 12). This 
resulted in the highest enantioselectivities of both series: 75, 79, 70, and 66% ee, 
respectively. Typically, reactions had complete conversion of the starting materials 
within 24 hours. Those that did not convert fully include catalysts 4.38d and 4.38f, which 
both contained the largest substituents and are unable to activate MAC. This led to using 
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catalyst 4.38f as the chosen catalyst, as it fully converted  the desired material within 24 
hours with 79% ee. 
Table 4.2 Organocatalyst Screen  
 
Entry Substrate Organocatalyst Time 
(h) 
Conversion 
(%) 
eeb 
(%) 
1 
 
4.38a 
 
24 100 50 
2 
 
4.38b 
 
8 100 72 
3a 
 
4.38c 
 
24 100 69 
4 
 
4.38d 
 
24 100 51 
5 
 
4.38e 
 
24 100 75 
6 
 
4.38f 
 
24 100 79 
7a 
 
4.39a 
 
24 100 56 
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8 
 
4.39b 
 
8 100 28 
9 
 
4.39c 
 
5 100 70 
10c 
 
4.39d 
 
96 87 -- 
12 
 
4.39e 
 
8 100 66 
13 
 
4.39f 
 
24 77 17 
14 
 
4.39g 
 
24 100 12 
15 
 
4.40a 
 
24 0 -- 
16 -- No catalyst 120 0 -- 
Note: a) Substrates synthesized in the Donahue Research Group. b) enantioselectivity was determined by chiral HPLC. c) Due to the 
length of conversion, the %ee was not obtained. 
With the best identified catalyst 4.38f determined, the next steps involved an 
extensive solvent screen (Table 4.9). Common organic solvents used in Michael additions 
were screened first (entries 1-6). Solvent had a large effect on the enantioselectivity and 
 127 
yield of the reaction. In general, non-polar, polar protic, and polar aprotic solvents, were 
all tolerated, although there were several solvents that had very low conversions (entries 
12-14, and 21). This could be due to the higher dielectric strengths of those solvents 
[acetone (20.7 k) and acetonitrile (11.1 k)]. THF, though, had similar dielectric constants 
to other solvents that fully converted such as DCM, therefore other factors must be 
present, such as the ability of THF to serve as a hydrogen bond acceptor via its lone pair 
electrons on oxygen. 
Table 4.3 Solvent screen with organocatalyst 4.38f 
 
Entry Solvent eea (%) Yieldb (%) Conversion (%) 
1 DCM 79 74 100 
2 CHCl3 88 96 100 
3 hexanes 77 67 100 
4 toluene 77 79 100 
5 Et2O 61 85 100 
6 THF 47 43 60 
7 CDCl3 87 87 100 
8 CCl4 78 76 100 
9 toluene-D8 74 83 100 
10 toluene-F8 79 86 100 
11 trifluorotoluene 82 86 100 
12 acetone 10 15 13 
13 acetonitrile 5 23 38 
14 ethyl acetate 48 50 75 
15 cyclopentyl methyl 
ether 
63 73 91 
16 2-MeTHF 55 89 100 
17 MTBE 43 77 91 
18 nitromethane 45 54 88 
19 perfluorodecalin 52 72 91 
20 hexafluoroisopropanol 58 89 97 
21 trifluoroethanol 44 71 68 
Note: a) enantioselectivity was determine by chiral HPLC. b) yields are of compounds purified by chromatography. 
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The best solvent was CHCl3 providing the desired product in 96% yield and 88% 
ee. CDCl3 was a close second, followed by trifluorotoluene with enantioselectivities of 
87% and 82%, respectively. Using halogenated solvents also clearly led to higher 
enantioselectivities (78-88%) as well as non-polar solvents such as hexanes and toluene 
(each 77% ee). Polar ether solvents such as THF and Et2O gave lower 
enantioselectivities. 
With the reaction parameters defined, they were then applied to the variety of β-
nitrostyrenes that had been previously synthesized. Initially, catalyst loading started at 0.5 
mol% of 4.38f as it converted the model system with good enantioselectivity. However, 
when this was applied to substrates with substitution at the 4-position, full conversion 
was not occurring as was expected after 24 hours (Table 4.10, entries 2 and 5). Therefore, 
the catalyst load was increased to 2 and 5 mol% with 4.28b which resulted in 95% 
conversion within 24 hours (entries 3 and 4). Since the results were similar between these 
two catalyst loadings, all substrates were carried through using 2 mol% of catalyst (Table 
4.10).  
All β-nitrostyrene derivatives 4.28a-k converted to the desired product within 24 
hours with ≥ 95% conversion. Most of the substrates also converted with 
enantioselectivities greater than 85%, with two converting with enantioselectivities in the 
70’s (entry 7 and 12), one in the 60’s (entry 14), and the last at 50% ee (entry 11). Pyridyl 
4.28h had the lowest enantioselectivity at 50% ee, which is unsurprising due to the  
ability of the nitrogen to participate as a base, enabling the substrate to self-catalyze the 
racemic reaction. A separate background reaction was carried out using 4.28h without 
catalyst to see if a reaction would occur on its own. The reaction was left in an NMR tube 
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at room temperature for 72 hours. After being checked, there was approximately 5% 
conversion of starting material to product, conforming the background reaction had 
occurred. Substrate 4.28k was the only non-aromatic nitroolefin that was screened and 
although it did convert to the desired material, it also produced a by-product that led to a 
decreased yield and ee (entry 14). 
Table 4.4 Enantioselective substrate scope 
 
Entry Substrate R 
Catalyst Load 
(mol %) 
Conversiona 
(%) 
Yieldb 
(%) 
eec 
(%)a 
1 4.28a Ph 0.05 100 96 88 
2 4.28b 4-Me 0.05 87 -- -- 
3 4.28b 4-Me 0.2 95 74 88 
4 4.28b 4-Me 0.5 95 88 88 
5 4.28c 4-Cl 0.05 52 -- -- 
6 4.28c 4-Cl 0.2 95 78 84 
7 4.28d 4-CF3 0.2 95 49 72 
8 4.28e 4-OMe 0.2 95 65 86 
9 4.28f 3-OMe 0.2 100 69 87 
10 4.28g 2-Br 0.2 98 90 85 
11 4.28h 3-pyridyl 0.2 100 65 50 
12 4.28i 2-furyl 0.2 100 72 76 
13 4.28j cinnamoyl 0.2 100 99 87 
14 4.28k cyclohexyl 0.2 100 47 67 
Note: a) Conversions were determined by 1H NMR integration of product to remaining starting material. b) Yield is recorded for 
compounds purified by column chromatography. c) Enantioselectivities were calculated from HPLC integration after the peaks had 
been compared to the racemic mixtures. A table of retention times and absorbances can be seen in section 4.7.2.3 Table 4.5. 
The proposed mechanism uses squaramide organocatalysts to bind to the nitro 
group of 4.8a and dock via hydrogen bonding to form complex 4.41. MAC (4.26) has a 
pKa of ~ 10, enabling deprotonation through the basic nitrogen of the quinine ring. and 
bringing it within 5 Å of 4.8a allowing addition to occur (4.42) producing 4.28a.  
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Scheme 4.4 Catalytic cycle for the addition of MAC to β-nitrostyrene 
 
4.4.2.3 Derivatization of Nitro-MAC Analogs  
The products were then converted to desirable natural product synthons including 
β-amino acids, β-lactams, and indolines (Scheme 4.11). Silyl deprotection of 4.28a using 
TBAF in the presence of N-methylamine converted the MAC group to nitroamide 4.46 
with a 94% yield. Also, HF·Pyr in the presence of MeOH converted the MAC group to 
nitroesters 4.44 and 4.45 with yields of 64 and 52%, respectively. Reduction of the nitro 
group was accomplished via H2 and Pd/C to synthesize amines 4.47 and 4.48 with yields 
of 80 and 75%, respectively.  
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Scheme 4.5 Derivatization of β-nitrostyrenes to for desirable natural product synthons 
The remaining derivatizations shown in Scheme 4.5 have yet to be completed. 
Chiral β-amino acids can be produced from 4.44 using LiOH in THF/H2O.160 The 
rotation of 4.46 will be measured and compared to a known amino acid to determine the 
exact configuration of the stereocenter. Based on the proposed catalytic cycle, the R-
enantiomer is predicted. Exposure of 4.44 to MeMgBr and Et2O will trigger lactonization 
to form chiral β-lactams.161 Additionally amine 4.45 can undergo a reductive cyclization 
using Bu3SiH and AIBN to synthesize indoline 4.48.
162 These remaining reactions serve 
to both identify the enantiomer formed in the addition of MAC reagents to β-
nitrostyrenes and to highlight the utility of the method by forming useful natural product 
synthons.
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4.5 Summary and Conclusion 
The understanding of the important noncovalent interactions within 
organocatalyzed reactions is undoubtedly an underexplored area of research, providing 
new avenues of catalyst design and reaction development. The research group is 
interested in squaramide and thiourea catalysts that serve as dual catalysts able to both 
hydrogen bond to activate the substrate and to deprotonate a nucleophile. With these 
properties in mind, an initial screen of new Michael addition reactions was undertaken 
and the addition of a masked acyl cyanide (MAC) reagent to β-nitrostyrene was realized. 
MACs are unique one carbon nucleophiles providing the synthetic equivalent of an acyl 
anion addition to a substrate. Squaramide and thiourea organocatalysts contain tertiary 
amines that are basic enough to deprotonate the MAC. The products are enantiopure 
nitroolefins with a chiral center adjacent to an aromatic ring. A catalyst screen identified 
a quinine-derived squaramide organocatalyst as the ideal catalyst and a solvent screen 
identified chloroform as the solvent that provided the best conversions and 
enantioselectivity. A variety of substituted β-nitrostyrenes were synthesized to 
demonstrate the substrate scope. Using only 2 mol% of catalyst, all substrates converted 
in ≥ 95% within 24 hours. Product yields ranged from 50-96% with 50-88% ee. 
Additionally, a route to desirable natural product synthons such as β-amino acids, β-
lactams, and 2-substituted indolines is in progress and demonstrates the utility of the 
products.  
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4.6 Experimental 
4.6.1 General Methods 
4.6.1.1 Experimental Techniques 
Starting materials were purchased from commercial vendors and used without 
purification unless noted. Unless otherwise noted, all reactions were carried out using 
flame-dried glassware and standard syringe, cannula, and septa techniques, when 
necessary.67 Tetrahydrofuran (THF), diethyl ether (Et2O), hexanes, dichloromethane 
(CH2Cl2), and toluene (PhCH3) were dried by passage through a column of activated 
alumina on an mBraun SPS.68 Acetonitrile (ACN) was dried by passage through a 
column of activated alumina on an Innovative Technologies system. Analytical thin layer 
chromatography was performed using Sorbent Technologies 250 m glass-backed 
UV254 silica gel plates. The plates were first visualized by fluorescence upon 254 nm 
irradiation then by iodine chamber. The plates were then dipped in one of the following 
stains followed by heating: p-anisaldehyde, phosphomolybdic acid, vanillin, ceric 
ammonium molybdate, potassium iodoplatinate, ninhydrin or bromocresol green. Flash 
column chromatography was performed using Sorbent Technologies 40-63 µm, pore size 
60 Å silica gel with solvent systems indicated. Solvent removal was affected using a 
Buchi R3 rotary evaporator with a V900 diaphragm pump (~10 mmHg).  All yields refer 
to isolated material that is chromatographically (TLC or HPLC) and spectroscopically 
(1H NMR) homogenous.  
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4.6.1.2 Characterization 
All melting points were taken with a Thomas Hoover melting point apparatus and 
are uncorrected. Infrared spectra were recorded on a Nicolet Nexus 470 FTIR 
spectrometer as neat liquids, oils, solids or as thin films formed from evaporation of 
NMR solvent over the ATR plate. HPLC were recorded on an Agilent 1260 Infinity using 
a CHIRALPAK IC (4.6 x 250 mm, 5 micron) column with a isocratic gradient of 5% 
iPrOH in hexanes monitoring at 214 nm. High-resolution mass spectra were recorded at 
the Old Dominion University College of Science Major Instrumentation Center 
(COSMIC) on a Bruker 12 Tesla APEX-Qe FTICR-MS with an Apollo II ion source. 
Combustion analysis was performed at Atlantic Microlabs on samples taken from the 
bulk of the material. Optical rotation analysis was done with a Rudolph Research 
Analytical Autopol IV Automatic Polarimeter. 
 
4.6.1.3 NMR Parameters 
Proton nuclear magnetic resonance spectra were recorded on a Bruker UltraShield 
Plus 400 MHz spectrometer and are recorded in parts per million from internal 
chloroform (7.26 ppm), methanol, benzene, or dimethylsulfoxide on the  scale and are 
reported as follows: chemical shift [multiplicity (s=singlet, d=doublet, t=triplet, 
q=quartet, qu=quintet, m=multiplet, and derivatives thereof), coupling constant(s) in 
hertz, integration, interpretation].69 13C NMR data were recorded on a Bruker UltraShield 
Plus 100 MHz spectrometer and are reported as follows: chemical shift (multiplicity as 
determined from DEPT (CH, CH3 up and CH2 down) and/or HSQC experiments). 
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4.6.1.4 General Procedures for the Synthesis of β-Nitrostyrene Derivatives 
Method 1:156 
 
To a flask fitted with a thermometer in an ice salt water bath, aldehyde (16.65 
mmol, 1 eq) followed by methanol (16.65 mmol, 5 M) and nitromethane (16.65 mmol, 1 
eq) were added. The solution cooled to -10 °C and sodium hydroxide (16.65 mmol, 25 
M) was added dropwise via syringe keeping the temperature between 0 – 10 °C. A white 
precipitant formed. If the solution became too thick to stir properly, 1-2 mL of methanol 
was added. The slurry stirred for fifteen minutes. To this, 6-7 mL of ice water was added 
slowly, and was added dropwise via pipette to a solution of hydrochloric acid (16.65 
mmol, 1.67 M) that was in an ice and salt water bath. The temperature was kept below 
10 °C. This stirred for 30 minutes at 10 °C. The resulting solid or oil was purified as 
needed.  
If solid formed, it is filtered out by suction and washed with ice water. The 
resulting solid is recrystallized with cold ethanol producing a pure product. If an oil 
formed, it was extracted with Et2O (20 mL x 3). The combined organic phase was 
washed with brine, dried over sodium sulfate, filtered, and condensed to a crude oil 
which was purified by column chromatography. 
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Method 2:158 
 
An aldehyde (2.87 mmol, 1 eq) was added dropwise via syringe into a solution of 
ammonium acetate (6.80 mmol, 2.4 eq), nitromethane (2.87 mmol, 0.5 M), and acetic 
acid (2.87 mmol, 0.25 M) that was refluxing at 90 C. The reaction refluxed for 5 hours 
and then was poured into water and extracted with EtOAc (20 mL x 3). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered and 
concentrated into a crude oil. The crude was purified by column chromatography.  
Method 3:157 
 
Aldehyde (15.13 mmol, 1 eq) and nitromethane (15.13 mmol, 0.33 M) were 
added to a flask followed by ammonium acetate (4.54 mmol, 0.3 eq) and stirred for 5 
hours at 100 C. The reaction cooled and ethyl acetate ( 30 mL) and water (30 mL) were 
added to the reaction flask. The reaction was extracted by EtOAc (60 mL) three times. 
The combined organic layers were washed with brine, dried over sodium sulfate and 
filtered. The resulting crude was either purified by column chromatography or 
recrystallization with cold ethanol. 
Characterization data can be found at the provided references for substrates 4.8a-k. 
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4.6.1.5 General Procedure for the Synthesis of TBS protected Masked Acyl Cyanide 
 
Part A:163 NaH (0.17 mol) was added to a flame dried, 250 mL, two-necked, round 
bottom flask. The flask was capped with a rubber septum and then purged with N2 for 5 
minutes. THF (90 mL) was added to the flask via syringe, and the reaction was cooled to 
0 C for 10 minutes. Malononitrile (5.0 g, 0.076 mol) was added to a separate flamed 
dried 50 mL recovery flask and fully dissolved in THF (5 mL) before it was transferred 
via syringe to the 250 mL round bottom flask. The reaction stirred for 30 minutes before 
acetic anhydride (0.076 mol) was added dropwise via syringe before stirring for an 
additional 60 minutes. The reaction was then warmed to room temperature and the 
solvent removed in vacuo. The resulting solid is then slurried with acetone before being 
filtered. The filter cake is collected, slurried again with acetone and filtered an additional 
two times. The brown filtrate is then collected and concentrated to produce a light tan 
solid. The solid is then transferred to a flame dried 250 mL round bottom flask and 
dissolved in diethyl ether (40 mL). The reaction is then cooled to 0 C before a solution 
of 2 M HCl in diethyl ether (40 mL) is added. The reaction is then warmed to room 
temperature over a 2-hour period, before the solid is filtered and rinsed with DCM (25 
mL). The brown solid is then collected and dried over night to produce acetyl 
malononitrile as a tacky brown solid. (7.56 g, 98% yield) 
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Part B:142 Acetyl malononitrile (1.3g, 12 mmol) was added to a 200 mL round bottom 
flask and dissolved in H2O (10 mL). AcOOH (10 mL) and AcOH (20 mL) were mixed 
together in a secondary container before being added to the acetyl malononitrile. The 
reaction stirred at room temperature for 2 hours before the solvents were removed in 
vacuo to produce a white oil. The oil was then dissolved in DMF (20 mL) and cooled to 0 
C. TBS-Cl (3.07g, 20.4 mmol) was added followed by imidazole (1.23g, 18 mmol). The 
reaction stirred for 30 minutes at 0 C and then 30 minutes at room temperature. The 
reaction as diluted with Et2O (40 mL) and H2O (30 mL) and extracted 3 times with Et2O 
(20 mL). The organic layer was collected washed with saturated NaHCO3 (20 mL) and 
Brine (20 mL) before being dried over Na2SO4. The resulting solution was concentrated 
and purified on SiO2 ( 0%, 3%, 6% EtOAc/Hex). Pale Yellow Oil. 
 
4.6.1.6 General Procedure for the Racemic Base Catalzyed Addition of Masked Acyl 
Cyanides to β-Nitrostyrenes 
 
To a flame dried 4 mL vial fitted with a stir bar, 2-((tert-butyldimethylsilyl)oxy)-
malononitrile (MAC) (43 mg, 1.1 eq) was added and dissolved in deuterated chloroform 
(0.670 mL, 0.3 M). β-Nitrostyrene (30 mg, 1.0 equiv) was added followed by base (0.1 
eq). The reaction was monitored by 1H NMR until complete. The crude material was 
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purified by SiO2 (5-10% EtOAc/hexanes), and analyzed by HPLC Chiralpak IC 95% 
hexanes/iPrOH, flow rate 1 mL/min. 
Table 4.5 Racemic synthesis of the MAC addition to β-nitrostyrenes 
Entry R1 R2 Base (0.1 
eq) 
Conversion 
(%) 
Yield 
(%) 
Peak 1 
(min) 
Peak 2 
(min) 
1a Ph H TEA 0 --- --- --- 
1b Ph H Pyridine 32 --- --- --- 
1c Ph H DMAP 0 -- --- --- 
1d Ph H Imidazole 51 --- --- --- 
1e Ph H NaOH 100  5.374 6.549 
2 4-MePh H NaOH 100 54.7 5.289 6.743 
3 4-ClPh H NaOH 100 33.5 6.305 7.713 
4 4-CF3Ph H NaOH 100 51.0 5.110 6.468 
5 4-OMePh H NaOH 100 95.0 7.197 8.757 
6 3-OMePh H NaOH 100 52.8 6.696 7.721 
7 2-BrPh H NaOH 100 65.0 5.450 6.376 
8 3-Pyridine H NaOH 100 30.3 3.484 4.130 
9 Furan H NaOH 100 28.2 5.227 6.161 
10 Cinnamoyl H NaOH 100 72 5.797 6.462 
11 Cyclohexyl H NaOH 100 30 4.241 
(6.218) 
4.580 
(6.603) 
 
4.6.1.7 General Procedure for the Organocatalyzed addition of Masked Acyl 
Cyanides to β-Nitrostyrenes 
 
To a flame dried 4 mL vial fitted with a stir bar was added 2-((tert-
butyldimethylsilyl)oxy)malononitrile (MAC) (43 mg, 1.1 eq). Chloroform (0.670 mL, 0.3 
M) was added followed by β-nitrostyrene (30 mg, 1.0eq). The reaction was then placed in 
the freezer to stir for 10 minutes while cooling to 0 C before organocatalyst (0.4 mg, 
0.005 eq) was added. The reaction was left to stir at 0 C for 24 hours before the solvent 
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was removed. The crude material was purified on SiO2 (5%-10% EtOAc/hexanes) and 
analyzed by HPLC Chiralpak IF 95% hexanes/iPrOH at a flow rate of 1 mL/min. 
2-((tert-Butyldimethylsilyl)oxy)-2-(2-nitro-1-
phenylethyl)malononitrile (4.28a): Following the general procedure 
for the enantioselective addition of MAC to β-nitrostyrenes., 4.8a was 
isolated as a white solid (67.0 mg, 96% yield, 88% ee). Rf = 0.41 (20% EtOAc/Hex). mp 
63-65 C; IR (thin film) 3020, 2932, 2859, 2246, 1558, 1379, 1129 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 7.47-7.39 (m, 5H), 5.07 (dd, J = 13.8, 5.8 Hz, 1H), 4.93 (dd, J = 
13.8, 8.4, Hz, 1H), 4.26 (dd, J = 8.4, 5.8 Hz, 1H), 0.93 (s, 9H), 0.37 (s, 3H), 0.32 (s, 3H); 
13C NMR (CDCl3, 100 MHz) δ 130.5 (d), 130.4 (s), 129.5 (d, 2C), 113.8 (s), 113.4 (s), 
74.8 (t), 66.9 (s), 53.4 (d), 25.3 (q), 18.2 (s), ‒4.59 (q), ‒4.62 (q); HPLC: Rt 7.29 min 
(major), 5.81 min (minor); [α]25D  = +7.5 (c = 1.0, CHCl3); HRMS ESI: Exact mass calcd 
for C17H23N3O3SiNa [M+Na]
+, 368.1400. Found 368.1402. 
2-((tert-Butyldimethylsilyl)oxy)-2-(2-nitro-1-(p-
tolyl)ethyl)malononitrile (4.28b): Following the general procedure 
for the enantioselective addition of MAC to β-nitrostyrenes, 4.8b was 
isolated as a pale yellow oil (48.2 mg, 73% yield, 88% ee). Rf = 0.43 (20% EtOAc/Hex).  
IR (thin film) 2931, 2860, 2240, 1562, 1375, 1128 cm-1; 1H NMR (CDCl3, 400 MHz) δ 
7.30 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 5.04 (dd, J = 13.6, 5.8 Hz, 1H), 4.90 
(dd, J = 13.6, 8.4 Hz, 1H), 4.22 (dd, J = 8.4, 5.8 Hz, 1H), 2.37 (s, 3H), 0.94 (s, 9H), 0.38 
(s, 3H), 0.32 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 140.5 (s), 130.1 (d), 129.2 (d), 127.1 
(s), 113.8 (s), 113.3 (s), 74.2 (t), 67.0 (s), 53.0 (d), 25.2 (q), 21.3 (q), 18.1 (s), ‒4.72 (q), ‒
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4.74 (q); HPLC: Rt 6.59 min (major), 5.24 min (minor); [α]25D  = +6.5 (c = 1.0, CHCl3); 
HRMS ESI: Exact mass calcd for C18H25N3O3SiNa [M+Na]
+, 382.1557. Found 382.1559. 
2-((tert-Butyldimethylsilyl)oxy)-2-(1-(4-chlorophenyl)-2-
nitroethyl)malononitrile (4.28c): Following the general procedure 
for the enantioselective addition of MAC to β-nitrostyrenes, 4.8c was 
isolated as a yellow oil (48.4 mg, 78% yield, 84% ee). Rf = 0.46 (20% EtOAc/Hex).  IR 
(thin film) 2931, 2860, 2237, 1562, 1375, 1130 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.43 
(d, J = 8.5 Hz, 2H), 7.36 (d, J = 8.5 Hz, 2H), 5.05 (dd, J = 13.8, 5.5 Hz, 1H), 4.89 (dd, J 
= 13.8, 8.8 Hz, 1H), 4.23 (dd, J = 8.8, 5.5 Hz, 1H), 0.94 (s, 9H), 0.38 (s, 3H), 0.33 (s, 
3H); 13C NMR (CDCl3, 100 MHz) δ: 136.6 (s), 130.7 (d), 129.7 (d), 128.7 (s), 113.5 (s), 
113.1 (s), 73.9 (t), 66.4 (s), 52.7 (d), 25.2 (q) 18.1 (s), ‒4.71 (q), ‒4.75 (q); HPLC: Rt 7.55 
min (major), 6.20 min (minor); [α]25D  = ‒0.03 (c = 1.0, CHCl3); HRMS ESI: Exact mass 
calcd for C17H22ClN3O3SiNa [M+Na]
+, 402.1011. Found 402.1013. 
2-((tert-Butyldimethylsilyl)oxy)-2-(2-nitro-1-(4-
(trifluoromethyl)phenyl)ethyl)malononitrile (4.28d): Following 
the general procedure for the enantioselective addition of MAC to 
β-nitrostyrenes, 4.8d was isolated as a yellow oil (28.0 mg, 49% yield, 72% ee). Rf = 0.20 
(5% EtOAc/Hex). IR (thin film) 2955, 2933, 2860, 2237, 1562, 1325, 1119 cm-1; 1H 
NMR (CDCl3, 400 MHz) δ 7.72 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 5.09 (dd, J 
= 13.9, 5.4 Hz, 1H), 4.95 (dd, J = 13.9, 8.9 Hz, 1H), 4.33 (dd, J = 8.9, 5.4 Hz, 1H), 25.1 
(s, 9H), 18.1 (s), ‒4.72 (s, 3H), ‒4.77 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 134.2 (s), 
132.4 (q, J = 33.0 Hz)*, 129.9 (d), 126.4 (q, J = 3.6 Hz)*, [127.5, 124.8, 122.1, 119.4] 
(s), 113.4 (s), 113.0 (s), 73.8 (t), 66.2 (s), 59.2 (d), 25.1 (q), 18.1 (s), ‒4.72 (q), ‒4.77 (q); 
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HPLC: Rt 6.27 min (major), 5.02 min (minor); [α]25D  = -20.2 (c = 0.63, CHCl3); HRMS 
ESI: Exact mass calcd for C18H22F3N3O3SiNa [M+Na]
+, 436.1274. Found 436.1277. 
*Due to C-F coupling. 
2-((tert-Butyldimethylsilyl)oxy)-2-(1-(4-methoxyphenyl)-2-
nitroethyl)malononitrile (4.28e): Following the general 
procedure for the enantioselective addition of MAC to β-
nitrostyrenes, 4.8e was isolated as a pale-yellow oil (54.1 mg, 86% yield, 86% ee.). Rf = 
0.20 (5% EtOAc/Hex). IR (thin film) 2932, 2860, 2245, 1262, 1515, 1376, 1255, 1128 
cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.34 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.7 Hz, 1H), 
5.03 (dd, J = 13.6, 5.7 Hz, 1H), 4.88 (dd, J = 13.6, 8.6 Hz, 1H), 3.82 (s, 3H), 4.21 (dd, J = 
8.6, 5.7 Hz, 1H), 25.2 (s, 9H), 0.38 (s, 3H); 0.33 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 
161.0 (s), 130.6 (d), 121.9 (s), 114.8 (d), 113.8 (s), 113.3 (s), 74.3 (t), 67.0 (s), 55.3 (q), 
52.7 (d), 25.2 (q), 18.1 (s), ‒4.72 (q), ‒4.74 (q); HPLC: Rt 8.57 min (major), 7.08 min 
(minor); [α]25D  = +8.1 (c = 1.0, CHCl3); HRMS ESI: Exact mass calcd for 
C18H25N3O4SiNa [M+Na]
+, 398.1506. Found 398.1509. 
2-((tert-Butyldimethylsilyl)oxy)-2-(1-(3-methoxyphenyl)-2-
nitroethyl)malononitrile (4.28f):Following the general procedure for 
the enantioselective addition of MAC to β-nitrostyrenes, 4.8f was 
isolated as a white solid (43.3 mg, 69% yield, 87% ee.). Rf = 0.36 (20% EtOAc/Hex). mp 
77-80 C;  IR (solid) 2958, 2931, 2860, 2243, 1559, 1259, 1136 cm-1; 1H NMR (CDCl3, 
400 MHz) δ 7.34 (t, J = 8.0 Hz, 1H), 7.04-6.91 (m, 3H), 5.04 (dd, J = 13.8, 5.8 Hz, 1H), 
4.90 (dd, J = 13.8, 8.3 Hz, 1H), 4.22 (dd, J = 8.3, 5.8 Hz, 1H), 3.82 (s, 3H), 0.94 (s, 9H), 
0.38 (s, 3H), 0.33 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 160.1 (s), 131.6 (d), 130.4 (d), 
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121.3 (d), 115.7 (d), 115.3 (d), 113.7 (s), 113.3 (s), 74.2 (t), 66.7 (s), 55.4 (q), 53.2 (d), 
25.2 (q), 18.1 (s), ‒4.71 (q), ‒4.75 (q); HPLC: Rt 7.44 min (major), 6.50 min (minor); 
[α]25D  = +7.0 (c = 0.96, CHCl3); HRMS ESI: Exact mass calcd for C18H25N3O4SiNa 
[M+Na]+, 398.1506. Found 398.1509. 
2-(1-(2-Bromophenyl)-2-nitroethyl)-2-((tert-
butyldimethylsilyl)oxy)malononitrile (4.28g): Following the general 
procedure for the enantioselective addition of MAC to β-nitrostyrenes, 
4.8g was isolated as a yellow oil (50.2 mg, 90% yield, 85% ee). Rf = 0.44 (20% 
EtOAc/Hex). IR (thin film) 2932, 2859, 2244, 1567, 1376, 1136 cm-1; 1H NMR (CDCl3, 
400 MHz) δ 7.72 (dd, J = 8.0, 1.2 Hz, 1H), 7.49 (dd, J = 7.8, 1.6 Hz, 1H), 7.40 (td, J = 
7.6, 1.2 Hz, 1H), 7.30 (td, J = 8.0, 1.6 Hz, 1H), 5.15 (dd, J = 9.0, 5.2 Hz, 1H), 5.06 (dd, J 
= 13.7, 5.2 Hz, 1H), 4.89 (dd, J = 13.7, 9.0 Hz, 1H), 0.94 (s, 9H), 0.40 (s, 3H), 0.33 (s, 
3H); 13C NMR (CDCl3, 100 MHz) δ 134.4 (d), 131.5 (d), 130.4 (s), 128.4 (d), 128.2 (d), 
127.4 (s), 113.3 (s), 113.2 (s), 74.3 (t), 65.5 (s), 50.5 (d), 25.2 (q), 18.1 (s), ‒4.65 (q). ‒
4.70 (q); HPLC: Rt 6.13 min (major), 5.32 min (minor); [α]25D  = +29.0 (c = 1.0, CHCl3); 
HRMS ESI: Exact mass calcd for C17H22BrN3O3SiNa [M+Na]
+, 446.0506. Found 
446.0508. 
2-((tert-Butyldimethylsilyl)oxy)-2-(2-nitro-1-(pyridin-3-
yl)ethyl)malononitrile (4.28h): Following the general procedure for the 
enantioselective addition of MAC to β-nitrostyrenes, 4.8h was purified 
by SiO2 (25%, 50%, 100% EtOAc/hexanes) and isolated as a brown oil (45.0 mg, 65% 
yield, 50% ee). IR (thin film) 2927, 2854, 2212, 1715, 1375, 1104 cm-1; 1H NMR 
(CDCl3, 400 MHz) δ 8.62 (dd, J = 4.8, 1.6 Hz, 1H), 8.60 (d, J = 2.2 Hz, 1H), 7.68 (dt, J 
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=8.0, 2.1 Hz, 1H), 7.30 (ddd, J = 8.0, 4.8, 0.6 Hz, 1H), 5.01 (dd, J = 13.9, 5.3 Hz, 1H), 
4.85 (dd, J = 13.9, 9.1 Hz, 1H), 4.20 (dd, J = 9.1, 5.3 Hz, 1H), 0.84 (s, 9H), 0.28 (s, 3H), 
0.22 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 151.6 (d), 150.7 (d), 136.5 (d), 126.5 (s), 
123.9 (d), 113.3 (s), 112.9 (s), 73.5 (t), 66.1 (s), 51.2 (d), 25.2 (q), 18.1 (s), ‒4.73 (q), ‒
4.78 (q); HPLC: Rt 3.42 min (major), 4.01 min (minor). [α]25D  = ‒44.1 (c = 0.54, CHCl3)  
2-((tert-Butyldimethylsilyl)oxy)-2-(1-(furan-2-yl)-2-
nitroethyl)malononitrile (4.28i): Following the general procedure for 
the enantioselective addition of MAC to β-nitrostyrenes, 4.8j was 
isolated as a pale-yellow oil (52.1 mg, 72% yield, 87% ee). Rf = 0.28 (20% EtOAc/Hex). 
IR (thin film) 2931, 2860, 2237, 1565, 1375, 1261, 1136 cm-1; 1H NMR (CDCl3, 400 
MHz) δ 7.50 (dd, J = 1.8, 0.6 Hz, 1H), 6.60 (d, J = 3.4 Hz, 1H), 6.45 (dd, J = 3.4, 1.8 Hz, 
1H), 4.97 (d, J = 6.3 Hz, 1H), 4.95 (d, J = 7.4 Hz, 1H), 4.47 (dd, J = 7.4, 6.3 Hz, 1H), 
0.92 (s, 9H), 0.38 (s, 3H), 0.34 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 144.6 (d), 143.7 
(s), 113.5 (s), 113.0 (s), 112.3 (d), 111.3 (d), 72.6 (t), 65.5 (s), 47.8 (d), 25.1 (q), 18.0 (s), 
‒4.76 (q), ‒4.79 (q); HPLC: Rt 6.04 min (major), 5.17 min (minor); [α]25D  = ‒5.6 (c = 
1.0, CHCl3); HRMS ESI: Exact mass calcd for C15H21N3O4SiNa [M+Na]
+, 358.1193. 
Found 358.1195. 
 (E)-2-((tert-Butyldimethylsilyl)oxy)-2-(1-nitro-4-phenylbut-3-
en-2-yl)malononitrile (4.28j): Following the general procedure for 
the enantioselective addition of MAC to β-nitrostyrenes, 4.8i was 
isolated as a yellow oil (63.0 mg, 99% yield, 76% ee). Rf = 0.43 (20% EtOAc/Hex). IR 
(thin film) 2930, 2860, 2240, 1561, 1376, 1135 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.37 
(m, 5H), 6.87 (d, J = 15.7 Hz, 1H), 6.00 (dd, J = 15.7, 9.4 Hz, 1H), 4.85 (dd, J = 10.3, 5.1 
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Hz, 1H), 4.59 (dd, J = 13.0, 8.7 Hz, 1H), 3.85 (ddd, J = 9.1, 8.9, 5.1 Hz, 1H), 0.95 (s, 
9H), 0.41 (s, 3H), 0.39 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 141.0 (d), 134.8 (s), 129.3 
(d), 128.8 (d), 127.1 (d), 116.8 (d), 113.7 (s), 113.2 (s), 74.3 (t), 66.0 (s), 52.0 (d), 25.2 
(q), 18.1 (s), ‒4.65 (q), ‒4.68 (q); HPLC: Rt 6.27 min (major), 5.66 min (minor); [α]25D  = 
‒3.2 (c = 1.0, CHCl3); HRMS ESI: Exact mass calcd for C19H25N3O3SiNa [M+Na]+, 
394.1557. Found 394.1559. 
2-((tert-Butyldimethylsilyl)oxy)-2-(1-cyclohexyl-2-
nitroethyl)malononitrile (4.28k): Following the general procedure for 
the enantioselective addition of MAC to β-nitrostyrenes, 4.8k was 
separated on a ACCQ Prep HP125, Phenomenex Prodigy 5 micron ODS(3) 100 Å, 
water/acetonitrile gradient. 4.8k was isolated as a colorless oil (31.9 mg, 47% yield, 67% 
ee). Rf = 0.51 (20% EtOAc/Hex). IR (thin film) 2969, 2930, 2860, 1563, 1377, 1157 cm
-
1; 1H NMR (CDCl3, 400 MHz) δ 4.60 (dd, J = 14.5, 6.8 Hz, 1H), 4.53 (dd, J = 14.5, 4.5 
Hz, 1H), 3.08 (ddd, J = 7.3, 4.3, 3.2 Hz, 1H), 2.04-0.97 (m, 10H), 0.90 (s, 9H), 0.42 (s, 
9H), 0.36 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ 114.4 (s), 114.1 (s), 72.0 (t), 66.0 (s), 
52.6 (d), 37.9 (d), 32.5 (t), 28.2 (t), 26.4 (t), 26.0 (t), 25.7 (t), 25.1 (q), 18.0 (s), ‒4.64 (q), 
‒4.75 (q); HPLC: Rt 4.24 min (major), 4.58 min (minor); HRMS ESI: Exact mass calcd 
for C17H29N3O3SiNa [M+Na]
+, 372.187039. Found 372.186843.  
Methyl 3-nitro-2-phenylpropanoate (4.44): To a 20 mL vial, 4.34a 
(50 mg, 0.14 mmol) was dissolved in THF (0.15 M). The reaction was 
left to cool at -25 C for 10 minutes before HF·Pyr in THF (1.35 eq, 0.6 
M) was added dropwise. The reaction stirred for 2 hours before MeOH (0.16M) was 
added followed by TEA in MeOH (3 eq, 0.98 M) 10 minutes later. The reaction stirred an 
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additional 10 minutes before warming to 0 C and quenching with 5 mL 1 N HCl. The 
reaction was extracted 2x with Et2O. The combined organic layers were collected, dried 
over Na2SO4, filtered through Celite and concentrated. Purification on SiO2 (5-10-20% 
EtOAc/hexanes) yielded a pale yellow oil (20.4 mg, 64% yield). Characterization data 
matched that found at the following reference. 164  
Methyl 2-(2-bromophenyl)-3-nitropropanoate (4.45): To a 20 mL 
vial, 4.34a (50 mg, 0.14 mmol) was dissolved in THF (0.15 M). The 
reaction was left to cool at -25 C for 10 minutes before HF·Pyr in THF 
(1.35 eq, 0.6M) was added dropwise. The reaction stirred for 2 hours before MeOH 
(0.16M) was added followed by TEA in MeOH (3 eq, 0.98 M) 10 minutes later. The 
reaction stirred an additional 10 minutes before warming to 0 C and quenching with 5 
mL 1 N HCl. The reaction was extracted 2x with Et2O. The combined organic layers 
were collected, dried over Na2SO4, filtered through Celite and concentrated. Purification 
on SiO2 (5-10-20% EtOAc/hexanes) yielded a yellow oil (17.8 mg 59% yield); IR (thin 
film)1H NMR (CDCl3, 400 MHz) δ 7.63 (m, 1H), 7.32 (m, 1H), 7.22 (m, 2H), 5.01 (m, 
2H), 4.57 (m, 1H), 3.77 (s, 3H); 13C NMR (CDCl3, 100 MHz) δ: 170.7 (s), 133.8 (d), 
133.0 (s), 130.2 (d), 129.2 (d), 128.3 (d), 124.4 (s), 74.4 (t), 53.1 (q), 48.0 (d) 
N-Methyl-3-nitro-2-phenylpropanamide (4.46): To a 10 mL round 
bottom flask under N2, 4.63 was dissolved in THF. MeNH2 (4 eq, .578 
mmol) was added and the reaction cooled to -25 C for 10 minutes 
before TBAF (1.2 eq, .173 mmol) was added dropwise. The reaction was left to stir for 2 
hours before being quenched with NH4Cl and extracted three times with Et2O. The 
organic layers were collected, dried over Na2SO4, filtered through Celite and 
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concentrated. Purification on SiO2 (25-50-100% EtOAc/hexanes) provided an orange 
solid ( 8.3 mg, 94% yield). Rf = 0.07 (20% EtOAc/Hex). mp 90-93 C; IR (thin film) 
3306, 2909, 1648, 1543 cm-1; 1H NMR (CDCl3, 400 MHz) δ: 7.40-7.25 (m, 5H), 5.68 (s, 
1H), 5.22 (dd, J = 14.2, 8.4 Hz, 1H), 4.55 (dd, J = 14.2, 6.3 Hz, 1H), 4.28 (dd, J = 8.4, 
6.3 Hz, 1H), 2.77 (d, J = 4.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 170.2 (s), 134.6 (s), 
129.5 (d), 128.7 (d), 128.1 (d), 76.3 (t), 50.0 (s), 26.7 (q). HRMS ESI: Exact mass calcd 
for C10H12N2O3Na [M+Na]
+, 231.074013. Found 231.073962. 
Methyl 3-amino-2-phenylpropanoate (4.47): To a 10 mL flame dried 
round bottom flask, 4.65 (245 mg, 1.2 mmol) was added and dissolved 
in EtOH (1.2 mL). Pd/C (10% by weight, 0.2 eq) was weighed out and 
added to the stirring reaction. A full H2 balloon was added and used to purge the reaction 
before it was refilled and attached. The reaction stirred 18 h before being filtered through 
Celite and washed with EtOAc. The reaction was concentrated to provide a yellow oil 
that did not need purification (167 mg, 80% yield). Characterization data can be found at 
the provided reference.165 
Methyl 3-amino-2-(2-bromophenyl)propanoate (4.47): To a 10 mL 
flame dried round bottom flask, 4.65 (105 mg, 0.36 mmol) was added 
and dissolved in EtOH (1.2 mL). Pd/C (10% by weight, 0.2 eq)  was 
weighed out and added to the stirring reaction. A full H2 balloon was added and used to 
purge the reaction before it was refilled and attached. The reaction stirred 18 h before 
being filtered through Celite and washed with EtOAc. The reaction was concentrated to 
furnish an orange oil that did not require further purification (160 mg, 75% yield).IR (thin 
film) 3029, 1731, 1550, 1375 cm-1; 1H NMR (CDCl3, 400 MHz) δ 7.41-7.23 (m, 3H), 
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7.28 (d, J = 2.0 Hz, 1H), 5.11 (dd, J  = 14.6, 9.9 Hz, 1H), 4.55 (dd, J = 14.6, 5.1 Hz, 1H), 
4.45 (dd, J = 9.9, 5.1 Hz, 1H), 3.74 (s, 3H), 1.74 (br s, NH2, 2H); 
13C NMR (CDCl3, 100 
MHz) δ: 171.1 (s), 133.2 (s), 129.4 (d, 2C), 128.8 (d), 127.9 (d, 2C), 75.8 (t), 52.9 (d), 
48.7 (q). 
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 - CONCLUSION 
Presented in this dissertation is an overarching theme of using noncovalent 
interactions to manipulate organic reactions for the synthesis of natural product synthons 
and the binding of natural products with enzymes. In the first project, a method was 
established to convert esters to ethers in a two-step process. The first step was a DIBAL-
H reduction followed with a TMS protection to form a stable acetal. It was monitored 
using ReactIR enabling the time to drastically decrease to currently set literature 
precedent, as well as to determine the exact number of equivalents of DIBAL-H 
necessary for each substrate. Additionally, this reaction did not require further 
purification of the acetal with crude yields mainly above 80%. The reduction of the acetal 
to ether was also carried out successfully with a broad range of substrates. The 
intermediate is an oxonium ion and in cases where the yield was lower, a reaction 
bifurcation with a competing oxonium ion was identified which led to the formation of 
byproducts including a symmetric ether. In total 13 esters were successfully converted to 
the ether product. 
The second project involved the synthesis of trisubstituted biaryl quinolines for 
the inhibition of HIV-1 integrase. These substrates bind noncovalently in the hydrophobic 
pocket of the allosteric site of HIV-1 integrase, causing enzyme multimerization and 
rendering it unable to function. The work focused on developing a short synthetic 
strategy that provided a late stage derivatization. A structure activity relationship at the 4-
position of the quinoline was initiated to probe the noncovalent interactions in the 
hydrophobic pocket of the enzyme. The total synthesis of these quinolines was completed 
in 8 steps starting with 2-methyl-4-hydroxyquinoline. Highlights include the ability to 
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scale to as much as 25 g and requiring no purifications within many initial steps of the 
synthesis. Late stage derivatization utilized a Suzuki coupling with various aromatic 
boronic acids to install the 4-position probe, followed by saponification of the ester side 
group to produce the acetic acid side chain. Out of 36 compounds that were synthesized, 
the best substrates contained a para-chlorophenyl group as well as a benzodioxane 
derivative which resulted in multimerization inhibitions of 0.10 µM and 0.08 µM, 
respectively.  
The third and final project honed in on the importance of the manipulation of 
noncovalent interactions in organic synthesis via the utilization of squaramide 
organocatalysts for organic transformations. This class of organocatalysts rely on 
noncovalent interactions, such as hydrogen bonding,  π-π, and π-H stacking interactions 
to initiate the reaction and provide enantioselectivity. Using these organocatalysts, a new 
reaction was identified to synthesize nitroolefins via a Michael addition of masked acyl 
cyanides (MAC) to β-nitrostyrenes achieving yields of 50-99% and enantioselectivities in 
of 50-88%. This class of compounds as natural product synthons is apparent in their 
ability to access chiral indolines, β-lactams, and β-amino acids. This strategy also 
highlights the use of MAC as a versatile acyl anion equivalent that can be activated and 
added in an enantiopure fashion using organocatalysts. 
Overall, it has been shown that noncovalent interactions should always be 
considered when developing new reaction methodologies, as they are of vital importance 
in reaction mechanisms. Noncovalent interactions are a key factor in organic synthesis, 
and if used correctly, can provide the necessary momentum to a reaction to produce a 
single product, as well as producing the product in an enantioselective fashion. 
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Noncovalent interactions are also a key factor in binding and inhibition of enzymes, and 
the synthesis of small molecules for their inhibitory purposes must be designed with 
noncovalent interactions in mind.  
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APPENDIX A  
Supplementary data (NMR, IR, MS, and Elemental Analysis) for Chapter 2 compounds is 
provided in the supporting text titled “Supplementary Spectral Data”. 
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APPENDIX B  
Supplementary data (NMR, IR, MS, and Elemental Analysis) for Chapter 3 compounds is 
provided in the supporting text titled “Supplementary Spectral Data”. 
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APPENDIX C  
Supplementary data (NMR, IR, MS, and Elemental Analysis) for Chapter 4 compounds is 
provided in the supporting text titled “Supplementary Spectral Data”. 
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